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Amino acids: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D-amino acids are described by D-Xaa in the three-letter code and with 
the small letter in the one-letter code. 
 
 
 
 
 
Amino acid One-letter code Three-letter code 
Alanine A Ala 
Arginine R Arg 
Asparagine N Asn 
Aspartic acid D Asp 
Cysteine C Cys 
Glutamine Q Gln 
Glutamic acid E Glu 
Glycine G Gly 
Histidine H His 
Isoleucine I Ile 
Leucine L Leu 
Lysine K Lys 
Methionine M Met 
Phenylalanine F Phe 
Proline P Pro 
Serine S Ser 
Threonine T Thr 
Tryptophan W Trp 
Tyrosine Y Tyr 
Valine V Val 
Unspecified amino acid X Xaa, Yaa 
CO2Me
H2N COOH
(-)-β-ACC
CO2Me
H2N COOH
(+)-β-ACC
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A. Introduction 
 
 
 
 
 
 
4.6 billion years ago our Earth was a lifeless, inhospitable place. A billion years later life 
began, and its development to todays known complexity continues to generate fascinating 
conjectures and ingenious experiments. In the early 1950s Miller and Urey did the first 
experiment designed to clarify the chemical reactions that probably occurred on the primitive 
earth with a reducing atmosphere. From an atmosphere consisting of methane, ammonia, 
hydrogen, water vapor, and electrical discharge they obtained many amino acids as products.1 
Recent investigations indicate that the Earth’s atmosphere was never reducing as Urey and 
Miller presumed, and under oxidizing conditions no amino acids are formed.2 As an 
alternative it was proposed that the amino acids and the nitrogen-containing bases needed for 
the life might be have delivered by interstellar dust, meteorites and comets.3 
 
 
 
 
Figure 1. Comet Hale-Bopp, spring 1997.4 
 
 
Spectroscopic studies have shown that comets contain organic material including components 
of amino acids, and moreover they carry water as well.  
“Almost all aspects of life are engineered  
at the molecular level,  
and without understanding molecules we can only have  
a sketchy understanding of life itself” 
Francis Crick 
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Bernstein and coworkers reproduced interstellar/cometary ice and irradiated it with 
ultraviolet photons, similar to the ones emitted from stars, at very low temperature and 
pressure. The bonds of simple molecules like hydrogen, methanol and ammonia were broken 
and more elaborate molecules were formed.5 
Blank and coworkers simulated comets impact with Earth in presence of amino acids and 
found that not only a good fraction of the amino acids survived but also many amino acids 
polymerized into small peptides.6  
In the dusty interstellar clouds that form solar systems, starlight tends to get polarized, so it is 
possible that somehow, some way, one-handed light has produced left-handed amino acids 
that end up on Earth, and lead to the amazing characteristic of the life that is the one-
handedness of its molecules.7 Amino acids, mostly left-handed, have been found in 
meteorites8 that are just fragments of old comets, suggesting that this idea might be right.  
These simple molecules would have accumulated in the early oceans providing the raw 
material for subsequent prebiotic polymerization9 to give the first self-replicating entities, 
RNA analogues or peptide nucleic acid molecules10 that began the life and create the 
complexity that we are trying to understand now. 
 
 
 
Figure 2. Francis Crick and James Watson with a model of DNA11 (left), Crystal structure of a 
protein with unknown function from Leishmania major, a parasite of the human immune system12 
(right).  
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A.1 About α-Peptides... 
 
In nature, polymers composed of only 20 different amino acids are enough to provide 
molecules capable of innumerable activities. Structural proteins such as collagen or elastin 
provide support in organisms. Defensive proteins such as antibodies provide protection. 
Proteins, called enzymes, are used as catalysts in various chemical reactions. Besides this, 
proteins can be used to transport small molecules or to regulate metabolic processes.  
The key factor that determines the unique function of a protein is its 3-dimensional shape. 
Experiments have shown that the amino acid sequence itself contains all the instructions 
needed for proper folding.13  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The folding of the polypeptide chain.14 
 
The discovery of peptide hormones, growth factors and neuropeptides implicated in vital 
biological functions of our organism has increased interest in peptides, peptide analogues and 
peptide mimetics to further understand their molecular mechanism of action and to use them 
as therapeutic drugs. The development of peptides as clinically useful drugs however, has to 
overcome their poor metabolic stability and to increase their low bioavailability, due in part 
to their inability to cross biological membrane barriers.  
 
 
 
 
 
 
FOLDING 
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Name 
 
Sequence 
 
Biological function 
 
Insulin 
 
Chains A (21 length) and B (30 
length)  
S-S (A7-B7, A20-B19, A6-A11) 
 
 
 
Decreases glucose level in blood 
 
Somatostatin 
 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-
Lys-Thr-Phe-Thr-Ser-Cys  
(S-S, 3-14) 
 
 
Inhibit the secretation of growth 
hormone, insulin and glucagon 
 
Oxytocin 
 
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-
Gly-NH2  (S-S, 1-6) 
 
Vasopressin 
(VP) 
 
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-
Gly-NH2 (S-S, 1-6; Arg8 or Lys8) 
 
Induce contraction of smooth 
muscles, especially uterine muscle 
for oxytocin. VP is also used as an 
antidiuretic hormone 
 
Neurotensin  
 
pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-
Arg-Pro-Tyr-Ile-Leu 
 
Angiotensin II 
 
Asp-Arg-Val-Tyr-Ile-His-Pro-Phe 
 
 
 
 
Cause constriction of blood vessels 
 
Met-enkephalin 
 
Tyr-Gly-Gly-Phe-Met 
 
Leu-enkephalin 
 
Tyr-Gly-Gly-Phe-Leu 
 
 
Morphine-like properties, analgesic 
 
Table 1. Some examples of biologically active endogenous peptides. 
 
Therefore it is necessary to perform chemical modifications to arrive at peptidomimetics that 
maximize enzymatic stability and bioavailability while simultaneously preserving or even 
enhancing the potency and selectivity of the bioactive peptide.15 
Specificity is also a problem: peptide receptors can be widely distributed in organisms and 
their stimulation results in a variety of desired and undesired effects, especially, when the 
peptide is conformationally flexible and hence able to interact with alternative receptors.16 
Peptide modifications are a useful tool to investigate how the secondary structure can affect 
activity and using this knowledge it may be possible to regulate it.  
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Moreover, the introduction of new restricted building-blocks with discrete and predictable 
folding properties into peptides can allow to mimic the spatial orientation of the functional 
groups in the active site of enzymes and will help to design low molecular weight catalyst. 
 
Figure 4. Development of peptide drugs.17 
 
Polymers of α-amino acids present a well known set of secondary structures, characterized by 
precise hydrogen-bond patterns and torsional angles along their backbone. 
A repeated hydrogen-bond between residue i+4 and residue i leads to the α-helix. In the 310-
helix the hydrogen-bond is between the i+3 residue and the i residue. 
 
 
 
Figure 5. Some possible Hydrogen-bonds patterns in α-Peptides helices.18 
 
Turns are required along the backbone to change the direction and are often involved in the 
recognition sites of the peptide/protein ligands with receptors.19 Figure 6 shows the most 
common turns present in proteins. A γ-turn involves 3 amino acids with a i←i+2 hydrogen-
bond. β-turns involve 4 amino acids with a i←i+3 hydrogen-bond. 
The repeating of the β-turn type III along the peptide chain leads to a 310-helix. 
 
38%
56%
5%
1%
 on the market
 in registration
 advanced preclinical phases
 clinical phases
 
 
6  A. Introduction 
 
                               
 
β-turn-type I β-turn-type II β-turn-type III γ-turn 
 
Turn type Φ2 Ψ2 Φ3 Ψ3 
β-turn-type I (I’) -60 (+60) -30 (+30) -90 (+90) 0 
β-turn-type II (II’) -60 (+60) +120 (-120) +80 (-80) 0 
β-turn-type III (III’) -60 (+60) -30 (+30) -60 (+60) -30 (+30) 
γ-turn 70 -70 
inverse γ-turn -70 70 
 
Figure 6. Torsional angles of β-turns and γ-turns. 
 
To improve enzymatic stability, at least against the exopeptidases, one of the most simple 
strategies is end-protection. For example, the in vivo half-life in plasma of the N-terminal 
acetylated somatostatin, whose sequence is shown in Table 1, was improved from 3 minutes 
for the natural peptide, to more than 400 minutes.20 
To also increase stability against the endopeptidases, the peptide should be modified in its 
sequence, in the recognition site of the enzyme. 
Some common modifications are the methylation of amide nitrogen, the introduction of a 
number of key amide bond isosters or the substitution of some L-amino acids in the sequence 
with D-amino acids, CαAlkyl-amino acids or dehydroamino acids.  
All these modification can have significant consequences on molecular flexibility. The 
methylation of amide nitrogen, can change the network of the intra-molecular hydrogen 
bonds and promotes cis-amide conformation. 
The introduction of amide bond isosters completely prevents protease degradation of the 
amide bond and it may also significantly modify the biochemical properties of a peptide, 
particularly its conformation and its hydrophobicity. Those are used to investigate the role 
and function of backbone peptide bonds and to modify the properties of the parent peptides.21 
Figure 7 lists some examples. 
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Figure 7. Some examples of amide bond surrogates, ψ(CONH) replacements. 
 
The replacement of CONH with a CH2NH or CH2SH can help to investigate the possible 
functional role of the carbonyl group.  
The replacement with a CH=CH is the best replacement to maintain the planarity and rigidity 
of the amide bond. Enkephalin analogues with the CH=CH N-terminus amide bond surrogate 
were found to have similar activity to the original peptide, simultaneously providing 
protection from degradation.22 
There are also some examples of replacement of CONH with the retro amide NHCO23. 
Chorev, Goodman, and co-workers synthesized the first highly bioactive, partially modified 
retro-inverso peptides, i.e. some enkephalin analogues that display higher activity than Met-
enkephalin and prolonged duration of action in vitro and in vivo.24  
Among the modifications of the backbone, arguably the most common one is the substitution 
of the native sequence with other amino acids. 
The single exchange of each residue with amino acids like L-Ala or L-Pro can be useful in 
understanding the function of each part of the ligand in the interaction with a receptor. This 
so called Ala or Pro scan can be used on bioactive peptides that present for example no 
selectivity to different receptors, as in the case of neuropeptide Y.25 
To prevent the proteolytic degradation by enzymes or to stabilize a particular turn it is also 
useful to introduce a D-amino acid into a bioactive sequence as already demostrated by 
N
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Kessler et al. who synthesized the cyclo(-RGDfV-), a peptide integrin αVβ3-receptor 
selective antagonist.26 D-Phe promoted a β-turn that oriented the side chain of the –RGD– 
sequence into a position that caused it to interact selectively with this receptor subtype. 
 
Nowadays, protein residues are often replaced with Cα-tetrasubstituted α-amino acids. The 
introduction of a further α-Alkyl group, strongly effects the available conformational space. 
Approximately 70% of the conformational space available to glycine is precluded by the 
addition of one methyl group (Ala). The addition of a second methyl group (Aib, α-
aminoisobutyric acid or Cα,α-dimethylglycine) eliminates an additional 20%.27  
Toniolo et al. summarized the conformational preference of the Cα-tetrasubstituted α-Amino 
Acids. 28 Aib is the simplest achiral amino acid of this family. It promotes type III/III’ β-turns 
and 310 and α helices.  
 
 
 
Amino Acid Residue 
 
Backbone Conformation Preference 
 
       
HN CO
CH3H3C
 ,   HN CO
(CH2)n-2H2C
  
                Aib               Acnc, (n = 4-12) 
 
regular 310/α-helices; 
i+1 position type I/I’ β-turn 
i+1 and i+2 position type III/III’ β-turn 
 
                       
HN CO
 
                              Ac3c 
 
distorted 310/α-helices; 
i+2 position type I/I’ β-turn 
i+2 position type II/II’ β-turn 
 
                       
HN CO
CH2H2C R2R1
 
                            R1 = R2 ≠ H 
 
 
 
fully extended (C5) 
 
Table 2. Preferred backbone conformation of Achiral Cα-Tetrasubstituted α-Amino Acids.28 
 
 
In peptides containing achiral Cα,α tetrasubstituted amino acids and also Cβ-substituents, the 
energy difference between the helical and the fully extended conformation is smaller. For 
example, Deg (Cα,α-diethylglycine), Dpng (Cα,α-di-n-propylglycine) rich peptides can adopt 
either the fully extended or the helical conformation depending upon physical state.  
The structural preferences imposed by 1-amino-1-cyclopropane carboxylic acid (Ac3c) are 
for the position i+2 of type I/I’ and type II/II’ β-turns or distorted type III/III’ β-turns and 310 
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helices. The preferences imposed by 1-amino-1-cycloalkane carboxylic acids (Acnc, n=4-12) 
containing peptides are similar to the corresponding ones containing Aib’s (Table 2).  
 
The addition of another carbon between the nitrogen atom and the carboxyl group of α-
amino acid leads to the β-amino acids class. 
The conformational preferences imposed by these amino acids has been extensively studied, 
in particular by the groups of Seebach and Gellman. 
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A.2 β-Amino acids and β-Peptides 
 
β-amino acids and β-peptides have been extensively investigated in recent years with 
increasing interest because of their stability towards proteases, including pepsin, 
chymotrypsin, trypsin and carboxypeptidase.29 Moreover they show stable secondary 
structures in short peptides, containing only six or seven β-amino acids.30  
The conformation of β-peptides can be analyzed in terms of the main chain torsional angles, 
which are depicted with the angles ω, φ, θ and ψ (Figure 8) using Balaram’s conventions.31  
 
 
Figure 8. Definition for the torsional angles in β-peptides (left); β-amino acids used by Gellman and 
coworkers (right). 
 
Folded helical or turn-like structures require a gauche conformation about the θ torsional 
angle. A very modest alteration of this value can switch between two completely different β-
peptides helices as found by Gellman and coworker.32 
β-peptides containing the conformationally fixed cyclic trans-2-aminocyclohexane 
carboxylic acid (ACHC, 1), with θ = ± 60°, show a 314-helix. The smaller ring size of the 
trans-2-aminocyclopentanecarboxylic acid (ACPC, 2) has a θ which is biased towards larger 
values and a 2.512-helix is stabilized.  
Acyclic residues with different side chains investigated by Seebach and coworkers also adopt 
the 314-helix depending on the positions and on the stereochemistry of the side chains. The 
β2-amino acids form a less stable 314-helix than the corresponding all-β3-peptides. In β-
peptides made up of alternating β2-and β3-building blocks a mixed 2,710,12-helix is obtained.33 
 
 
H
N
H
N
O O
ω φ ψθ
NH2
COOH
(R,R)-trans-ACHC 
NH2
COOH
(R,R)-trans-ACPC 
1 2 
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There are several examples where the ability of β-peptides to adopt stable conformations has 
been used for the synthesis of potent bioactive peptides. 
The cyclic β-tetrapeptide shown in Figure 9 (right), with the side chains Phe, Trp, Lys and 
Thr, can mimic the natural peptide hormone somatostatin and also displays biological activity 
and micromolar affinity for human receptors.34 
 
 
 
 
 
 
 
 
 
Figure 9. The α-peptide hormone somatostatin (left) and the cyclic β-tetrapeptide analogue (right).34 
 
Cyclic β3-tetrapeptides subunits can form nanotube-like structures, which can create 
transmembrane ion channels with ion conductance levels similar to those observed with 
gramicidin A and D (Figure 8, left).35 
The β-17 peptide shown in Figure 10 (right) adopts a amphipathic 2.512-helix and shows an 
antimicrobial activity that is comparable to that of a well-characterized magainin derivative. 
But more significantly, it has a much lower hemolytic activity.36 
 
 
Figure 10. self-assembled transmembrane channels formed from cyclic β3-tetrapeptides (left); 
structure of the β-17 that mimic peptide antibiotic magainins (right).  
 
 
HN O
H
N
O
OH
HN
O
NH2
H
N
O
H
NHH-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp
HO-Cys-Ser-Thr-Phe-Thr-Lys
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A.3 β-amino acids incorporated into α- Peptides 
 
Proteolytic stability in α-peptides can be enhanced by replacement of an α-amino acid with a 
β-residue at the specific cleavage site. In addition, the incorporation of β-residues has been 
found to be a successful peptidomimetic tool for obtaining potent biological activity, in some 
cases higher than the native peptide. The β-residue can be an analogue of the corresponding 
α-amino acid (same side chains) or a conformationally restricted β-amino acid, for example a 
cyclic β-residue, that can induce a specific conformation in the sequence.37  
Cyclic and bicyclic β-amino acids have been used to produce potent analogues of RGD-
based molecules for the development of GPIIb/IIIa antagonists. Differences in ring size 
produced significant differences in the geometry of the resultant peptides and in the 
biological activity.38 
β-Peptides have been found to form β-hairpins. β-Amino acids can build β-peptide reverse 
turns, that allow for changes in the direction of the peptide backbone.39 
 
 
Figure 11. β-turn that promote β-hairpin found in β-peptides (left); The two enantiomers of β-ACC 
(right). 
 
Cyclic β-amino acids were also used by Gellman and coworkers to generate a heterogeneous 
backbone with antimicrobial properties.40 They built different α/β alternated foldamers that 
form an amphiphilic helix showing high antimicrobial activity with low eukaryotic cell 
toxicity. 
RGD peptides modified by β-amino acids are active integrin αIIbβ3 and αvβ3 antagonists.41 
 
The applications of unnatural building blocks that can induce a predictable conformation, 
require further investigation into their conformational preferences. 
N
O
O
N
O
HN
CO2Me
H2N COOH
(-)-β-ACC
CO2Me
H2N COOH
(+)-β-ACC
3 (+)-4 (-)-4 
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In our group we investigated the conformational preferences of the two enantiomers of a 
constrained cyclic β-alanine analogue, the β-aminocyclopropane dicarboxylic acids (+)-4 and 
(–)-4, in which the amino and the carboxylic functions involved in the peptide bond are cis to 
each other. 
The introduction of the (+)-β-ACC unit into the C-terminus of the NPY (Figure 12) was 
found to be active and selective for the Y1-receptor subtype.42 
 
 
Figure 12. The most selective NPY analogue containing (+) β-ACC, Y1-receptor Ki = 37 ±20 nM; 
Y5-receptor Ki = 724 nM; Y2-receptor Ki >1000 nM. 
 
It is already known that α-pentapeptides containing only one β-ACC unit show stable turn 
like structures43. The variety of these β-ACCs, which can be introduced as building blocks 
has been greatly extended, by synthesis β-ACCs with different side chains.44 
The aim of this work is to develop an understanding of the conformational preferences of 
these β-amino acids. Different mixed α-amino acids/β-ACC peptides were synthesized and 
their conformation were investigated. 
This knowledge will allow a projection of particular turns or structures that have discrete and 
predictable folding properties. Thereby helping to stabilize the conformation of biologically 
active α-peptide analogues, that may be used pharmacologically or in receptor-ligand 
interactions studies. The production of new building-blocks with particular conformational 
preferences could also be used for the design of spacer or low molecular weight catalysts, 
small molecules having a definite spatial orientation of functional groups. 
 
 
 
H
N
N
H
H
N
N
H
CONH2Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr
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B. Model Peptides containing β-ACC: Synthesis and 
Conformational Investigations 
 
B.1 Synthesis 
 
The model peptides containing either of the enantiomers of β-ACC that were synthesized and 
investigated in the course of this study are shown in Figure 13. 
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Figure 13. β-ACC containing peptides that have been synthesized and investigated in this work. 
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The synthesis of the β-ACC building blocks, being suitably functionalized to be introduced in 
peptides, has been carried out as developed in our group1 from Boc-pyrrole in racemic or 
enantiomerically pure form. (Figure 14). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. β-ACC building blocks for peptide synthesis. 
 
The synthesis of peptides 5 and 6 was carried out in solution using Boc/OBn as orthogonal 
protecting groups.  
As already described by Zorn2, the β-ACC was deprotected at the N-terminus by treatment 
with HCl in ethyl acetate to afford the stable hydrochloride salt. The N-terminus of the 
protected β-ACC was reacted with a C-protected-L-alanine in the presence of the coupling 
reagents EDC and HOBt, using pyridine as base in dichloromethane.  
The resulting diastereomeric dipeptides (+)-10 and (–)-10 were then separated by 
crystallization.  
The C-terminal part of (+)-10 or (–)-10 was deprotected by hydrogenation in the presence of 
palladium charcoal and 1,4-cyclohexadiene in methanol. The carboxyl function was activated 
with EDC/HOBt and after the coupling with N-deprotected alanine it was possible to obtain 
the tripeptides (+)-12 and (–)-12 (Figure 15). 
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Figure 15. Introduction of β-ACC units into peptides. 
 
Repeated N-terminus deprotections and couplings with the C-deprotected dipeptide Boc-L-
Ala-β-ACC-OH were carried out to afford the heptapeptides (+)-5 and (–)-5 and 
nonapeptides (+)-6 and (–)-6 as shown in Figure 16. 
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Figure 16. Solution synthesis of the protected hepta- and nonapeptides 5 and 6. 
 
The synthesis of the (–)-β-ACC containing peptides and the (+)-heptapeptide (+)-5 was 
carried out with good yield and without epimerisation. However epimerisation did occur 
when peptide (+)-5 was elongated to afford the nonapeptide (+)-6. The 1H-NMR spectra of 
the peptide after column chromatography purification showed more than one Boc-signal 
indicating the presence of epimers or at least rotamers. When the NMR spectra was measured 
at higher temperature no changes were observed, excluding the hypothesis of rotamers. After 
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recrystallization with ethyl acetate and petroleum ether it was possible to isolate the required 
peptide (+)-6, the purity of which was determined by HPLC to be greater than 90%. 
 
The deprotection of the final peptides was achieved by treatment first with a saturated 
solution of HCl in ethyl acetate to remove the Boc-group. Next the benzyl ester deprotection 
was performed. This involved an overnight hydrogenation using a solution of cyclohexadiene 
in pentane in the presence of Pd/C in methanol. (Figura 17).   
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Figure 17. Deprotection of the peptides (+)-5 and (+)-6. The same procedure was carried out for the 
hepta- and nonapeptide containing the (–)-β-ACC unit. 
 
The peptide (–)-7 was synthesized as shown in Figure 18 using a solid phase protocol. It was 
carried out by manual coupling using Fmoc/tBu strategy on the acid labile HMPA-AM resin. 
The first amino acid, alanine, was attached activating the carboxylic function with DIC and 
HOBt in the presence of DMAP as catalyst and stirring overnight. The loading of the resin 
was determined spectrophotometrically by Fmoc cleavage with piperidine in DMF.3 After 
capping by treatment with acetic anhydride and DIPEA in DMF, the peptide chain was 
assembled by single manual coupling of the dipeptides Fmoc-Xaa-βACC-OH activated by 
DIC/HOBt overnight in DCM/DMF 9:1 in the presence of DIPEA (Figure 18). After every 
two coupling-steps small scale cleavages were performed to control with analytical HPLC 
and mass analysis the growing peptide chain.  
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Figure 18. Solid phase synthesis of (–)-7. 
 
 
-AlaFmoc-Phe-βACC-Ala-βACC-Phe-βACC-Lys(Boc)-βACC-Phe-βACC
-AlaFmoc-Lys(Boc)-βACC-Phe-βACC-Ala-βACC-Phe-βACC-Lys(Boc)-βACC-Phe-βACC
1. 20% piperidine in DMF
2. Fmoc-Phe-βACC-OH
    DIC, HOBt, DiPEA, DCM
1. 20% piperidine in DMF
2. Fmoc-Lys(Boc)-βACC-OH
    DIC, HOBt, DiPEA, DCM
22              B. Model Peptides containing β-ACC units 
 
To synthesize the longer β-ACC containing peptides a first attempt was carried out using the 
most common coupling reagent HBTU in DMF. In this case it was not possible to obtain the 
desired peptide probably because of epimerization especially in the last two coupling-steps. 
Therefore DIC in DCM were then used.  
The cleavage of the peptide from the resin with simultaneous side chains deprotection was 
achieved by treatment with a TFA/water/TIS mixture (95:5:5) for 2,5 hours (Figure 19). The 
peptide was precipitated from ice-cold diethyl ether and recovered by centrifugation. The 
purification was achieved by using RP-preparative HPLC and the product (–)-7 was 
characterized by analytical HPLC and MALDI-MS spectroscopy. 
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Figure 19. Cleavage and deprotection of the peptide (–)-7 from the resin. 
 
 
 
 
 
 
 
 
 
 
Figure 20. HPLC of the peptide (–)-7 after purification. 
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For the synthesis of the peptide (–)-7 by means of solid phase synthesis using an acid labile 
resin, Fmoc protected dipeptides (–)-14a and (–)-15a were prepared as shown in Figure 21. 
The enatiomerically pure (–)-9 was deprotected at the N-terminus by treatment with HCl in 
ethyl acetate, followed by coupling with the corresponding Fmoc-protected amino acid to 
afford the protected dipeptide (–)-14 and (–)-15. Final deprotection of the benzyl ester 
yielded (–)-14a and (–)-15a , respectively, being suitably functionalized for further coupling 
by treatment for 18 hours with cyclohexadiene and Pd/C. 
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Figure 21. Synthesis of the Fmoc-β-ACC derivatives. 
 
According to the same procedure the dipeptides (+)-16a, (–)-16a, (+)-17a, (–)-17a, (+)-18a 
shown in Figure 21 and 22 were synthesized as well, necessary in the synthesis of RGD-
containing peptides and NPY-analogues (Chapter C). 
 
 
 
 
 
 
 
24              B. Model Peptides containing β-ACC units 
 
 
 
 
 
 
 
 
Figure 22. Dipeptides that were used in the synthesis of biological active analogues.  
 
In the case of the dipeptide containing alanine (–)-19a the synthesis started from the Boc-
protected dipeptide (–)-10. After deprotection at the N-terminus with HCl in ethyl acetate, 
treatment with Fmoc-OSu afforded the Fmoc derivative (–)-19 in good yield, which was then 
deprotected at the C-terminus to yield (–)-19a, being ready for solid phase synthesis.  
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Figure 23. Synthesis of the Fmoc-protected dipeptide containing Alanine. 
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B.2 Conformational Investigations 
 
The conformation of peptides depends in principal on the kind of amino acids that are present 
and their sequence. A knowledge of the three dimensional structure of a peptide is essential 
in understanding its physical, chemical and biological properties.  
There are many techniques used to investigate the three dimensional structure of peptides. X-
ray diffraction allows structural investigations at atomic resolution. However single crystals 
are needed and there always exists the possibility of a difference in the conformation between 
the solid state and the one seen in solution. 
To gain information about the secondary structure of a peptide in solution, important tools 
such as circular dichroism spectroscopy, 1D and 2D NMR and FT-IR spectroscopy are 
employed.  
 
 
B.2.1 Circular dichroism 
 
Circular dichroism is an important spectroscopic technique, used to investigate the 
conformations of peptides and proteins. An optically active substance is able to interact with 
polarized light in a different way, depending on its “chirality”. UV-CD is based on planar 
polarized light. Planar polarized light is the sum of the left and the right circularly polarized 
light. When an optically active substance intercepts planar polarized light rays, the left and 
the right circularly polarized components are adsorbed by different amounts. When these are 
recombined, they appear as elliptically polarized light. The extent of this ellipticity is then 
measured. 
The absorbance values of the peptide chromophore are due to a low energy npi* transition 
centered around 220 nm and a higher energy pipi* transition around 190 nm.4 
The advantage of CD measurements when investigating a polymer conformation is that the 
spectrum is no longer reflected by the absorbance of a single individual chromophore. The 
combination of the orientated chromophores in the three dimensional arrangement of the 
polymer gives rise to a new set of excited transitions. Therefore each type of peptide 
secondary structure has a unique and distinct CD spectrum.5 
Additionally there can be some contributions from aromatic residues (Phe, Tyr, Trp and His) 
and disulfide bonds. If there are a significant number of aromatic residues present in a 
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molecule, the CD spectra can be affected in the region of far-UV. The contribution seen in 
near-UV is smaller. This region can be used to investigate changes of tertiary structures, for 
instance, those caused by ligand binding or folding/unfolding precesses.5 
Shown below are the typical CD spectra seen for some secondary structures of α-peptides. 
 
 
Figure 24. CD spectra of the common secondary structures seen for α-peptides.6 
 
 
B.2.2 NMR investigation 
 
The most common and useful tool used to investigate the secondary and tertiary structure of 
peptides and proteins in solution is Nuclear Magnetic Resonance (NMR) spectroscopy. 
NMR spectroscopy allows an investigation of the structure of biopolymers on an atomic level 
in solution. Moreover, NMR investigations can highlight the presence of conformational 
equilibria. Important structural information can be obtained from both monodimensional and 
twodimensional NMR spectra.   
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B.2.2.1 Information from 1D-proton NMR spectra 
 
Even though the NMR-spectra of biopolymers are derived from the nuclear spins of the 
constituent monomers, there is no straightforward correlation between the NMR spectra of 
the low molecular weight components and those of the whole polymer.7 
A dispersion of nucleus’s chemical shift values is the first indication of the presence of 
spatial folding in the polymer chain. When a polymer has a defined conformation in solution, 
a proton in the sequence will have a different microenvironment compared to those in a 
random coil structure. It will also be different from the same proton contained in an identical 
residue type at a different point in the sequence. This fact leads to different specific chemical 
shift values compared to those for an unfolded structure and to a good dispersion of the 
signals.  
The presence of a secondary structure in solution can lead to a slower exchange rate for  
labile protons, which can be measured by time dependent NMR-spectroscopy, while in small 
molecules proton exchange is too fast to be observed. Moreover the slower diffusional 
motions of the macromolecule in solution can substantially affect the spin relaxation and the 
Nuclear Overhauser Enhancement (NOE).7 
 
12345678910 δ (ppm)
-CH3
β−H, other aliphatic CHNH(sc)NH(bb)NH(W)
αH, βH(S,T)aromatic
 
 
Figure 25. 1H-chemical shift positions for α-peptides. Adapted from Ref. 7. 
 
The presence of hydrogen-bonds can be detected in a 1D-NMR spectra. These techniques are 
based on the assumption that the NHs involved in a H-bond are less sensitive with respect to 
perturbations, such as changing of temperature, concentration or solvent, than the NHs that 
are exposed to the solvent.  
Considering the NHs that are been exposed to the solvent, it has been established that the NH 
shift deviation with temperature (∆δ/∆T) is less negative than -4 ppb/°C.8 However such data 
should be confirmed by other observations, because of possible errors in interpretation. For 
example, in the case of a conformational change towards a random coil structure with 
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increasing of temperature, when a small negative ∆δNH/∆T is observed, the H-bonded NH 
should be downfield and the protection of H/D exchange should provide a more secure 
measurement of solvent access.9 
The secondary structures of peptides are characterized by distinct torsion angles along the 
backbone. Since the size of the spin-spin coupling constant 3JHNα depends on the torsion 
angle NH-CHα, the measurement of 3JHNα is another approach that can give information on 
the torsion angle φ, and thus, on the peptide’s conformation.7,10 Small values indicate turn or 
helical conformations, values bigger than 6 Hz correspond to an unordered structure or an 
extended conformation. Shown below (Figure 26) are the 3JHNα  values associated with some 
common peptide secondary structures.  
 
 
Secondary structure φ 3JHNα (Hz) 
α-helix - 57° 3.9 
310-helix - 60° 4.2 
antiparallel β-sheet - 139° 8.9 
parallel β-sheet - 119° 9.7 
 
Figure 26: Table of the 3JHNα-values in regular secondary structures7, also displayed are of the φ and 
ψ torsion angles present along the backbone of an α-peptide. 
 
 
B.2.2.2 Information from 2D-proton NMR spectra 
 
The most useful data relating to a peptide conformation is gained from 2D NMR 
investigation. Of particular interest are the DQF-COSY, TOCSY and NOESY/ROESY 
experiments.  
The COSY displays [1H-1H]-correlations due to scalar (through bond) couplings. The 
TOCSY reveals the proton cross peaks in the same spin system. With the help of these two 
experiments it is possible to assign completely all the chemical shifts of the protons in a 
peptide. The NOESY, Nuclear Overhauser Effect Spectroscopy, displays cross peaks due to 
dipolar coupling resulting from through space interactions. 
NOESY cross peaks depend on the distance between two protons. Therefore it can connect 
pairs of hydrogen atoms in amino acids that may be far away along the peptide sequence but 
close together in space because of the presence of a stable three dimensional structure. 
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Figure 27. NOE signals can depend to the three dimensional structure of the peptide. 
 
NOE cross peaks are normally defined as sequential distances when they are between 
backbone protons or between a backbone proton and a β proton in residues that are nearest 
neighbours in the sequence. Medium-range distances are all non-sequential signals between 
residues within a segment of five consecutive residues. Long-range backbone distances are 
between backbone protons in residues that are at least six position away in the sequence.7 
Depending on the torsion angles that characterize the secondary structure of a peptide, 
sequential and medium-range 1H-1H-distances will have different values.  
For instance the sequential NH-NH and CHα-NH contacts for a regular α-helix are about 2.8 
Å and 3.5 Å respectively. The CHβ-NH contacts, since they depend also on the torsion angle 
on the side chain χi, vary between 2.5 and 4.1 Å for a α-helix.7  
In the case of peptides, including proline or non proteinogenic amino acids there exists an 
increased possibility of cis-trans isomerization of the peptide bond. The influence of the cis-
trans isomerization on the sequential 1H-1H-distances allows closer CHα (i)-CHα (i+1) and 
NH (i)-CHα (i+1) contacts in the cis form whereas shorter CHα (i)-CHδ (i+1) and NH (i)-
CHδ (i+1) contacts are observed for the trans form.7 
Medium-range distances indicating helical-structures are i,i+2, i,i+3 and i,i+4 contacts. In 
particular i,i+4 contacts are especially useful since they are present in a regular α-helix and 
not in a 310-helix. Tight turns have close i,i+2 values. In the case of β-structure short medium-
range distances are not observed, since the polypeptide segments are almost fully extended .7 
Table 3 lists short sequential and medium-range distances that are found in known α-peptide 
conformations. 
 
 
 
NOE ~ r -6 
H H 
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Distance α-helix 310-helix β-sheet 
dαN 3.5 3.4 2.2 
dαN(i,i+2) 4.4 3.8  
dαN(i,i+3) 3.4 3.3  
dαN(i,i+4) 4.2   
dNN 2.8 2.6 4.2-4.3 
dNN(i,i+2) 4.2 4.1  
dβN 2.5-4.1 2.9-4.4 3.2-4.7 
dαβ(i,i+3) 2.5-4.4 3.1-5.1  
 
Table 3. Short sequential and medium-range 1H-1H distance in some common secondary structures in 
α-peptides.7 
 
 
  B.2.2.3 Structure calculations from NOE data    
 
The NMR data can be finally used as an indirect source of structural information, from which 
the overall 3D structure can be calculated.  
Programs like DYANA11 are used for these structural calculations. DYANA performs 
simulated annealing by molecular dynamics in torsion angle space using conformational 
restraints obtained from the volumes of the corresponding NOE crosspeaks. It starts from 
conformers that possess random torsion angle values and fits them to the conformational 
restrains collected from the NMR measurements.12  
Among the 50 calculated structures, the resulting 20 best ones were selected according to the 
lowest values of their target function. 
 
 
B.2.3 FT-IR spectroscopy   
 
Infrared light is energetic enough to excite molecular vibrations to higher energy levels. The 
main characteristic bands of the peptide group are called amide A, amide I and amide II. 
Evidence exists, which suggest that the position of these bands is related to the conformation 
of the peptide.13 The amide A band is mainly due to the N-H stretching vibration. It is very 
sensitive to the strength of a hydrogen bond, thus providing an opportunity to gain 
information about any intra- or intermolecular hydrogen bond. Usually in a non polar solvent, 
non hydrogen-bonded NHs adsorb above 3400 cm-1 while NHs that are involved in 
hydrogen-bonds, absorb below 3400 cm-1.14 The amide I and II bands are related to the 
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backbone conformation. The amide I is associated with the C=O stretching vibration, while 
the amide II results from the N–H bending and from C–N stretching vibrations.  
 
 α-helix 310-helix β-sheet 
Amide I 1652 1666-1662 1648-1645 
Amide II 1548 1533-1531 1533-1536 
 
 
Table 4. Frequencies (cm-1) of the Amide I and Amide II bands found for different α-peptide 
conformations. 
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B.3 Results on alternated α-Xaa/β-ACC peptides 
 
Reverse turns play a crucial role in the globular architecture of folded proteins. They are 
often implicated in the recognition motif, in protein-peptide interactions, especially regarding 
interactions with G-protein couple receptors.15 
The discovery of small systems that mimic different types of turns or inducing modifications 
at specific sites in the bioactive sequence able to enhance its reverse-turn propensity is a 
fascinating and important field of research in developing biologically active molecules. 
There are already some examples of the introduction of cyclopropane-derived 
peptidomimetics into bioactive peptides such as HIV-1 protease inhibitors16, matrix 
metalloprotease inhibitors17 or enkephalin analogues18.  
Cyclopropane-containing dipeptide isosteres -XaaΨ[COcpCO]Yaa- and –XaaΨ[NHcpNH] 
Yaa- were synthesized as well. A trans-substituted cyclopropane was found to stabilize 
extended conformations in oligopeptides while molecular modeling studies suggested that the 
cis-backbone substituents could stabilize a reverse turn.18 
The influence of β-amino acids in the secondary structure of β-peptides has been extensively 
studied by the groups of Gellman and Seebach. As reviewed by Cheng et al.19, the 
substituents on the β-amino acid backbone, strongly affect the torsion angle θ leading to 
different preferences in the secondary structure of the resulting β-peptide. 
In our case the presence of the cyclopropane ring constrains the amine and the carboxyl 
functions used in the peptide bond in the cis (syn) conformation, providing a unique 
conformational preference for this β amino acid compared to those already reviewed. 
 
 
 
 
 
 
 
Figure 28. θ torsion angle in β-ACC.   
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Small model peptides containing only one β-ACC unit, (+)-20 and (–)-20, were previously 
synthesized by Zorn2. NMR investigations and molecular dynamic calculations on these 
peptides showed that they have a tendency to adopt a turn like structures as displayed in 
Figure 29.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Structures of model peptides containing only one β-ACC unit.2 
 
 
Moreover it was found with molecular modelling calculations and IR investigations in 
dichloromethane that the β-ACC unit could close a 6-membered ring (C6) via an 
intermolecular H-bond.2  
In this chapter the influence of the β-ACC units on the secondary structure of longer peptides, 
in which the β-unit is alternated with α-amino acids are described. 
The possible H-bond patterns that can be found theoretically in helicies, in which α-amino 
acids are alternated with β-amino acids are shown in Figure 30. Mixed 14/15- and 11-helices 
were found by Gellman et al.20 in small α/β-peptides containing cyclic β-amino acids.  
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Figure 30. Possible helices in α-/β- alternated peptides. 
 
Computer calculations on a alternating Gly-βACC nonapeptide was performed in vacuum by 
Baldauf et al.21 Through these studies it was possible to show that this peptide should adopt a 
mixed helix C9/C11 with  i→i+1 / i← i+3 interactions. (Figure 31) 
 
 
Figure 31. Baldauf et al. were able to predict the most stable helix in vacuum for an alternating Gly-
βACC nonapeptide using computer calculations.21 
 
The β-ACC containing peptides were investigated with 2D-NMR, CD and FT-IR 
spectroscopy. 
While structure determination of smaller globular proteins using NMR spectroscopy is well-
established, particular care must be taken with smaller peptides. In this class of molecules 
folded conformations are possibly in (fast) exchange with extended forms, or differently 
folded forms may rapidly interconvert. It was therefore tried to monitor a number of 
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parameters in order to determine whether a single, well-folded conformation predominates. 
The following approach was used in order to determine predominant structures of the 
heptapeptides (–)-5a, (+)-5a and the nonapeptides (–)-6a, (+)-6a in methanol and to quantify 
to what extend these peptides are folded. Structures were calculated according to 
conventional methodology using NOE-derived distance restraints as the sole source of 
(upper) distance limits. It was assumed that a peptide adopts a well-folded form 
predominantly when the following three criteria are fulfilled: (1) No consistent restraint 
violations of the distant restrains are found; (2) A uniform calibration (NOE volume integral-
distance conversion) can be used, and known distances adopt reasonable values; (3) All 
distances shorter than 3.5Å that occur in more than half of the low-energy DYANA 
structures give rise to crosspeaks in the NOESY spectrum. It was found that the third 
criterion was particularly useful in determining whether a single conformer predominates. If 
NOE-derived distance restraints are due to two different conformers, the calculated structure 
representing only a single conformer usually displays short distances for which no NOEs can 
be found in the spectra.  
To further verify that the proposed conformers are realistic, molecular dynamics (MD) 
simulations were conducted. The NMR structures were subjected to extensive temperature 
cycling in order to extensively screen conformational space and to perform statistical analysis 
on the resulting low-energy structures. For the structures that fulfilled the criteria described 
above, well-folded conformers resulted that were in agreement with the NMR data. 
All investigated peptides displayed helical conformations, as is apparent from the presence of 
NOEs between sequential amide protons. However, they largely differ in the extent to which 
they are uniquely folded.  
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B.3.1 Alternated α-L-Ala/(–)β-ACC peptides 
 
The peptides which contained the (–)-β-ACC unit were less subject to conformational 
averaging. They are structurally best defined. A representative conformer from the low-
energy NMR structures computed from the NOESY data with the program DYANA is 
displayed in Figure 32 (left).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Structure calculated for the heptapeptide (–)-5a. 
 
The heptapeptide (–)-5a forms a left-handed 313-helix. Hydrogen bonds occur between the 
amide proton of the β-ACC in position 2 and the carbonyl oxygen of the β-ACC in position 
4. An intraresidual hydrogen bond between amide proton and carbonyl oxygen of the β-ACC 
in position 6 occurs in most of the low-energy structures22 (Figure 32, right). This structure 
was surprisingly well defined for a non-cyclic heptapeptide without disulfide bonds or other 
constraints. The helical fold23 was supported by a larger number of medium-range NOEs, in 
particular by a range of i, i+3 contacts (Table 5).  
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Peptide Contacts  Contacts 
Ala1 HA  Ala5 HA Ala3 HN ACC6 HG 
Ala1 HA  ACC4 HG Ala3 HA ACC6 HG 
Ala1 QB  ACC4 HA Ala3 HA Ala7 HA 
Ala1 HA  Ala5 HA Ala3 QB Ala7 HA 
ACC2 HB Ala5 HA ACC4 HN Ala7 HA 
ACC2 HN Ala5 HA ACC4 HB ACC6 HN 
 
(–)-5a 
ACC2 HN ACC4 HG 
 
ACC4 HA Ala7 HA 
    
Ala5 HN ACC8 HG ACC4 HA Ala7 HA 
ACC4 HA ACC8 HN ACC6 HA Ala9 HA 
Ala3 HN Ala7 HA Ala5 HA ACC8 HG 
ACC2 HN Ala5 HA Ala3 HA ACC6 HG 
Ala1 HA Ala5 HA ACC4 HN Ala7 HA 
Ala3 HA Ala7 HA ACC6 HN Ala9 HA 
Ala5 HA Ala9 HA Ala1 QB ACC4 HA 
ACC4 HA ACC8 HG Ala5 QB ACC8 HG 
 
(–)-6a 
Ala3 QB ACC6 HG 
 
Ala1 QB ACC4 HG 
 
Table 5. Medium-range NOEs for the peptides (-)-5a and (-)-6a. In the table, A=α; B=β, G=γ, D=δ, 
E=ε. The letter Q instead of H is used when there is a signal due to more than one hydrogen and it is 
not possible to distinguish between them, for example the CH3 of Alanine. 
 
Moreover, in the heptapeptide (–)-5a the 3JHNα scalar coupling constants were less than 4.2 
Hz (Table 6). All NOESY cross peaks due to intraresidual distances smaller than 3.5 Å in the 
20 low-energy DYANA structures of the heptapeptide (–)-5a were found in the NOESY 
spectrum. In the spectra no i, i+1 Hα, Hα peaks were found indicating the absence of any cis 
Xaa-ACC bonds. In order to detect possible aggregation effects and to exclude 
intermolecular NOEs from the analysis, the sample was diluted to approx. 0.8 mM. Chemical 
shifts remained constant during dilution and the same NOE cross peaks were observed in the 
NOESY spectrum at this lower concentration. Signals were sufficiently separated so that all 
the NOESY crosspeaks could be assigned unambiguously.  
 
(–)-5a 3JHNα (Hz) (–)-6a 3JHNα (Hz) 
NH-2 3.4 NH-2 3.9 
NH-3 6.4 NH-3 6.0 
NH-4 3.4 NH-4 3.4 
NH-5 6.0 NH-5 5.9 
NH-6 4.2 NH-6 3.5 
NH-7 7.2 NH-7 6.7 
  NH-8 5.6 
  
 
NH-9 6.8 
 
Table 6. Vicinal coupling constants for HN, Hα in CD3OH for peptide (–)-5a and (–)-6a. 
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The temperature coefficients (∆δ/∆T) for the heptapeptide (–)-5a were also measured (Figure 
33). Although any reduced temperature coefficient should be interpretated with care, together 
with a 2D-NMR investigation we confirmed that the NH of the β-ACC in position 2 was 
involved in a hydrogen-bond leading to the most downfielded chemical shift among the β-
ACC-NHs and to a temperature coefficients ∆δ/∆T less negative than -4 ppb/°C. 
 
 
 
 
 
 
 
 
 
 
 
Temperature NH-2 NH-3 NH-4 NH-5 NH-6 NH-7 
280.0 K 8.3630 8.6373 8.2756 8.8667 8.1678 8.8216 
290.0 K 8.3344 8.5829 8.2244 8.8037 8.1213 8.7576 
300.0 K 8.3042 8.5277 8.1757 8.7409 8.0816 8.6930 
310.0 K 8.2739 8.4750 8.1320 8.6816 8.0470 8.6320 
320.0 K 8.2391 8.4140 8.0838 8.6129 8.0082 8.5621 
328.0 K 8.2124 8.3693 8.0492 8.5626 7.9809 8.5108 
 
      ∆δ/∆T 
       (ppb) 
 
  - 3.14 
 
  - 5.58 
 
  - 4.72 
 
  - 6.34 
 
  - 3.90 
 
  - 6.48 
 
Figure 33. Temperature coefficient for the NHs in the heptapetide (–)-5a. 
 
 
The structure of the nonapeptide (–)-6a was found to be similar to that of the heptapetide (–)-
5a. It displayed a 313 helical fold (Figure 34, right) and no indications for significant 
conformational averaging in this peptide are found. Low scalar couplings and a high number 
of medium-range NOEs indicate that this peptide is well structured. 
The CD investigations performed in methanol (Figure 34, left) stressed that the heptapeptide 
(–)-5a and the nonapeptide (–)-6a adopt the same conformation. Both peptides show a 
minima at about 200 nm that correspond probably to the Cotton effect associated with this 
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kind of turn. There is unfortunately no CD-reference for α-/β-alternated peptides that adopt a 
313-turn conformation. 
 
 
 
 
 
 
 
 
 
 
Figure 34. CD spectra of the heptapeptide (–)-5a and the nonapeptide (–)-6a in methanol and the 
NMR structure of (–)-6a. 
 
The structure of the alternated α-Ala/(–)-βACC peptides was found to be solvent dependent. 
The CD spectra of these peptides in different solvents, as shown in Figures 35 and 36, display 
the instability of the helix-turn that was found from NMR investigations by changing the 
environment. The intensity at 200 nm decreases, indicating an unfolding process or a 
conformational change. TFE are known to be a helix-inducing solvent. However it has been 
also found for proteins that the preferred conformation in TFE it is not necessarily correlated 
with the one in the native state.24 Since TFE can disrupt the native state of proteins, for 
example in loop or β-sheet regions, to induce α-helices, it is possible that for our peptides 
TFE is not able to stabilized the 313-helix . 
 
 
 
 
 
 
 
 
 
 
Figure 35. CD spectra of the heptapeptide (–)-5a in different solvents. 
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Figure 36. CD spectra of the nonapeptide (–)-6a in different solvents. 
 
Although a slightly red-shift is present, the intensity of the ellipticity at 200 nm does not vary 
significantly over the concentration range of 330 µM and 1 mM in methanol indicating no 
conformational changes or eventual aggregation effects. (Figure 37) 
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Figure 37. CD spectra of the nonapeptide (–)-6a measured in methanol at different concentrations. 
 
In HFA the peptides show a maximum at about 216 nm, which is probably due to a different 
conformation. To further investigate the conformational changes on the secondary structure 
of the peptides containing the (–)-βACC moiety, we measured the CD spectra in methanol in 
the presence of varying amounts of HFA. (Figure 38) 
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Figure 38. CD spectra of (–)-6a in methanol in the presence of different amounts of HFA. 
 
By addition of HFA the 200 nm band intensity decreases and the new band at 216 nm is 
forming. Since there is no isodichroic point, it can be assumed that the structure found in 
methanol is in equilibrium with at least two different conformations in HFA. It is likely that 
in HFA the peptide is unfolded. The addition of this solvent to the folded peptide in methanol 
leads to a “melting” process of the structure. This process carried out via non-cooperative 
mechanism since the intensity at 200 nm with the amount of HFA has a almost linear 
dependence (Figure 38, right). Similar results were found also investigating the “melting” 
mechanism of the secondary structure for β-peptides.25 
The peptide at concentration of 1 mM in methanol were studied in the presence of increasing 
ratios of water. When the temperature is increased or urea, guanidinium hydrochloride, or 
water are added, the secondary structure of α-peptides generally collapses. As shown in 
Figure 39, increasing amount of water does not decrease the ellipticity at 200 nm, as expected 
for a unfolding process, but instead an increase was observed. Superficial NMR investigation 
on the peptide in water suggests a conformational change from methanol to water. Either the 
helical fold adopted in water is similar to that found in methanol, with a similar CD pattern 
or, more likely, a smaller amount of methanol, less than 100%, is better to stabilize the 313 
helix-turn.  
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Figure 39. CD spectra of the nonapeptide (–)-6a in methanol with different amount of water. Right 
the behaviour of the ellipticity at 200 nm by increasing of percentage of water. 
 
Shown below, in Figure 40, is the IR spectra of the peptide (–)-6a measured in methanol. It 
highlights the Amide I region. 
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Figure 40. Amide I region of IR spectra of (–)-6a in methanol. 
 
α-Helices are generally assumed to absorb in D2O at around 1652 cm-1. However intrinsic 
absorbencies, even for the same secondary structure-type, are not the same.26 
By calculating the second derivative, it was possible to identify the position of each 
component of the Amide I band. There are two maxima at about 1655 and 1664 cm-1 and a 
shoulder at around 1650 cm-1 that probably characterized the 313 helix-turn previously found 
by NMR investigation. 
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According to computer calculations presented in Figure 31, the alternated α-Xxx/β-ACC 
peptides could have under gone a conformational change depending on the solvent polarity. 
The CD spectra of (–)-6 was then measured when different amount of methanol and 
cyclohexane were added to the same volume of 1,2 dichloroethane. The presence of 1,2 
dichloroethane was necessary for the solubility and the solution homogeneity. The peptide 
shows a different pattern depending on the ratio of polar and non polar solvents.  
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Figure 41. CD spectra of the nonapeptide (–)-6 with different ratio of polar and non polar solvent. 
 
The isodichroic point (Figure 41) suggests that an equilibrium exist between the two 
conformational states. In a non polar solvent a peptide’s secondary structure is stabilized. Its 
CD pattern has two minima at about 218 and 227 nm and a maximum at a wavelength lower 
than 205 nm. Due to the high absorbance associated with the solvent-mixture itself, it was not 
possible to extend these measurements beyond this value.  
NMR investigation of the peptide (–)-6 was performed in the non polar solvent CDCl3. 
Measuring the proton NMR at different temperatures it was possible to observe a splitting in 
some of the signals, especially in the case of some NHs. This decrease in temperature was 
probably responsible for the formation of a different rotamer (Figure 42). Further 
conformational investigations were carried out at 300 K. At this temperature the above 
phenomena became negligible and the best signal dispersion was seen.  
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COSY and TOCSY experiments were used to assign the chemical shifts of all the protons. A 
ROESY spectrum was then implemented in order to understand the connectivity of the amino 
acids in the sequence. Finally the non sequential interresidue contacts were found.  
Table 7 and Figure 42 show the medium range NOEs and some of the i,i+3 and i,i+4 
contacts found for this peptide in CDCl3 respectively.  
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Figure 42. Some Medium-range NOEs for the peptide (–)-6 in the ROESY spectra, in CDCl3. 
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Peptide Contacts  Contacts 
Ala1 HN ACC4 HG ACC6 HN ACC2 HB 
Ala1 HN ACC4 HN ACC6 HN ACC2 HG 
Ala1 HN Ala5 HA ACC6 HN ACC2 HA 
ACC2 HN Ala5 HA ACC6 HA ACC2 HB 
ACC2 HA ACC6 HG Ala7 HN Ala9 HA 
Ala3 HA ACC8 HA ACC8 HN ACC4 HA 
ACC4 HG Ala1 HG ACC8 HA ACC4 HB 
ACC4 HG Ala9 HG ACC8 HA ACC4 HG 
ACC4 HB Ala9 HG Ala9 HN Ala5 HA 
Ala5 HA ACC2 HA Ala9 HA Ala5 HG 
(-)-6 
Ala5 HA ACC2 HB 
 
 
 
Table 7. Medium-range NOEs for the peptide (–)-6 found in CDCl3. 
 
 
Temperature NH-1 NH-2 NH-3 NH-4 NH-5 NH-6 NH-7 NH-8 NH-9 
300 K 6.3851 7.7134 7.9819 7.0666 8.0781 6.9161 7.0878 7.6843 7.1376 
310 K 6.3356 7.6858 7.9198 7.0180 8.0084 6.8905 7.0180 7.6471 7.0797 
320 K 6.2797 7.6474 7.8533 6.9522 7.9346 6.8649 6.9522 7.6094 7.0194 
∆δ/∆T 
(ppb) -5.3 -3.3 -6.4 -5.7 -7.2 -2.6 -6.8 -3.7 -5.9 
 
Table 8. Temperature coefficients for the NHs in the nonapeptide (–)-6 in CDCl3. 
 
 
Temperature coefficients and the two dimensional NMR investigation suggested that a 
helical conformation was present. This probably involved a hydrogen bond NH→CO from 
the NH of the residue 2 in the same direction of the peptide chain. As well as a hydrogen 
bond CO←NH in the opposite direction from either the residue 6 or 8. It was also important 
to keep in mind that at a lower temperature than 300 K, a mixture of rotamers would be 
present. It is likely that chloroform is not able to stabilize the well defined structure, which 
was suggested by the CD investigations done using 1,2 dichloroethane and cyclohexane 
mixture.   
 
 
 
46              B. Model Peptides containing β-ACC units 
 
 
B.3.2 Alternated α-L-Ala/(+)β-ACC peptides 
 
Previous results by Zorn2 suggest that the β-ACC moiety is able to reside in a hydrogen-
bonded conformation in solution of dichloromethane as shown for the compound (±)-21 in 
Figure 43. The strong hydrogen-bond acceptor capability of a tertiary amide carbonyl 
overcomes the not optimal N-H--O geometry and allows the hydrogen-bond highlighted by 
the main absorption at 3364 cm-1. However, in the solid state this C6 conformation is no 
longer favoured, which became evident in the X-ray structure in Figure 43 (right).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. N-H stretching region FT-IR spectrum at 1 mM concentration in CH2Cl2 at r.t (left) and 
the crystal structure (right) for (±)-21.2 
 
 
Unfortunately, in this work it was not possible to obtain crystals of the longer peptides with 
incorporated β-ACC units. We could only measure the X-ray structure for the C-terminal 
deprotected (+)-11 dipeptide (Figure 44). From this data we could get no information on the 
conformational preference of the β-ACC, since the dipeptide has a extended spatial structure 
in a dimeric crystal packing with no intramolecular H-bond present. 
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Figure 44. Crystal structure of the C-terminal deprotected dipeptide Boc-L-Ala-(+)β-ACC-OH. 
 
The IR investigation of the amide A region of the heptapeptide (+)-5 being carried out in the 
non polar solvent dichloromethane is shown in Figure 45. The main absorption at 3296 cm-1 
suggested that the peptide should adopt a secondary structure in which almost all NHs are 
involved in an intramolecular H-bond. 
However this result was not confirmed in a polar solvent such as methanol.  
 
  
Figure 45. N-H stretching region FT-IR spectra for (+)-5 at 1 mM concentration in CH2Cl2 at r.t. 
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The conformation in methanol of the heptapeptide (+)-5a, having (+)-β-ACC unit 
incorporated in its sequence, is less well defined than the corresponding (–)-5a. Although a 
number of medium-range NOE correlations could be found in the spectra (Table 10) and 
structures of reasonable energy may be computed from the NMR data. A large number of 
cross peaks corresponding to non sequential distances smaller than 3.5 Å were actually 
missing in the NMR spectra. This indicates that the NOEs are not due to a single, 
predominant conformation but rather a set of conformers which rapidly interconvert on the 
NMR timescale. This view is supported by the magnitude of the vicinal HN, Hα coupling, 
which, for all the residues, except for the β-ACC in position 2, adopted values in the range of 
6-7 Hz (Table 9), indicating rotationally-averaged φ backbone angles.  
 
(+)-5a 3JHNα (Hz) (+)-6a 3JHNα (Hz) 
NH-2 4.6 NH-2 4.5 
NH-3 6.2 NH-3 5.3 
NH-4 6.3 NH-4 6.8 
NH-5 6.5 NH-5 5.8 
NH-6 7.2 NH-6 6.9 
NH-7 8.0 NH-7 6.3 
  NH-8 7.3 
  
 
NH-9 7.4 
 
Table 9. Vicinal coupling constants for HN, Hα in CD3OH for peptide (+)-5a and (+)-6a. 
 
 
Considering that most medium-range contacts were found in the first half of the sequence and 
that rather strong NOEs occurred between sequential amide protons, give rise to the 
conclusion that predominantly helical portions interconvert locally with extended 
conformations so that the full helix is unable to persist. This view is related to the observation 
that medium-range NOEs such as α(i),  β(i+3) correlations are required to distinguish stably-
folded α-helices from nascent helices.23 
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Peptides Contacts  Contacts 
ACC4 HB ACC2 HA Ala1 QB ACC4 HG 
ACC2 HB Ala5 HA Ala1 QB ACC4 HN 
 
(+)-5a 
ACC4 HG Ala7 HA 
 
  
    
Ala1 QB Ala3 HA ACC6 HG Ala9 HA 
ACC4 HG Ala7 HA ACC6 HA Ala9 QB 
ACC2 HG Ala5 HA ACC6 HG Ala9 QB 
Ala3 QB ACC6 HB ACC4 HG Ala7 QB 
 
(+)-6a 
Ala5 QB ACC2 HG 
 
  
 
Table 10. Medium-range NOEs found for the peptide containing the (+)-β-ACC unit. 
 
The CD spectra of these two peptides in different solvents are shown in Figure 46. Both 
peptides show a minima with different intensities at about 204-205 nm with the exception of 
a shoulder at around 223 nm in HFA. NMR investigation in methanol suggested that a set of 
conformers is present. Despite this, the conformation of these peptides was unaffected when 
the solvents was changed. The solvents in question were unable to stabilize one conformation 
with respect to another one. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. CD spectra of peptides (+)-5a and (+)-6a in different solvents. 
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B.3.3 Alternated α-L-Xaa/(–)-β-ACC peptide 
 
The trideca peptide (–)-7a was synthesized in order to investigate what effect the (–)-β-ACC 
unit elicits when contained in a longer α-/β-alternated peptide. Different α-amino acids were 
incorporated with the view to achieve a better understanding of the NMR signals. Two 
lysines were chosen to improve the solubility of the final peptide and three phenylalanine 
residues were introduced at positions 3, 7 and 11. In Figure 47 the positions 3 and 7 of the 
nonapeptide (–)-5a are highlighted. The side chains of the amino acids at these positions 
along the 313 helix, were discovered to be on the same side and aligned one over another. 
Phenylalanine in these positions should cause a stabilizing effect on the overall structure 
through phenyl ring stacking.  
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Upper and lateral view of the (–)-6a. 
 
As for the shorter peptides, all NMR investigations involving the trideca peptide (–)-7a were 
performed in methanol. The medium-range NOE cross-peaks are summarized in Table 11. In 
the N-terminus of the sequence only very weak helical contacts are present, while in the 
region from residue 4 along the all sequence, strong i,i+3 and i,i+4 contacts were found. 
Excepted for the N-terminus, NH(i)-NH(i+1); HA(i)-NH(i+1) and HB(i)-NH(i+1) contacts 
were seen for the Xaa-ACC segment and HA(i)-NH(i+1) and HB(i)-NH(i+1) were seen for 
the ACC-Xaa segment along the entire length of the sequence. These findings provide strong 
evidence for the presence of a helical conformation. 
 
ca. 4-5 Å  
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Peptide Contacts  Contacts 
Lys1 QB ACC4 HG Ala5 QB ACC8 HA 
Lys1 QG ACC4 HG Ala5 QB ACC8 HG 
Lys1 QD ACC4 HG Ala5 QB Lys9 HA 
ACC2 HN Ala5 HA ACC6 HN ACC8 HN 
Phe3 HN ACC6 HG ACC6 HB ACC8 HN 
Phe3 HA Ala5 QB ACC8 HN ACC12 HN 
Phe3 HA Phe7 HA ACC8 HA ACC12 HG 
ACC4 HN ACC6 HN Lys9 QB Ala13 HA  
ACC4 HN Phe7 HA Lys9 QB ACC12 HG 
Ala5 HA Phe7 HN Lys9 QB Ala13 HN 
Ala5 QB Phe7 HN Lys9 QB Ala13 HA 
(-)-7a 
Ala5 QB ACC8 HN 
 
ACC10 HN Ala13 HA 
 
Table 11. Medium-range NOE cross-peaks found for peptide (–)-7a. 
 
The structure calculated with DYANA shows a helical conformation which is well defined 
from residue 4. The N-terminal part remains partially unfolded as displayed in Figure 48.  
 
 
 
 
 
 
 
 
 
 
 
Figure 48.  Lateral view (left) and the sausage display (right) of backbone atoms of 10 minimized 
superimposed structures. In both representation, the β-ACCs at position 6, 8, 10 and 12 are shown. 
 
The instability of the secondary structure in methanol is probably due to the N-terminal 
deprotonated Lys1. The presence of two positive charges does not allow the peptide to 
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undergo folding. Changes in the ionization degree of the peptides could affect inter-residual 
interactions and thereby cause conformational changes. CD studies confirmed that some 
conformational changes occur depending on the solvent or in the case of water solution, on 
the pH. 
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Figure 49. CD spectra of (–)-7a in methanol and in water at different pH. 
 
The CD spectrum performed in methanol shows two bands of virtually the same intensity at 
about 205 and 212 nm (Figure 49). When the peptide was in a water solution, the relative 
intensities of the two bands were found to change, depending on the pH of the solution. At an 
acidic pH value the negative Cotton effect at ca. 205 nm became more relevant. NMR 
investigation in acetate buffer highlighted a destabilization of the secondary structure found 
in methanol, thus, supporting the idea that the two proximal positive charges at the N-
terminus were responsible for the observed instability.  
The CD spectrum of this peptide cannot be compared directly to those of the shorter 
alternated α-L-Ala/β-ACC peptides, due to the presence of the phenylalanine residues. Three 
phenilalanine in thirteen total residues represent the 23 % of aromatic amino acids in the 
sequence. Moreover the position of these residues was chosen so as to give stacking in a 313 
helix.  
In most cases values below 260 nm in a CD spectrum are predominantly governed by the 
amide chromophore, but the environment of the aromatic residues is also particularly 
important in determining the extent of their contributions. Strong coupling between aromatic 
transitions can occur if two or more aromatic rings are in close proximity. In proteins such 
interactions are more important in determining the aromatic CD than the number of aromatic 
B. Model Peptides containing β-ACC units  53 
rings.27 Calculations performed by Sreerama et al. showed that the phenylalanine transitions 
occurred at around 257 nm (Lb transition), 208 nm (La transition), and 188 nm (B transition). 
The latter is the strongest one because it couples strongly with the peptide transition. In many 
proteins with aromatic residues, a positive interfering band is also found at around 224 nm 28. 
In this case the transition B could have been the reason why there is no minima at 200 nm, 
expected for the turn-helix structure found in the shorter peptides. However the sensitivity of 
CD techniques to the relative orientations of the aromatic side chains is very high. Different 
orientations or various arrangements of the aromatic rings in the three-dimensional structure, 
leads to different CD spectra.27  
The helix-promoting solvent TFE, as already found for peptide (–)-5a and (–)-6a, does not 
stabilize any secondary structure. The CD pattern remains almost the same as in methanol but 
with a lower intensity probably due to an aggregation phenomena.  
 
 
 
 
 
 
 
 
 
 
Figure 50. CD spectra of (–)-7a in different solvents. 
 
In HFA the intensity of the negative band at 212 nm increases and a positive Cotton effect 
was observed around 224 nm (Figure 50). In water, under basic conditions, a negative Cotton 
effect at around 212 nm was seen to become more intense. While another band displaying a 
negative Cotton effect at around 224 nm was formed as shown in Figure 51.  
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Figure 51. CD spectra of (–)-7a in water (pH=8) and in HFA. 
 
The larger intensities of the CD spectra seen in HFA and in TRIS buffer could have been 
attributed to the presence of the phenylalanines. Different solvents could affect the solvation 
of the aromatic rings, possibly promoting aromatic ring stacking29, and leading to different 
CD patterns. 
Even for the β-peptides, a class which has been extensively studied, no clearly and 
unambiguously CD-“fingerprints” for certain secondary structure is yet possible.30 A lot of 
work still has to be done in this area in order to achieve a complete understanding of the CD 
spectra of α-/β-alternated peptides.  
All CD spectra for peptide (–)-7, even if not shown, were recorded from 190 or 200 nm to 
260 nm, depending on the solvents absorbance. The samples in methanol and in water at pH 
= 8.5 were also investigated in the near UV, from 260 to 300 nm and no bands could be 
detected in this part of the spectra.  
The IR spectra of the Amide I region in methanol presented new absorptions at about 1675 
cm-1, compared to the spectrum found for the nonapeptide (–)-6a in the same solvent. The 
presence of an additional phenyl ring and the protonated amino functions of lysine could not 
affect this region, since the absorbance of these two groups are found at lower values.13 
Therefore the absorbance at ca. 1675 cm-1 in the Amide I region could have arisen from the 
contributions of the conformationally unfolded N-terminus. 
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Figure 52. IR spectra in the Amide I region of the nonapeptide (–)-6a and the trideca peptide (–)-7a 
measured in methanol. 
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C.1 RGD-Analogues  
 
C.1.1 Introduction 
 
Cell adhesion is crucial for the three-dimensional tissue architecture of animals. The 
functional units mediating cell adhesion are multiprotein complexes arising by interaction of 
three general classes of proteins: the cell adhesion receptors, the extracellular matrix (ECM) 
proteins and the adhesion plaque proteins.1 
The cell adhesion receptors determine the specificity of cell-cell and cell-ECM recognition.2 
They are typically transmembrane glycoproteins that mediate binding to the components of 
the ECM or to counter-receptors on other neighboring cells. ECM proteins are usually large 
glycoproteins, including the collagens, fibronectins, laminins, and proteoglycans that 
assemble into fibrils or other complex macromolecular systems. The intracellular plaque 
proteins (or peripheral membrane proteins) provide structural and functional linkages 
between the adhesion systems and the cytoskeleton and transduce signals initiated on the cell 
surface by the adhesion receptors.1 
 
 
Figure 53. Overview of the macromolecular organization responsible for cell-cell and cell-matrix 
adhesions.3 
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Cell adhesion receptors include selectins, immunoglobulins, cadherins and integrins. In 
particular, integrins are involved in cell-cell adhesion processes and are the most important 
family of adhesion receptors that attach cells to their extracellular microenviroment.4 They 
are a class of heterodimeric transmembrane cell surface receptors made up of an α-subunit 
and a β-subunit. Each subunit presents a large extracellular domain, a single membrane-
spanning region and, in most cases, a short cytoplasmatic domain.2 Multiple combinations of 
the different 16 α- and 8 β-subunits lead to ligand binding specificity and different biological 
function of the distinct receptors.5 The α and β chains are both involved in ligand recognition. 
Common sequences in integrin ligands are found to be critical for the recognition by most 
integrins. A exposed aspartic acid or glutamic acid residue is required. Typical integrin-
recognition are for example RGD, LDV, RDL and KQAGDV sequences (Table 12).6  
 
Sequence Integrin 
RGD α5β1, α8β1, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, 
αIIbβ3, α2β1, α3β1, α4β1, α7β1, 
KQAGDV α5β1, αIIbβ3 
LDV α5β1, α4β1 
RLD αvβ3, αMβ2 
 
Table 12. Some typical integrin-recognition sequence. 
 
Each integrin can bind a number of divalent cations, including Ca2+, Mg2+ and Mn2+. Bound 
cations exert significant effects on integrin function. They can act as effectors, promoting 
ligand binding; as antagonists, inhibiting ligand binding or selectors, changing the ligand 
binding specificity. This influential role of the cations is explained by a probable sharing of a 
common binding pocket on the integrin with the ligand.7 The glutamic acid or aspartic acid in 
ligands form a ternary complex with the receptor-bound divalent cations.  
The concentration of the divalent cations could have a regulation effect in vivo, given that 
Mg2+ and Mn2+ support physiological ligand binding at a broad range of concentrations while 
Ca2+ does so only at micromolar range. A millimolar concentrations of Ca2+ (as generally 
present in the plasma) is generally inhibitory for the integrin-ligand binding, increasing the 
rate of ligand dissociation.8 For example the adhesion of the osteoclast to the bone surface, 
mediated by αVβ3, must be tightly regulated to prevent excessive resorption. The regulation is 
controlled by the concentration of free Ca2+, that increase beneath the osteoclast when 
mineralized bone is resorbed, inducing the detachment of the osteoclast with following 
cessation of resorption.7  
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Cell adhesion complexes are dynamic entities and are regulated by a two-way signaling 
system between the cell and its external environment.  
Most integrins are present on the cell surface in the inactive form. Events within the cell can 
alter the conformation of the cytoplasmic domains. Conformational changes are then 
propagated through the molecule, increasing the integrin’s affinity for an extracellular ligand. 
This “inside-out” regulation of integrin affinity protects the host from pathological integrin-
mediated adhesion.4 
Apart from cell-cell and cell-ECM recognition, integrins are involved in fundamental cellular 
processes such as migration, proliferation, differentiation and survival and contribute to the 
initiation and/or progression of many diseases including neoplasia, tumor metastasis, immune 
dysfunction and osteoporosis.9 They are implicated in an “outside-in” signaling allowing the 
transmission of signals from the external environment to the cell interior.4 In these cases the 
binding of a ligand to the receptor extracellular domain induces conformational changes at 
the cytoplasmic end alterating the interaction of the integrin with the cytoplasmic proteins 
and a signal transduction cascade can be initiated.4   
 
Integrins are involved in a variety of physiological and pathophysiological events and 
therefore are potential important pharmaceutical target. The integrin αIIbβ3, for instance, 
mediates the aggregation of platelet, antagonists to this receptor are effective antithrombotics. 
The α2β1 is a receptor for collagen and laminin and it is required for the arrest of platelets 
under conditions of blood flow on the collagen fiber surface exposed as a consequence of 
injury.10 In particular, αVβ3 integrin is found to be involved in  apoptosis, tumor growth, 
metastasis, control of bone density, and in general, αV-integrins seems to be essential during 
angiogenesis and blood vessel formation and/or maturation in these tissues.11,12 
Recent studies have been focused the attention on anti-angiogenesis products as tumor 
treatment. When a solid tumor reaches a certain size and mass, it needs new blood 
vasculature to grow more, therefore it releases specific growth factors which stimulates the 
growth of new blood vessels. Several αVβ3 antagonists, such as Vitaxin13, a monoclonal 
antibody antagonist of αVβ3 now in Phase II, have been already found to perturb the growth 
and/or maturation of new blood vessels without detectably influencing the preexisting ones. 
In tumor models, not only tumor associated angiogenesis is blocked, but in some cases tumor 
regression is observed.11  
A schema of the integrin αvβ3 is outlined in Figure 54. 
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Figure 54. Schematic representation14 of the integrin dimer αvβ3 (left), and the formula of the RGD 
sequence (right). 
 
Integrins are grouped into two classes based on the presence or absence of an extracellular A-
type domain. This so called αA domain is involved in the ligand interaction. A metal ion is 
coordinated at the ligand-binding interface of αA through a conserved five amino acid motif, 
the Metal Ion-Dependent Adhesion Site (MIDAS), and the metal coordination is completed 
by the ligand. In αA-lacking integrins, ligand recognition requires an αA-like domain (βA) 
present in all integrin β subunits.15 
The αVβ3 integrin is a αA-lacking integrin consisting of 12 domains assembled into a ovoid 
head and two “legs”.15 
The tripeptide Arg-Gly-Asp is the most common sequence motif that is recognized by 
integrins. RGD-containing proteins that interact with integrins are for instance fibronectin, 
vitronectin, fibrinogen, von Willebrand factor, thrombospondin, laminin, entactin, tenascin, 
osteopontin, bone sialoprotein and, under some conditions, collagens.6 Interestingly the RGD 
sequence is also used by bacteria, viruses and yeasts to get into the host cell.16   
The orientation of the Arg and Asp side chains and of the amide groups adjacent to Gly plays 
an important role for the recognition. The protein places conformational constrains on the 
pharmacophoric group Arg-Gly-Asp leading to the distinct orientation of the functional 
groups. 17  
The crystal structure15 of the extracellular segment of αVβ3 in complex with a RGD ligand, 
the pentapeptide c(Arg-Gly-Asp-D-Phe-N(Me)Val), reveals that the ligand is in a crevice 
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between the propeller and βA domain on the integrin head. Each residue of the RGD 
sequence participates extensively in the interaction. The Arg and Asp side chains point in the 
opposite directions, exclusively contacting the propeller and βA domain, respectively. The 
remaining two residues face away from the αβ interface. Tertiary and quaternary changes in 
the integrin structure are observed. The “liganded” structure, compared to the “unliganded” 
one, held two Mn2+ more. One is in the MIDAS and the second one is near the MIDAS, into 
the so called Ligand-Associated Metal Binding Site (LIMBS). The coordination sphere for 
LIMBS does not exist in the “unliganded” complex. LIMBS does not contact directly the 
ligand but adds conformational stability and structural rigidity to the ligand-binding surface.15  
 
 
 
 
 
 
 
 
 
 
Figure 55.  The ligand-integrin binding site from ref. 15. Left: surface representation of the ligand-
binding site with the ligand peptide shown as ball-and-stick model in yellow. Right: the interactions 
between ligand and integrin. αV and β3 residues are labelled blue and red, respectively. The 
Mn2+ ions in β3 at MIDAS and LIMBS are shown as cyan and grey, respectively.   
 
 
The finding that short RGD containing peptides could lead to the same effect observed with 
large ligands has intensified the search for selective small molecules as pharmacological 
tools. In linear peptides, the nature of residues flanking the RGD sequence highly influences 
receptor affinity and receptor selectivity, especially on the C-terminal side.6  
However, cyclic peptides are generally much more potent and more specific than their linear 
counterparts. The cyclization induces a specific conformation on the RGD sequence leading 
to higher receptor specificity.16  
Several cyclic RGD peptides were synthesized in the last years as fibrinogen receptor (αIIbβ3) 
antagonists or as αVβ3 integrin antagonists for treatment of human tumors, bone remodelling, 
osteoporosis, diabetic retinopathy or acute renal failure.16 
62               C. β-ACC units into Biologically Active α-Peptides 
 
 
The conformational preferences of a D-amino acid in cyclic peptides consisting of L-amino 
acids allowed the synthesis of biological active analogues. The hexapeptide c(Arg-Gly-Asp-
D-Phe-Val-Gly) efficiently inhibits the binding of fibrinogen to the integrin αIIbβ3, while the 
cyclic pentapeptide c(Arg-Gly-Asp-D-Phe-Val) led to nanomolar IC50 values at αVβ3 
integrin.18 Kessler et al. further investigated the latter peptide by creating the retro-inverso 
isomers or by introducing the corresponding N-methylated amino acids.17,19 The N-
methylation scan led to the peptide c(Arg-Gly-Asp-D-Phe-N(Me)Val) with biological 
activity in the subnanomolar range and increasing metabolic stability, being currently in 
clinical studies as drug against Kaposi’s sarcoma, brain tumors and solid tumor by Merck 
KGaA, Darmstadt.  
Recently, it was also found that a selective inhibition of the integrin receptors αVβ3 and αVβ5  
through an antagonist such as c(Arg-Gly-Asp-D-Phe-Val) is able to inhibit retinal pigmented 
epithelial (RPE) cell attachment, migration and invasion.20 These steps are important for the 
progression of proliferative vitreoretinopathy (PVR) suggesting the use of cyclic integrin 
antagonists as possible treatment of this disease. 
Structure activity relationship studies on RGD peptides suggest that the interaction with αVβ3 
integrin requires a kinked structure of the RGD fragment compare to a more stretched 
structure required from the αIIbβ3 integrin. Many cyclic peptides display a high selectivity to 
the vitronectin receptor if the RGD fragment occupies the positions i to i+2 of a regular γ-
turn.  
The tetrapeptide c(Arg-Gly-Asp-D-β-hPhe) synthesized by Sewald et al. is a selective αVβ3  
antagonist and the β-amino acid acts as a pseudo γ-turn inducer. 21 
Nevertheless, the difference between the binding conformations for the αIIbβ3 or αVβ3 integrin 
receptors is probably very small.17 The introduction of the β-turn mimic dipeptide isosteric 
pyranoid δ-SAA in the peptide 22 (Figure 56) led to a loss of selectivity. The peptide shows 
good affinity to both αIIbβ3 and αVβ3 integrins probably due to a more flexible structure that is 
able to assume both binding conformations for the two different receptors.22 
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Figure 56. Formula of the peptide c(Arg-Gly-Asp-β-SAA(Bn)3) containing a sugar amino acid unit 
and of the αIIbβ3 antagonist c(D-Abu-N(Me)Arg-Gly-Asp-Mamb). 
 
The peptide c(D-Abu-N(Me)Arg-Gly-Asp-Mamb) shown in Figure 56 has a high affinity to 
αIIbβ3 integrin receptor.23 Conformational investigation found a type II’ β-turn centered at the 
D-Abu-N(Me)Arg dipeptide as expected for a dipeptide consisting of a D-amino acid 
followed by a Nα-methylamino acid. Replacement of the D-Abu-N(Me)Arg dipeptide with L-
Ala-L-Arg or L-Pro-L-Arg resulted in a striking reversal of the selectivity.24 These peptides 
have high affinity and selectivity to αVβ3 and NMR investigation evidences a shift from a 
type II’ to a type I β-turn centered at the dipeptide L-Ala-L-Arg or L-Pro-L-Arg. The spatial 
relationship of the Arg and Asp side chains in the αVβ3 antagonist resulted in a closer 
approach compared to a αIIbβ3 integrin ligand even if the Arg-Gly-Asp segment does not 
occupy a regular γ-turn.   
In Table 13 are summarized the IC50 values of some integrin active peptides found in 
literature.  
 
Peptide Sequence αIIbβ3 
IC50 (nM) 
αVβ3 
IC50 (nM) 
24 c(Arg-Gly-Asp-D-Phe-N(Me)Val) 860 0.58 
25 c(Arg-Gly-Asp-D-β-hPhe) >300 63 
22 c(Arg-Gly-Asp-β-SAA(Bn)3) 13.4 25 
23 c(D-Abu-N(Me)Arg-Gly-Asp-Mamb) 2 500 
26 c(L-Ala-Arg-Gly-Asp-Mamb) 18000 20 
27 c(L-Pro-Arg-Gly-Asp-Mamb) 45000 13 
 
Table 13. IC50 values of some integrin active peptides found in literature. 
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C.1.2 RGD peptides containing β-ACC units 
 
Different building blocks were used to induce the spatial requirements of the pharmacophore 
RGD with the aim to yield high affinity and selectivity to integrin receptors. α-Amino acids 
such as proline, D-amino acids, N-methylated analogues and other structures, such as sugar 
amino acids, β-, γ-, δ- amino acids etc. were introduced. 
 
Accordingly, with the promising results obtained with the cyclopeptide c(Arg-Gly-Asp-(±)-
βACC-Val) containing β-ACC14 as racemate, the corresponding peptides with the 
enantiomerically pure β-ACCs were synthesized and tested in collaboration with the group of 
Prof. Sewald at the University of Bielefeld. 
The β-ACC units were introduced as dipeptide building blocks Fmoc-Asp(OtBu)-β-ACC-OH 
on the solid phase. Using the 2-chlorotrityl chloride resin the protected linear precursors were 
obtained. The peptides were then cyclized in solution under pseudo high dilution conditions 
using a dual syringe pump to avoid dimerization.25 After cleavage of the side chain protecting 
groups the peptides were purified by RP-HPLC and characterized using MALDI-TOF MS 
and NMR techniques. 
The biological activity of the peptides was investigated choosing the cyclic pentapeptide 
c(Arg-Gly-Asp-D-Phe-Val) as reference. Table 14 summarizes the results obtained 
measuring the ability of the RGD peptides to inhibit the binding of vitronectin to the αvβ3 
integrin receptor expressed on human melanoma skin cells. 
 
 
Peptide Sequence αVβ3 
IC50 (nM) 
(–)-28 c(Arg-Gly-Asp-(–)-βACC-Val) 630 
(+)-28 c(Arg-Gly-Asp-(+)-βACC-Val) 21 
29 c(Arg-Gly-Asp-D-Phe-Val) 197 
 
Table 14. Biological results obtained with cyclic peptides containing β-ACC units using human 
melanoma skin cells and vitronectin. 
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Combining their conformational bias and their already mentioned proteolitic stability, β-
amino acids are potential interesting building blocks to create small bioactive α-peptide 
analogues with a predictable conformation. 
Different non cyclic β-amino acids incorporated by Sewald et al. into cyclic peptides act as a 
turn mimetic, adopting a pseudo γ-turn conformation.21 The dipeptide R-nipecotic acid-S-
nipecotic acid incorporated into an enzyme mimic in the position of a β-turn is able to mimic 
the β-turn maintaining unchanged the enzyme activity.26 2-Amino cyclohexane carboxylic 
acids into cyclic penta- and hexapeptides are found in pseudo γ-turn conformation but also in 
β-turns, in particular the cis-stereoisomer is predominantly found in the position i of different 
β-turns.27 
As already described in the Chapter B, β-ACC units have been found to induce helical 
conformations in peptides containing more than one β-ACC units in an alternated mode. The 
conformational preference induced by a single β-ACC moiety in an α-peptide, especially in 
cyclic peptides, is still under investigation.  
 
NMR investigations on the most active peptide (+)-28 show the Arg-Gly-Asp segment in the 
positions i to i+2 of a type II’ β-turn in which the (+) β-ACC moiety occupies the position 
i+3 (Figure 57). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57. NMR structure found for the peptide (+)-28. 
 
 
66               C. β-ACC units into Biologically Active α-Peptides 
 
Further work is currently in progress to explore the selectivity of the β-ACC containing RGD 
peptides for their possible use as pharmacological tools and to further investigate the 
conformational bias of β-ACCs. Further knowledge could probably establish general 
principles for their application as a building block able to induce a reproducible conformation 
in small cyclic α-peptides analogues. 
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C.2 Conformational investigation on a β-ACC containing NPY analogue 
 
C.2.1 Introduction 
 
Neuropeptide Y (NPY) is one of the most abundant neuropeptide in the brain and was first 
isolated in the porcine brain.28 It is a member of a peptide family consisting of NPY, peptide 
YY (PYY) and pancreatic polypeptide (PP). All three peptides consist of 36 residues, have a 
high content of tyrosine residues and are C-terminally amidated. PP and PYY are mainly 
synthesized and released by intestinal and pancreatic cells. NPY is localized in the nervous 
system, high level are detected in the cerebral cortex. Peripherally, it is abundant in the 
sympathetic nervous system and it is also expressed in liver, heart spleen and in endothelial 
cells of blood vessels.29  
 
hNPY YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 
hPYY YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2 
hPP APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 
 
Figure 58. Amino acid sequences of human NPY (hNPY), human peptide YY (hPYY), and human 
pancreatic polypeptide (hPP). 
 
PP has found to have a hairpin-like three-dimensional structure (Figure 59, right), the so 
called PP-fold. A type II β-turn connects a polyproline-like type II helix (residues 1 to 9) to 
an amphiphilic α-helix (residues 14 to 30). The C-terminal end is a flexible turn projecting 
away from the hairpin loop.30 
Based on the high sequence homology, this secondary structure was assumed to be common 
to the whole NPY family peptides.  
 
Although NPY is thought to be entirely monomeric at physiological conditions, recent NMR 
studies show a dimeric NPY structure at high concentrations, in which the C-terminal part of 
the peptide (residues 14-36) adopts an α-helical conformation which is stabilized in the dimer 
by intermolecular hydrophobic interactions and there is no polyproline helix on the N-
terminus. Decrease of the concentration shift the dimerization equilibrium towards the 
monomeric form of NPY in which the N-terminus remain unfolded (residues 1-13).31 In 
Figure 59 a comparison between the two structures is shown. 
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Figure 59: Comparison of structures of NPY (left) bound to micelles and the typical PP-fold (right) 
of the bovine pancreatic polypeptide.32 
 
NPY performs its biological activity through the interaction with different heptahelical G-
protein-coupled receptors, the so called Y receptors that belong to a rhodopsin like 
superfamily (class 1) of G-protein-coupled receptors.  
Five distinct subtypes of NPY receptor have been cloned in mammals, Y1, Y2, Y4, Y5 and y6. 
These can be sorted into three distinct subfamilies based upon their degree of amino acid 
sequence identity. The subfamilies are Y1, Y2 and Y5 from their first member. These three 
receptors differ more from each other than any other G-protein-coupled receptors that can 
respond to the same peptide ligand. The Y1 subfamily includes the Y1, Y4 and y6.33 An 
additional putative receptor Y3 has been pharmacologically described but it has not been 
cloned and no specific agonists and antagonists are known. In primates the y6 receptor has 
not been found although its mRNA is present in several human tissues. Its gene may have 
become non functional during evolution.34 
NPY and PYY have high affinity to Y1, Y2 and Y5 receptor subtypes, the Y4 is the PP-
preferring receptor.35  
NPY is able to bind equally potently different receptor subtypes. The conformation of the 
peptide is probably enough flexible to allow more than one energetically favourable structure 
induced by different receptors, and it is likely that at concentrations at which hNPY is found 
to be active in vivo, it adops the monomer form with the PP-fold required for the receptor 
interaction.36  
C 
N 
C 
N 
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NMR investigations on NPY in the presence of micelles, produced with the predominant 
phospholipid in animal cell membranes, the zwitterionic detergent phosphatidylcholine, show 
that the NPY could interact with the cell membrane before the receptor recognition.37,38 NPY 
associates to DPC-micelles mainly through hydrophobic interactions which stabilized the α-
helical conformation at the C-terminus of the monomer. The N-terminus remains flexible and 
does not interact with the micelles (Figure 59, left).  
The pre-adsorption of the ligand to the cell membrane increases the effective peptide 
concentration in vicinity of the receptor and special conformations may be induced. Through 
two-dimensional diffusion on the cell membrane surface the peptide will be recognized from 
the receptor. In the case of NPY it is so far unclear how the secondary and the tertiary 
structure change into the bioactive conformation for the interaction to the corresponding 
receptor subtype. 
 
 
 Y1 Y2 Y4 Y5 
 
Preferred 
endogenous 
ligand 
NPY, PYY 
NPY, PYY, 
NPY(3-36), 
PYY(3-36) 
PP 
NPY, PYY, 
NPY(3-36), 
PYY(3-36) 
Expression 
profile 
Celebral cortex, 
thalamus, brain 
stem, smooth 
muscle of blood 
vessels 
 
Hippocampus, 
brain stem nuclei, 
hypothalamus, 
gastrointestinal 
tract, smooth 
muscle of blood 
vessels 
 
Colon, small 
intestine, 
prostate, very low 
in brain, 
paraventricular 
hypothalamus, 
interpeduncolar 
nucleus 
Hippocampus, 
plexiform cortex of 
the olfactory bulb, 
suprachiasmatic 
and acrcuate 
nuclei 
Physiological 
function 
Vasoconstriction, 
regulation of food 
intake, anxiety-
related 
behaviours, 
regulation of 
transmitter 
release, circadian 
rhythms 
 
Inhibition of 
glutamate 
release, inhibition 
of noradrenaline 
release, learning 
and memory, 
circadian rhythms 
 
Possible in 
regulation of LH 
secretion 
Possible 
regulation of food 
intake, circadian 
rhythms 
 
 
Table 15: Binding preferences, distribution and physiological functions of the NPY human-receptors. 
Adapted from ref. 39. 
 
NPY is involved in several physiological functions including stimulation of feeding, 
regulation of blood pressure, anxiety and related behaviours, stress, depression, circadian 
rhythms, memory and learning processes.40 
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It is not fully clear yet, which NPY receptor subtype regulate each function. Tabelle 15 
summarizes physiological functions of the NPY human-receptors. 
Studies using selective agonists and antagonists and knockout mice suggest that Y2 receptor 
subtype facilitate learning and memory41, it is involved in energy homeostasis, in body 
weight regulation,42 it may play a role in the regulation of bone formation43, and it play an 
important role in diabetic retinopathy and retinal neovascularization.44 
About physiological roles of the Y4 receptor subtype there are limited informations. It is 
probably involved in LH secretion45 and it may inhibit reproductive function.46 
The Y5 subtype can play a key role in regulating energy homeostasis. A chronic activation of 
this subtype produces hyperphagia and obesity probably due to metabolic changes.47 [D-
Trp34]NPY and [Ala31, Aib32] NPY, that are selective for this receptor subtype, shown that Y5 
is also involved in feeding behaviour.48 The Ala-Aib substitution induced a 310-helical turn at 
the C-terminus which seems to be the key motif for Y5 selectivity. 
The Y1 receptor subtype was the first Y receptor cloned.49 Strong evidences support the 
involvement of the NPY Y1 receptor subtype in the regulation of blood pressure, regulation 
of anxiety, and in feeding behaviour.50,51 Y1 antagonists might be useful for treatment of 
obesity.52 
Moreover recent investigations showed that the Y1 and Y2 subtypes can play an important 
role in different tumors.53  
Y1 receptor subtype is expressed in breast carcinomas, moreover the addition of NPY to Y1-
expressing human SK-N-MC tumor cells inhibit the cell growth suggesting a potential 
antiproliferation effect of NPY mediated by Y1 subtype receptor.54 NPY receptors are 
therefore potential new molecular target for diagnosis and therapy of several cancers, and 
specifically radiolabelled NPY analogues could be used as tumor imaging agents.55 
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Figure 60: Examples of non-peptidic Y1 selective antagonists.56 
 
The finding of peptidic ligands that adopt a particular secondary structure becoming selective 
to one receptor subtype allows to understand the bioactive conformation of the NPY at this 
subtype and is a useful tool for the further development of selective ligands.  
Structure-affinity and structure-activity relationship studies of NPY analogues suggest that 
the C-terminal part (residues 27-36) of the NPY is the key interaction site with the receptor. 
In particular the replacement of the arginine residue at positions 35 by alanine provoke 
complete loss of affinity at all receptor subtypes. The replacement of the arginine residue 33 
is not tolerated at Y1 and Y4 and decreases the affinity at the Y2 and Y5.57 
The introduction of conformationally constraining amino acids, cyclisation or other backbone 
modification that stabilized particular conformations can provoke selectivity to one receptor 
subtype if the conformation that is induced is the conformation required from this receptor 
subtype recognition.58  
One characteristic property of the Y1-receptor is that it seemed to require the intact length of 
NPY or PYY. The truncation of the peptides leads to rapid loss of affinity. Even the C-
terminal tyrosineamide is important for the affinity to this receptor subtype.59 
Selective peptide agonists were obtain by introduction of turn inducing element at the C-
terminal such as Pro in position 34 in the full length NPY. [Phe7,Pro34]-pNPY and 
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[Arg6,Pro34]-pNPY show a good affinity and selectivity to the Y1 subtype.60 Also the 
substitution with the corresponding D-amino acid at either position 25 or 26 of NPY, [D-
Arg25]-NPY, [D-His26]-NPY and the shorter cyclic Pro34-analogue Des-AA11-18[Cys7,21, D-
Lys9(Ac), D-His26, Pro34]-NPY, results in good selectivity.61 
The cyclic peptide c[D-Cys29-L-Cys34]NPY Ac-29-36, that mimic the C-terminal part of 
hNPY, exhibit high affinity and selectivity for the Y1 subtype showing that the lack of the N-
terminal part of the NPY is not required, as previously thought, at least for the binding to this 
subtype (Figure 61).62 
 
 
Tyr36
Arg35
Arg33
 
 
Figure 61. The modelled structure for the cyclic peptide c[D-Cys29-L-Cys34]NPY Ac-29-36, that 
mimic the C-terminal part of hNPY, exhibit high affinity and selectivity for the Y1 subtype. Adapted 
from Ref.62. 
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C.2.2 NPY analogues containing β-ACC units 
 
The introduction of a (+)-βACC moiety leads to dodecapeptide NPY analogues that present 
high selectivity to the Y1 receptor subtype. The two enantiomers of β-ACC were introduced 
in the C-terminus (residues 25-36) of the NPY in position 32 and/or 34.63 Depending on the 
position of the substitution and the absolute configuration of the respective β-ACC derivate, 
these short NPY analogues present good affinity and good selectivity to the Y1 receptor 
subtype. Table 16  reports the most active peptides found. 
 
Peptide Sequence Y1 
 
Y2 
Ki (nM) 
Y5 
 
Selectivity 
Y1:Y5 
34 NPYa 0.52(±0.02) 0.23(±0.02) 2.21(±0.03) 1:2 
35 Ac-RHYINLITRQRY-NH2 >1000 21 >1000 N/A 
36 Ac-RHYINL-IT-R▲RY-NH2 37(±20) >1000 724 1:20 
37 Ac-RHYINL-IT-R▼RY-NH2 >1000 >1000 >1000 N/A 
38 Ac-RHYINLI▲RQRY-NH2 >1000 >1000 >1000 N/A 
39 Ac-RHYINLI▼RQRY-NH2 >1000 >1000 >1000 N/A 
40 Ac-RHYINL-I▲-R▲RY-NH2 50(±10) >1000 617 1:12 
41 Ac-RHYINL-R▲-R▲RY-NH2 29(±13) >1000 118 1:4 
 
Table 16. Representative β-ACC containing NPY analogues (where ▲=(+)β-ACC; ▼=(–)βACC) 
tested by Koglin et al.63 (a Data from Ref. 64) 
 
The truncated peptide 35, having the native sequence of NPY, shows no affinity for Y1 or Y5. 
The replacement of a single residue, in position 34, with (+)-configurated β-ACC (peptide 
36) leads to a nanomolar biological affinity at the Y1-receptor with high selectivity. The 
absolute configuration of the β-ACC moiety plays a crucial role in the affinity since the 
peptide 37 with the (–)-configurated β-ACC in the same position is biologically inactive. The 
substitution with β-ACC only in position 32 (peptides 38 and 39) are inactive in both 
configurations, identifying the introduction of a turn-inducing residue in position 34 as 
crucial for selectivity at the Y1-receptor. The introduction of two (+)-configurated β-ACC 
moieties, in positions 32 and 34, (peptide 40) leads to significant affinity for Y5, probably due 
to a more helical conformation on the C-terminus, a structural feature being found in α-,β-
peptide sequences, with cyclic β-amino acids65 and especially with β-ACC residues, as 
described in Chapter B. As seen with peptide 41, a successive replacement of the Ile31 with 
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arginine increases further the Y5 affinity probably due to a new ionic interaction of the 
arginine side chain with the Y5 receptor. 
Accordingly, the conformation of the most selective of these NPY analogues which contain 
the (+)-configuration β-ACC-moiety in position 34 (Figure 62) was investigated in water in 
the presence of dodecylphosphocholine micelles as a model of the cell membrane using 
NMR spectroscopy.66  
 
 
 
 
 
 
 
 
Figure 62. NPY analogue containing (+) β-ACC, peptide 36, synthesized and investigated. 
 
The determination of the conformation in the presence of a membrane mimetic reveals 
information about the secondary structure of the membrane-bound species that is recognized 
by the receptor.  
The peptides was synthesized by solid-phase technique on Rink amide resin by using the 
orthogonal Fmoc/tBu strategy. The enantiomeric pure (+)-β-ACC was introduced in the 
growing peptide chain as dipeptide building block Fmoc-Arg(Pmc)-(+)-β-ACC-OH, (+)-18a, 
after activation by manual coupling as described by Koglin et al.63 The subsequent elongation 
was achieved by automated coupling steps. After cleavage from the resin and removal of the 
protecting groups by using TFA, the peptides were purified by preparative HPLC on a RP C-
18 column. The peptide was analyzed by MALDI-TOF mass spectrometry, which confirmed 
the intact cyclopropyl ring system, and by analytical reversed phase HPLC. 
The NMR assignments were made according to the sequence-specific sequential resonance 
assignment procedure as described in Chapter B, using COSY, TOCSY and NOESY 
experiments with the support of the XEASY software package.67 
 
The one-dimensional NMR spectrum of (+)-β-ACC34-NPY (25-36) displays good dispersion 
of amide proton chemical shifts indicating that the peptide is folded to some extent. 
 
H
N
N
H
H
N
N
H
CONH2
CO2Me
O
O
O
OH
N
H
NH
NH2N
H
NH
NH2
Ac-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr
C. β-ACC units into Biologically Active α-Peptides            75 
 
 
residue NH CHα CHβ CHγ CHδ others 
Arg1 8.98 3.86 2.14 1.83; 1.68 3.20  
His2 7.53 4.34 2.79    
Tyr3 7.54 4.25 2.92; 3.03   7.01; 6.86 
Ile4 7.71 3.79 1.97 
γCH3 0.94 
1.62; 1.25 
δCH3 0.87 
  
Asn5 7.97 4.50 2.79   γNH2 6.85 
Leu6 7.60 4.14 1.94; 1.78 1.61 0.96; 0.88  
Ile7 7.58 4.10 2.08 
γCH3 1.00  
1.71; 1.32 
δCH3 0.89 
  
Thr8 7.88 4.35 4.09 CH3 1.24   
Arg9 7.80 4.22 1.91; 1.82 1.68   
β-ACC10 8.04 3.58 2.51 2.70  CH3 3.72 
Arg11 8.36 4.32 1.70; 1.62 1.48 3.15  
Tyr12 8.16 4.47 3.03; 2.81   7.06; 6.76 
 
Table 17. Chemical shifts found at 310K, referenced to the water signal at 4.63 ppm. 
 
In the segment encompassing residues His2 to β-ACC10 sequential contacts between amide 
protons are present in the 2D NOESY spectrum, suggesting a helically folded conformation. 
The helical conformation is supported by a series of medium-range i,i+2 and i,i+3 NOE 
contacts. Although the structure is not well-defined enough to unambiguously define the type 
of helix the absence of i,i+4 contacts suggests it to be a 310-helix rather than an α-helix. No 
i,i+1-Hα-Hα peaks are observed throughout the sequence indicating the absence of cis-amide 
bonds, in particular for the Arg—β-ACC amide bond. Figure 63 summarized the sequential 
and medium-range NOEs found. 
The incorporation of the β-ACC moiety is still compatible with a turn of a helical 
conformation in the segment comprising Arg33 and Arg35, two residues believed to be 
directly involved in forming contacts with the receptor.  
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Figure 63. Summary of sequential and medium-range NOEs for β-ACC34-NPY (25-36) measured in 
the presence of DPC micelles, (where X = (+)β-ACC). The thickness of the lines is proportional to the 
integral value in the NOESY spectrum. 
 
From the NOESY data, using the program DYANA, the 20 structures with the lowest target 
function values were selected to present the NMR ensemble. The residue-specific atomic 
root-mean-square deviations (RMSD) for the backbone heavy atoms were 0.89 ± 0.36 Å for 
the Arg1-Tyr12 peptide and 0.35 ± 0.17Å for the 310 helical Ile4-Arg9 segment. 
The NMR ensemble reveals backbone dihedrals compatible with a helical conformation 
between Arg1 and ACC10 (Figure 64). Hydrogen bonds are present in the majority of 
computed structures corresponding to i,i+3 NH→CO hydrogen bonds for carbonyl atoms of 
residues 3,4 and 6. At the C terminus around the ACC residue no fixed H bond is observed. 
However, amide protons of both residues of Tyr12 and ACC10 need to be only slightly shifted 
in position to form hydrogen bonds to the carbonyl of Ile7 resulting in 10 or 17 membered 
rings. Considering the increased RMSD in the C-terminal segment Ile7 to Tyr12 (1.21 ± 0.5Å) 
it is possible that the CO of Ile7 is forming time-shared hydrogen bonds to both amide 
protons of ACC10 and Tyr12.  
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Peptide Contacts Contacts 
    2 Arg+ HA 5 Ile  HB 5 Ile  QG1 7 Leu  QQD 
2 Arg+ QB 4 Tyr  HN 6 Asn  HA 8 Ile  HN 
2 Arg+ QB 4 Tyr  QD 6 Asn  HA 9 Thr  HN 
2 Arg+ QB 4 Tyr  QE 8 Ile  HN 12 Arg+ QB 
3 His+ HA 6 Asn  HN 8 Ile  HA 12 Arg+ QB 
4 Tyr  HA 7 Leu  HN 8 Ile  HB 12 Arg+ QB 
4 Tyr  QD 7 Leu  QD1 8 Ile  QG2 10 Arg+ HN 
4 Tyr  QD 7 Leu  QD2 8 Ile  QG2 11 ACC  HN 
4 Tyr  QD 7 Leu  QQD 8 Ile  QG2 11 ACC  HG 
4 Tyr  QE 7 Leu  QD1 8 Ile  QG2 12 Arg+ QB 
4 Tyr  QE 7 Leu  QD2 8 Ile  QG1 12 Arg+ QB 
5 Ile  HA 8 Ile  HN 8 Ile  QD1 12 Arg+ QB 
5 Ile  HA 8 Ile  HB 9 Thr  HA 11 ACC  HN 
 
36 
   5 Ile  HA    8 Ile  QG2 11 ACC  HG 13 Tyr  QE 
 
Table 18. Non-sequential restraints used for the structure calculation. In the table, A=α; B=β, G=γ, 
D=δ, E=ε. The letter Q instead of H is used when there is a signal due to more than one hydrogen and 
it is not possible to distinguish between them, for example in the presence of a CH2 in the β position 
of Arginine. QQ is used in the case of two CH3 as for example in Leucine when it is not possible to 
distinguish them in the NMR spectra.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64. Superposition of low-energy conformers of (+)β-ACC34-NPY (25-36) 36 as determined in 
the presence of DPC micelles displaying bonds involving backbone atoms only (left). Single 
conformer displaying bonds between backbone atoms in blue and between side chain atoms in red 
(right). Hydrogen atoms are omitted.  
N-termini 
 
C-termini 
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The C-terminus of NPY from residues 17 to 36 shows an α-helical structure in the presence 
of DPC micelles68, the C-terminus of NPY from residue 25 to 36, as reported by Koglin et 
al63 shows the typical CD spectrum of a random peptide in buffer but it is able to adopt a 
structure with high α-helical content in the presence of the α-helical-promoting additive 2,2,2 
trifluoroethanol (TFE). 
The structure of (+)β-ACC NPY analogue results in an amphiphilic helix that exposes 
hydrophobic sidechains including the aromatic (Tyr) residues on one side, presumably 
forming the micelle-binding interface. In particular, Arg residues corresponding to positions 
33 and 35 in full-length NPY are positioned on the other, solvent exposed side of the helix as 
shown in Figure 64. 
The different receptor subtypes share the C terminus of NPY as one common recognition 
site. Previously studies suggested the need of a turn-like structure at the C-Terminus for the 
Y1 receptor selectivity (Figure 65).69  
Substitutions in this region can have subtype-specific effects on binding affinity. A structure 
elucidation of a peptide hormone in solution in the absence of the target receptor can deliver 
limited information into the bioactive conformation. 
 
 
 
 
Figure 65. Model of the binding mode of NPY at the different receptor subtypes.69  
 
However, keeping in mind that the NPY is probably first recognized from the cell membrane, 
the solution structure of (+)β-ACC34-NPY (25-36) analogue in the presence of micelles 
provides an idea about the conformation that is recognized by the receptor.  
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The presence of the (+)β-ACC unit in the shorted NPY analogue herein investigated imposed 
a defined turn-structure at the C-Terminus that could be responsible for the selectivity of this 
peptide.  
Further investigation on these peptide analogues are currently in progress in order to explore 
an eventual use of these peptides as pharmacological tool. 
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D. Summary 
 
The design of short conformationally constrained polymers, being able to display analogue 
functional properties found in large peptides or proteins, requires the identification of new 
polymeric backbones or building blocks with suitable folding properties. In this work 
different α-peptides containing two enantiomers of cis-β-amino cyclopropane carboxylic acid 
were synthesized in order to extend our knowledge regarding their conformational 
preferences.  
 
Alternated peptides α-L-Xaa-β-ACC were synthesized and their conformations were 
investigated by IR, CD and NMR spectroscopy.  
The synthesis of this compounds was carried out in solution or on the solid phase by adding 
the C-terminus deprotected dipeptide PG-Xaa-β-ACC-OH at each step as shown in Figure 
66. 
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Figure 66. Elongation reaction of α-Xxx/β-ACC alternated peptides. 
 
Short L-Ala-β-ACC alternated peptides in a polar solvent like methanol adopt well defined 
helical secondary structures. When the (–) β-ACC is incorporated, the peptides showed a 313 
helix turn involving a hydrogen-bond between the NH of the first β-ACC and the C=O of the 
following β-ACC unit as shown for the heptapeptide (–)-5a in Figure 67. 
 
 
 
 
 
 
 
 
Figure 67. Schema of the structure calculated for the heptapeptide (–)-5a. 
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The CD spectrum corresponding to this structure shows a minimum at about 200 nm. CD 
spectra, which were measured in different solvents such as trifluoroethanol or 
hexafluoroaceton and in methanol with different amounts of water, suggest that the stability 
of the 313 helix-turn found by NMR investigation in methanol, is strongly dependent on the 
environment. 
 
 
 
 
 
 
 
 
 
 
Figure 68. CD spectra of the heptapeptide (–)-5a and the nonapeptide (–)-6a in methanol and the 
NMR structure of (–)-6a. 
 
It is likely that those peptides in a non polar environment adopt a different conformation, as 
suggested from the isodichroic point obtained in the CD spectra of the nonapeptide (–)-6. 
However conformational investigation in chloroform by NMR were not in agreement with a 
well defined  folded secondary structure. 
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Figure 69. CD spectra of the nonapeptide (–)-6 with different ratio of polar and non polar solvent. 
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The investigation on the longer peptide (–)-7 in which different α-L-amino acid are alternated 
with (–)-β-ACC units confirm the presence of a helical conformation even if the N-terminus 
of the peptide is not well defined. This flexibility could be due to the presence of two positive 
charges at the N-terminal deprotected Lys1. In fact, changes in the ionization degree of 
polypeptides, obtained by using different solvents or different pH values in water solutions, 
led to some conformational changes. In methanol the CD spectrum shows two bands, at about 
205 and 212 nm. A more acidic environment increases the intensity at 205 nm compared with 
the 212 band. The opposite behaviour is found in a basic environment or in HFA (Figure 70).  
 
 
 
 
 
 
 
 
 
 
Figure 70. View of backbone atoms of 10 minimized superimposed structures for (–)-7, the β-ACCs 
in position 6, 8, 10 and 12 are shown (left). The CD spectra of (–)-7 measured in different solvents 
(right). 
 
The NMR data obtained from the analogues containing the (+) β-ACC moiety display a 
structure, which is less well defined than the corresponding (–) β-ACC derivatives. For the 
former, there is likely a set of conformers which rapidly interconvert on the NMR timescale.  
CD investigations in different solvents show patterns that are almost solvent independent. 
The solvents investigated are probably not able to stabilize one conformation with respect to 
another one. 
 
In the second part of this PhD work, β-ACC units were used as building blocks in biological 
active analogues of neuropeptide Y and RGD peptides, inducing a particular spatial 
orientation of important side chains for the interaction. Some β-ACC containing peptides are 
found to be able to enhance the biological affinity to the corresponding receptor. 
Conformational investigation on them allowed us to collect more information about the 
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active conformation being responsible for the binding or at least on the conformation that is 
recognized by the receptor. 
 
Cyclic pentapeptides containing the typical integrin recognition sequence Arg-Gly-Asp were 
synthesized and their affinities to the αVβ3 receptor were investigated. The αVβ3  integrin 
receptor subtype plays an important role in many physiological events and it is a potential 
pharmaceutical target for treatment of several diseases including tumors. 
The stereochemistry of the β-ACC moiety is found to be decisive for the receptor affinity. 
The pentapeptide c(Arg-Gly-Asp-(+)-β-ACC-Val) is found to have a IC50 value in a 
nanomolar range, which is a higher affinity compared to the reference peptide c(Arg-Gly-
Asp-D-Phe-Val) as shown in Table 19. 
 
 
Peptide Sequence αVβ3 
IC50 (nM) 
(–)-28 c(Arg-Gly-Asp-(–)-β-ACC-Val) 630 
(+)-28 c(Arg-Gly-Asp-(+)-β-ACC-Val) 21 
29 c(Arg-Gly-Asp-D-Phe-Val) 197 
 
Table 19. Biological results obtained with cyclic peptides containing β-ACC units using human 
melanoma skin cells and vitronectin. 
 
Conformational NMR investigation on (+)-28 shows the Arg-Gly-Asp segment in the 
positions i to i+2 of a type II’ β-turn in which the (+) β-ACC moiety occupies the position 
i+3. 
 
The introduction of the (+)-β-ACC moiety in the C-terminal dodecapeptide of the NPY, at 
the position 10 (position 34 corresponding to the full length NPY) led to a shorter NPY 
analogue which is able to bind the Y1 NPY receptor subtype with good affinity and 
selectivity. 
The secondary structure of the most selective analogue 36 was investigated by 2D NMR in 
the presence of micelles that mimic the cell membrane, in order to gain information about the 
conformation that is recognized by the Y1 receptor subtype after the absorption step on the 
cell membrane.  
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The observed secondary structure, differs substantially from the conformation present in the 
C-terminal part of the full length NPY, both from the helical structure found in solution in the 
presence of micelles, and from the typical PP-fold that has a flexible C-terminus (Figure 71).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 71. Comparison between the different conformations found concerning NPY. The C-termini 
are highlighted with a circle. The Hydrogen atoms in the β-ACC34 NPY (25-36) are omitted.  
 
As shown in Figure 71, the β-ACC-NPY analogue 36 adopts at the N-terminus an 
amphiphilic helix that exposes hydrophobic side chains on one side, presumably forming the 
micelle-binding interface. At the C-terminus, the (+) β-ACC moiety interrupts the helix and 
induced a turn-like structure. This conformation could be responsible for a particular 
orientation of the key side chains for the receptor recognition leading consequently to 
receptor selectivity. 
 
In conclusion, β-ACC moieties are found to be able to induce a defined secondary structure 
in short α-/β- mixed peptides. Alternated α-/β- peptides show helical conformations, which 
are better defined when the (–) enantiomer is used. The effect of only one β-ACC unit 
PP-fold 
Full-length NPY in the 
presence of micelles 
β-ACC34 NPY (25-36) in the 
presence of micelles. 
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surrounded by α-amino acids has to be further investigated. However, the (+) enantiomer 
investigated in the cyclic-RGD peptide and in the linear NPY analogue displayed a strong 
influence on the overall conformation, inducing turn structures. In particular it induces a 
pseudo β-turn in the cyclic analogue and a pseudo β-turn time-shared with a more extended 
17 membered-ring in the case of the NPY analogue. 
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E. Experimental part 
 
E.1 Instruments and general techniques  
 
NMR: Bruker Avance 600 (600.13 MHz), Bruker DRX-500, Bruker Avance 400 (400.13 
MHz), Bruker Avance 300 (300.13 MHz) spectrometers were used. 1H NMR: The chemical 
shifts are reported in δ (ppm) relative to chloroform (CDCl3, 7.26 ppm), dymethylsulfoxide 
(DMSO-d6, 2.49 ppm), methanol (CD3OD, 3.34 ppm) and tetramethylsilane (TMS, 0 ppm). 
The spectra were analysed by first order, the coupling constants are reported in Hertz (Hz). 
Characterisation of signals: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, s br 
= broad singlet, dd = double douplet, dt = double triplet, dq = double quartet, ddd = double 
double doublet. Integration is determined as the relative number of atoms. Diastereomeric 
ratios were determined by comparing the integrals of corresponding protons in the 1H NMR 
spectra. 13C NMR: The chemical shifts are reported in δ (ppm) relative to chloroform (CDCl3, 
77.0 ppm), dymethylsulfoxide (DMSO-d6, 36.9 ppm), methanol (CD3OD, 49.0 ppm) and 
tetramethylsilane (TMS, 0 ppm). 13C NMR resonance assignment were aided by the use of 
the DEPT 135 (DEPT = distortionless enhancement by polarisation transfer) or HSQC 
(Heteronuclear Single Quantum Correlation) techniques to determine the number of 
hydrogens attached to each carbon atom and is declared as: + = primary or tertiary (positive 
DEPT signal intensity or straight line in HSQC), - = secondary (negative DEPT signal or dot 
line in HSQC) and quat = quaternary (no DEPT signal intensity) carbon atoms. In some cases 
DEPT 90 spectra were recorded to distinguish between primary and tertiary carbon atoms 
and HMBC (Heteronuclear Multiple Bond Correlation) to distinguish between quaternary 
carbon and aromatic CH. 2D-NMR: The spectra were recorded using the solvent line 
(CD3OH, 1H δ 3.31 or CDCl3, 7.26 ppm) for referencing. DQF-COSY, 80 ms-TOCSY and 
500 ms-ROESY standard experiments were performed with suppression of the methanol OH 
line by low-power presaturation. 
IR-spectra were recorded with a Bio-Rad Excalibur series FT-IR or a Tensor 27 Bruker. 
MS-spectra: masspectroscopy department of the University of Regensburg. 
Elemental analysis: microanalytical department of the University of Regensburg. 
Melting points (mp) were determined with a Buchi SMP 20 and are uncorrected. 
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Thin layer chromatography (TLC) was performed on alumina plates coated with silica gel 
(Merck silica gel 60 F 254, layer thickness 0.2 mm). Visualisation was accomplished by UV-
light (wavelenght λ = 254 nm) and a Molybdatophosphoric acid solution. 
Optical rotations were measured on a Perkin-Elmer-Polarimeter 241 with sodium lamp at 
589 nm in the specified solvent. The optical rotation was calculated with the following 
formula: 
 
[ ]ϑα D  = ([α]exp x 100)/ (c x d) 
 
 
 
 
CD spectra were measured on a JASCO model J-710/720 at the Institut für Bioanalytic und 
Sensorik of the University of Regensburg (research group of Prof. Dr. O. Wolfbeis) at 21° C  
between 300 and 200-180 nm in the specified solvent, the number of scans ranging between 
10 and 50. The length of the cylindrical cuvettes was 0.1 mm, the resolution was 0.2 nm, the 
band width 1.0 nm, the sensitivity 20 mdeg, the response 0.25 s, the speed 20 nm/min. The 
background was subtracted to each spectrum. The absorption value is measured as Molar 
Ellipticity per Residue (deg cm2 dmol-1).  
Column chromatography was performed on silica gel Geduran SI 60 (70-230 mesh) 
purchased from Merck and flash chromatography on flash-silica gel 60 (230-400 mesh 
ASTM) purchased from Merck. 
Solvents were purified according to standard laboratory methods. THF, diethyl ether and 
toluene were distilled over sodium/benzophenone before use. Dichlormethane, DMSO and 
DMF were distilled over calcium hydride and acetonitrile over P2O5. Methanol was refluxed 
2 h over magnesia, distilled and stored under nitrogen over 4 Å molecular sieves. The 
hexanes used had a boiling point of 40-60 °C. All solvents were distilled before use. Other 
chemicals were purchased from commercial suppliers and used as received. 
All reactions with oxygen or moisture sensitive reactants were performed under nitrogen 
atmosphere. 
For the elongation of the NPY-analogue peptide, after the manual coupling with the β-ACC 
containing dipeptide, the peptide synthesiser Syro from MultiSynTech was used. 
 
 
θ = temperature (°C) 
[α]exp = measured value 
c = concentration (g/100 ml) 
d = length of the cuvette 
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HPLC-chromatography: analytical and preparative reverse Phase HPLC was performed on 
Agilent equipment (Böblingen, Germany) by using the columns: Luna C18(2), 3 µm, 4.60 x 
150 mm and the Luna C18(2), 90 µm, 21.2 x 250 mm (Phenomenex, Aschaffenburg, 
Germany). The flow rate was 1 mL/min for the analytical HPLC runs and 21 mL/min for 
preparative applications. The binary solvent system (A/B) was: (A) ACN, (B) 0.0059% TFA 
in water. The absorbance was detected at 220 nm. 
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E.2 Solution Synthesis  
 
E.2.1 Peptides containing (+)-βACC units 
 
Boc
H
N
N
H
CO2Me
O H
N
O
CO2Bn
3
(+)-5
 
Boc-[Ala-(+)-β-ACC]3-Ala-OBn, (+)-5: 
 
methyl(1R,2R,3R)-2-{[((1S)-2-{[(1R,2R,3R)-2-{[((1S)-2-{[(1R,2R,3R)-2-({[(1S)-2-(benzy-
loxy)-1-methyl-2-oxoethyl]amino}carbonyl)-3-(methoxycarbonyl)cyclopropyl]amino}-1-
methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-methyl-
2-oxoethyl)amino]carbonyl}-3-({(2S)-2-[(tert-butoxycarbonyl)amino]propanoyl} amino) 
cyclopropanecarboxylate;  
(+)-13 (970 mg, 1.38 mmol) was deprotected by treatment with HCl 3 M in ethyl acetate (52 
ml) for 3 h at 0 °C. The solution was concentrated in vacuum, the salt was resuspended in 
CH2Cl2 (25 ml). Separately the (+)-11 (500 mg, 1.52 mmol, 1.1 eq.) was dissolved in CH2Cl2 
(20  ml) and cooled in an ice bath and activated with HOBt (205 mg, 1.52 mmol, 1.1 eq.) and 
EDC (292 mg, 1.52 mmol, 1.1 eq.). After 10 minutes the mixture of the deprotected (+)-
13and triethylamine (0.29 ml, 2.07 mmol, 1.5 eq.) were added. The mixture was stirred at 
room temperature 80 h. The solution was then concentrated in vacuum and the product was 
obtained by chromatography (CH2Cl2/MeOH 25:2) as a white solid (874 mg, 70 %). Rf ((+)-
5) = 0.6 in CH2Cl2/MeOH 9:1 - mp 185-187 °C. - [ ]21Dα  - 95.2 (c 0.5, CH3OH). - 1H NMR 
(CD3OD, 300 MHz) δ 1.24 (d, J = 7.4 Hz, 3H, CH3CH), 1.29 (d, J = 7.3 Hz, 3H, CH3CH), 
1.31 (d, J= 7.3 Hz, 3H, CH3CH), 1.39 (d, J= 7.3 Hz, 3H, CH3CH), 1.42 (s, 9H, (CH3)3C), 
2.30-2.40 (m, 3H, cyclopropyl-CH), 2.46-2.52 (m, 3H, cyclopropyl-CH), 3.64 (s, 3H, CH3O), 
3.66-3.78 (m, 3H, cyclopropyl-CHN), 3.70 (s, 3H, CH3O), 3.71 (s, 3H, CH3O), 3.95-4.02 (m, 
1H, Ala-CHN), 4.19-4.31 (m, 2H, Ala-CHN), 4.51 (q, J = 7.3 Hz, 1H, Ala-CHN), 5.12 (d, J 
= 12.3 Hz, 1H, CH2O), 5.20 (d, J = 12.3 Hz, 1H, CH2O), 7.33-7.36 (m, 5H, Ph-CH). - 13C 
NMR (CD3OD, 75.5 MHz) δ17.6 (+, CH3CH), 17.7 (+, CH3CH), 17.9 (+, CH3CH), 18.2 (+, 
CH3CH), 27.5 (+, cyclopropyl-CH), 27.6 (+, cyclopropyl-CH), 27.7 (+, cyclopropyl-CH), 
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28.4 (+, cyclopropyl-CH), 28.8 (+, (CH3)3C, 3C), 28.9 (+, cyclopropyl-CH), 29.0 (+, 
cyclopropyl-CH), 36.6 (+, cyclopropyl-CHN, 2C), 36.7 (+, cyclopropyl-CHN), 49.6 (+, Ala-
CHN), 50.7 (+, Ala-CHN, 2C), 51.6 (+, Ala-CHN), 52.9 (+, CH3O, 2C), 53.0 (+, CH3O), 
68.0 (-, CH2O), 80.7 (Cquat, (CH3)3C), 129.3 (+, Ph-CH, 2C), 129.4 (+, Ph-CH), 129.6 (+, Ph-
CH, 2C), 137.3 (Cquat, Ph-C), 157.7 (Cquat, N(CO)O), 169.7 (Cquat, C=O, 3C), 172.3 (Cquat, 
C=O, 2C), 172.4 (Cquat, C=O, 2C), 172.5 (Cquat, C=O), 173.9 (Cquat, C=O), 175.5 (Cquat, C=O), 
175.7 (Cquat, C=O). - MS FAB (MeOH/Glycerin) m/z (%) 916 (MH+, 56), 816 (M+-Boc, 100), 
726 (16). - IR (KBr) 3334, 2981, 1728, 1666, 1526, 1443, 1314 cm-1. - HR MS calcd for 
C42H57N7O16 916.39400, found 916.39183 
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HCl.H-[Ala-(+)-β-ACC]3-Ala-OH, (+)-5a: 
 
(2S)-1-{[(1R,2R,3R)-2-{[((1S)-2-{[(1R,2R,3R)-2-{[((1S)-2-{[(1R,2R,3R)-2-({[(1S)-1-
carboxyethyl]amino}carbonyl)-3-(methoxycarbonyl)cyclopropyl]amino}-1-methyl-2-
oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-methyl-2-oxo-
ethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-oxo-2-propana-
miniumchloride; 
(+)-5 (100 mg, 0.109 mmol) was stirred in HCl 3 M in ethyl acetate (2 ml) at 0°C for 3 h. 
The solution was then concentrated in vacuum and the salt redissolved in methanol (10 ml). 
Then Pd/C 10 % (20 mg) and cyclohexadiene (0.17 ml, 42 % in pentane) were added. The 
reaction mixture was stirred overnight, filtrated over a celite pad and concentrated in vacuum 
to afford the deprotected peptide as a white solid (75 mg, 90 %). - mp 190 °C decomposed. - 
[ ]21Dα  - 81.0 (c 0.5, MeOH). - 1H NMR (CD3OD, 300 MHz) δ1.30 (d, J = 7.7 Hz, 3H, 
CH3CH), 1.32 (d, J = 7.4 Hz, 3H, CH3CH), 1.40 (d, J = 7.1 Hz, 3H, CH3CH), 1.41 (d, J = 
6.9 Hz, 3H, CH3CH), 2.33-2.36(m, 1H, cyclopropyl-CH), 2.38-2.42 (m, 1H, cyclopropyl-
CH), 2.47-2.56 (m, 4H, cyclopropyl-CH), 3.55 (dd, J = 7.8, 4.8 Hz, 1H, cyclopropyl-CHN), 
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3.67-3.79 (m, 2H, cyclopropyl-CHN), 3.72 (s, 3H, CH3O), 3.73 (s, 3H, CH3O), 3.73 (s, 3H, 
CH3O), 3.89 (q, J = 6.9 Hz, 1H, Ala-CHN), 4.21 (q, J = 7.2 Hz, 1H, Ala-CHN), 4.28 (q, J = 
7.3 Hz, 1H, Ala-CHN), 4.43 (q, J = 7.2 Hz, 1H, Ala-CHN). - 13C NMR (CD3OD, 75.5 MHz) 
δ 16.1 (+, CH3CH, 2C), 16.3 (+, CH3CH), 16.4 (+, CH3CH), 25.6 (+, cyclopropyl-CH), 26.0 
(+, cyclopropyl-CH), 26.2 (+, cyclopropyl-CH), 27.0 (+, cyclopropyl-CH, 2C ), 27.5 (+, 
cyclopropyl-CH), 28.3 (+, cyclopropyl-CH), 35.0 (+, cyclopropyl-CHN, 2C), 35.1 (+, 
cyclopropyl-CHN), 48.6 (+, CHN, 2C), 49.2 (+, CHN), 49.4 (+, CHN), 51.4 (+, CH3O), 51.5 
(+, CH3O), 51.6 (+, CH3O), 167.3 (Cquat, C=O), 168.1 (Cquat, C=O), 168.2 (Cquat, C=O), 170.6 
(Cquat, C=O), 170.8 (Cquat, C=O), 170.9 (Cquat, C=O, 2C), 173.9 (Cquat, C=O), 174.2 (Cquat, 
C=O), 174.6 (Cquat, C=O). - MS  FAB (MeOH/Glycerin) m/z (%) 726 (MH+, 100). - IR (KBr) 
3360, 3054, 2980, 1731, 1654, 1533, 1450, 1315, 1209, 1174 cm-1. - HR MS calcd for 
C30H43N7O14 + H 726.29462, found 726.29401. 
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Boc-[Ala-(+)-β-ACC]4-Ala-OBn, (+)-6: 
 
methyl(1R,2R,3R)-2-{[((1S)-2-{[(1R,2R,3R)-2-{[((1S)-2-{[(1R,2R,3R)-2-({[(1S)-2-(benzy-
loxy)-1-methyl-2-oxoethyl]amino}carbonyl)-3-(methoxycarbonyl)cyclopropyl] 
amino}-1-methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-
1-methyl-2-oxoethyl)amino]carbonyl}-3-{[(2S)-2-({[(1R,2R,3R)-2-({(2S)-2-[(tert-butoxy-
carbonyl)amino]propanoyl}amino)-3-(methoxycarbonyl)cyclopropyl]carbonyl}amino) 
propanoyl]amino}cyclopropanecarboxylate; 
(+)-5 (200 mg, 0.22 mmol) was deprotected by treatment with HCl 3 M in ethyl acetate (9 
ml) for 3h at 0 °C. The solution was concentrated in vacuum, the salt was resuspended in 
CH2Cl2 (20 ml). Separately the (+)-11 (100 mg, 0.30 mmol, 1.35 eq.) was dissolved in 
CH2Cl2 (20  ml) and cooled in an ice bath and activated with HOBt (41 mg, 0.30 mmol, 1.35 
eq.) and EDC (58 mg, 0.30 mmol, 1.35 eq.). After 10 minutes the mixture of the deprotected 
(+)-5 and triethylamine (0.05 ml, 0.37 mmol, 1.70 eq.) were added. The mixture was stirred 
at room temperature 90 h. The solution was then concentrated in vacuum and the product was 
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obtained by chromatography (CH2Cl2/MeOH 25:3; Rf = 0.2) as a white solid (135 mg, 55 %), 
15 % epimerisation was observed. The product was isolated as a white solid by 
recrystallization from ethyl acetate/hexanes. - mp >200 °C. - [ ]21Dα  -50.0 (c 1, CHCl3). - 1H 
NMR (DMSO-d6, 600 MHz) δ 1.09-1.12 (m, 6H, CH3CH), 1.14 (d, J = 7.2 Hz, 3H, CH3CH), 
1.29 (d, J= 7.4 Hz, 3H, CH3CH), 1.36 (s, 9H, (CH3)3C), 2.17 (m, 1H, cyclopropyl-CH), 2.21-
2.26 (m, 3H, cyclopropyl-CH), 2.45-2.53 (m, 4H, cyclopropyl-CH) 3.44-3.50 (m, 2H, 
cyclopropyl-CHN), 3.54-3.60 (m, 2H, cyclopropyl-CHN), 3.60 (s, 3H, CH3O), 3.65 (s, 3H, 
CH3O), 3.65 (s, 3H, CH3O), ), 3.66 (s, 3H, CH3O), 3.84-3.90 (m, 1H, Ala-CHN), 4.11-4.19 
(m, 3H, Ala-CHN), 4.32-4.38 (m, 1H, Ala-CHN), 5.09 (d, J = 12.5 Hz, 1H, CH2O), 5.16 (d, J 
= 12.3 Hz, 1H, CH2O), 7.06 (d, J = 7.2 Hz, 1H, NH), 7.32-7.40 (m, 5H, Ph-CH), 8.00 (d, J = 
7.2 Hz, 1H, NH), 8.07 (d, J = 6.4 Hz, 1H, NH), 8.10 (d, J = 6.7 Hz, 1H, NH), 8.14 (d, J = 6.4 
Hz, 1H, NH), 8.63 (d, J = 7.2 Hz, 1H, NH), 8.66 (d, J = 7.7 Hz, 1H, NH), 8.68 (d, J = 7.2 Hz, 
1H, NH), 8.92 (d, J = 7.4 Hz, 1H, NH). - 13C NMR (DMSO-d6, 100.6 MHz) δ 16.8 (+, 
CH3CH), 17.5 (+, CH3CH), 17.6 (+, CH3CH), 17.7 (+, CH3CH), 17.8 (+, CH3CH), 25.2 (+, 
cyclopropyl-CH), 25.4 (+, cyclopropyl-CH), 25.6 (+, cyclopropyl-CH, 2C), 27.1 (+, 
cyclopropyl-CH, 2C) 27.4 (+, cyclopropyl-CH), 27.6 (+, cyclopropyl-CH) 28.0 (+, (CH3)3C), 
35.1 (+, cyclopropyl-CHN, 3C), 35.2 (+, cyclopropyl-CHN), 48.2 (+, Ala-CHN), 48.4 (+, 
Ala-CHN, 3C), 49.6 (+, Ala-CHN), 52.0 (+, CH3O), 52.0 (+, CH3O, 2C), 52.1 (+, CH3O), 
65.9 (-, CH2O), 78.0 (Cquat, (CH3)3C), 127.6 (+, Ph-CH, 2C), 128.0 (+, Ph-CH), 128.3 (+, Ph-
CH, 2C), 135.8 (Cquat, Ph-C), 166.2 (Cquat, N(CO)O), 166.4 (Cquat, C=O, 2C), 166.8 (Cquat, 
C=O, 2C), 169.3 (Cquat, C=O), 169.5 (Cquat, C=O), 170.5 (Cquat, C=O), 170.6 (Cquat, C=O). 
170.6 (Cquat, C=O, 2C) 172.0 (Cquat, C=O), 172.5 (Cquat, C=O), 172.6 (Cquat, C=O). - MS  
FAB (MeOH/Glycerin) m/z (%) 1150 (MNa+, 64), 1128 (MH+, 14), 1028 (MH+-Boc, 100). - 
IR (KBr) 3305, 2966, 1731, 1649, 1522, 1447, 1199, 1169, 752 cm-1. - HR MS calcd for 
C51H69N9O20 + Na 1150.45565, found 1150.45543 
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HCl.H-[Ala-(+)-β-ACC]4-Ala-OH, (+)-6a: 
 
(2S)-1-{[(1R,2R,3R)-2-{[((1S)-2-{[(1R,2R,3R)-2-{[((1S)-2-{[(1R,2R,3R)-2-{[((1S)-2-{[(1R, 
2R,3R)-2-({[(1S)-1-carboxyethyl]amino}carbonyl)-3-(methoxycarbonyl)cyclopropyl] 
amino}-1-methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-
1-methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-
methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-oxo-2-
propanaminium chloride; 
(+)-6 (30 mg, 0.027 mmol) was stirred in HCl 3 M in ethyl acetate (1 ml) at 0°C for 3 h. The 
solution was then concentrated in vacuum and the salt redissolved in methanol (5 ml). Then 
Pd/C 10 % (40 mg) and cyclohexadiene (0.03 ml, 42 % in pentane) were added. The reaction 
mixture was stirred overnight, filtrated over a celite pad and concentrated in vacuum to afford 
the deprotected peptide as a white solid (25 mg, 95 %). - mp 160 °C decomposed. - 1H NMR 
(CD3OD, 300 MHz) δ 1.25-1.31 (m, 9H, CH3CH), 1.36 (d, J = 7.1 Hz, 3H, CH3CH), 1.37 (d, 
J = 7.1 Hz, 3H, CH3CH), 2.30-2.37 (m, 2H, cyclopropyl-CH), 2.43-2.54 (m, 6H, 
cyclopropyl-CH), 3.49-3.56 (m, 1H, cyclopropyl-CHN), 3.62-3.76 (m, 2H, cyclopropyl-
CHN), 3.79-3.89 (m, 1H, cyclopropyl-CHN), 3.68 (s, 3H, CH3O), 3.69 (s, 3H, CH3O), 3.69 
(s, 3H, CH3O), 3.70 (s, 3H, CH3O), 4.13-4.30 (m, 4H, Ala-CHN), 4.35-4.44 (m, 1H, Ala-
CHN). - 13C NMR (CD3OD, 75.5 MHz) δ 15.9 (+, CH3CH), 16.0 (+, CH3CH), 16.1 (+, 
CH3CH), 16.2 (+, CH3CH), 16.3 (+, CH3CH), 26.2 (+, cyclopropyl-CH), 26.6 (+, 
cyclopropyl-CH), 27.2 (+, cyclopropyl-CH, 2C), 27.3 (+, cyclopropyl-CH), 27.4 (+, 
cyclopropyl-CH), 27.6 (+, cyclopropyl-CH), 27.9 (+, cyclopropyl-CH), 34.8 (+, cyclopropyl-
CHN), 34.9 (+, cyclopropyl-CHN), 35.0 (+, cyclopropyl-CHN), 35.1 (+, cyclopropyl-CHN), 
48.5 (+, Ala-CHN), 48.8 (+, Ala-CHN), 49.4 (+, Ala-CHN), 49.7 (+, Ala-CHN), 50.1 (+, 
Ala-CHN), 51.4 (+, CH3O, 4C), 167.3 (Cquat, C=O), 167.9 (Cquat, C=O), 168.0 (Cquat, C=O, 
2C), 170.7 (Cquat, C=O, 2C), 170.9 (Cquat, C=O), 171.0 (Cquat, C=O), 173.7 (Cquat, C=O), 
174.3 (Cquat, C=O), 174.6 (Cquat, C=O). 174.8 (Cquat, C=O), 175.0 (Cquat, C=O).- - FAB 
(MeOH/Glycerin) m/z (%) 938 (MH+, 100). - IR (KBr) 3362, 3060, 2960, 1725, 1645, 1520, 
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1440, 1315, 1210, 1120 cm-1. - HR MS  calcd for C39H55N9O18 + H 938.3743, found 
938.3759. 
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Fmoc-Val-(+)-βACC-OBn, (+)-16: 
 
1-methyl 2-phenyl (1R,2R,3S)-3-[((2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-
methylbutanoyl)amino]-1,2-cyclopropanedicarboxylate; 
A solution of (+)-9 (350 g, 1.0 mmol) in HCl 3 M in ethyl acetate (38 ml) was stirred at 0 °C 
for 3 h. The solvent was evaporated the solid was resospended in CH2Cl2 (30 ml)  Fmoc-Val-
OH (441 mg, 1.3 mmol, 1.3 eq.), EDC (346 mg, 1.8 mmol, 1.8 eq) and pyridine (104 µl, 1.3 
mmol, 1.3 eq.) were added. The mixture was stirred overnight at room temperature. The 
solution was washed with saturated NaHCO3 (40 ml), 1 M KHSO4 (40 ml) and saturated 
NaHCO3 (40 ml). The organic phase was dried over Na2SO4 and concentrated. The product 
was purified by chromatography (CH2Cl2/MeOH 50:1, Rf = 0.2). 493 mg, 86 % mp  164-
166 °C . [ ]21Dα  - 20.37 (c 0.5, CHCl3). - 1H NMR (CDCl3, 300 MHz): δ 0.88 (d, J = 6.7 Hz, 
3H, Val-CH3), 0.91 (d, J = 6.6 Hz, 3H, Val-CH3), 2.08 (dqq, J = 6.5, 6.6, 6.7 Hz, 1H, Val-
βCH), 2.32 (dd, J = 5.2, 4.9 Hz, 1H, cyclopropyl-CH), 2.57 (dd, J = 8.2, 5.2 Hz, 1H, 
cyclopropyl-CH), 3.70 (s, 3H, CH3O), 3.99 (dd, J = 8.3, 6.5, 1H, Val-αCH) 4.16 (ddd, J = 
8.2, 8.2, 4.9. 1H, cyclopropyl-CHN), 4.23 (t, J = 6.9 Hz, 1H, Fmoc-CH), 4.40 (d, J = 6.9 Hz, 
2H, Fmoc-CH2), 5.08 (d, J = 12.2 Hz, 1H, CH2O), 5.13 (d, J = 12.2 Hz, 1H, CH2O), 5.36 (d, 
J = 8.3 Hz, 1H, Val-NH), 6.70 (d, J = 8.2 Hz, 1H, cyclopropyl-NH), 7.29-7.43 (m, 9H, Ar-
CH), 7.59-7.63 (m, 2H, Fmoc-Ar-CH), 7.75-7.78 (m, 2H, Fmoc-Ar-CH). - 13C NMR (CDCl3, 
75.5 MHz): δ 17.7 (+, Val-CH3), 19.2 (+, Val-CH3), 26.1 (+, cyclopropyl-CH), 28.7 (+, 
cyclopropyl-CH), 31.0 (+, Val-βCH), 36.0 (+, cyclopropyl-CHN), 47.2 (+, Fmoc-CH), 52.5 
(+, CH3O), 60.4 (+, Val-CHN), 67.2 (-, Fmoc-CH2), 67.5 (-, Bn-CH2), 120.0 (+, Fmoc-Ar-
CH, 2C), 125.1 (+, Fmoc-Ar-CH, 2C), 127.1 (+, Ar-CH, 2C), 127.8 (+, Ar-CH, 2C), 128.4 (+, 
Ar-CH, 2C), 128.7 (+, Ar-CH), 128.7 (+, Ar-CH, 2C), 134.9 (Cquat, Ph-C), 141.3 (Cquat, 
Fmoc-Ar-C, 2C), 143.7 (Cquat, Fmoc-Ar-C, 2C), 156.4 (Cquat, N(CO)O), 169.8 (Cquat, C=O), 
170.1 (Cquat, C=O), 171.8 (Cquat, C=O). - MS ESI (DCM/MeOH + 10 mmol/l NH4Ac) m/z 
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(%) 593 (MNa+, 11), 588 (MNH4+, 40) 571 (MH+, 100). - IR 3306, 2957, 1726, 1664, 1533, 
1450, 1294, 1219, 1171, 771 cm-1. - Anal. Calcd for C33H34N2O7 C, 69.46; H, 6.01; N, 4.91. 
Found: C, 68.92; H, 5.46; N, 4.40. 
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Fmoc-Val-(+)-βACC-OH, (+)-16a: 
 
(1R,2R,3R)-2-[((2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-methylbutanoyl) 
amino]-3-(methoxycarbonyl)cyclopropanecarboxylic acid; 
 (+)-16 (130 mg, 0.23 mmol) was dissolved under nitrogen atmosphere in MeOH (10 ml), 
then 1,4-cyclohexadiene 4M in pentane (216 µl, 5 eq) and Pd/C 5% (80 mg) were added. The 
reaction mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm 
celite pad and concentrated. The product was purified by chromatography (from CH2Cl2 to 
CH3OH/CH2Cl2 90:10; Rf = 0.4 in CH3OH/CH2Cl2 90:10) to afford the product as a white 
solid (99 mg, 90 %).  
mp 185-187 °C . [ ]21Dα  -17.8 (c 1, CH3OH). - 1H NMR (CD3OD/CDCl3 10:1, 600 MHz): δ 
0.91 (d, J = 6.2 Hz, 6H, Val-CH3), 2.04-2.10 (m, 1H, Val-βCH), 2.25 (dd, J = 5.0, 4.6 Hz, 1H, 
cyclopropyl-CH), 2.30 (dd, J = 8.1, 5.0 Hz, 1H, cyclopropyl-CH), 3.66 (s, 3H, CH3O), 3.66-
3.68 (m, 1H, cyclopropyl-CHN), 3.87 (d, J = 7.0 Hz, 1H, Val-αCH), 4.20 (t, J = 7.1 Hz, 1H, 
Fmoc-CH), 4.31 (dd, J = 10.3, 7.1 Hz, 1H, Fmoc-CH2), 4.40 (dd, J = 10.2, 7.1 Hz, 1H, 
Fmoc-CH2), 7.27-7.38 (m, 4H, Ar-CH), 7.63 (pseudo t, J = 7.8 Hz, 2H, Fmoc-Ar-CH), 7.76 
(pseudo d, J = 7.5 Hz, 2H, Fmoc-Ar-CH). - 13C NMR (CD3OD/CDCl3 10:1, 150.9 MHz): δ 
18.7 (+, Val-CH3), 20.0 (+, Val-CH3), 28.9 (+, cyclopropyl-CH), 29.9 (+, cyclopropyl-CH), 
31.5 (+, Val-βCH), 36.5 (+, cyclopropyl-CHN), 48.4 (+, Fmoc-CH), 52.8 (+, CH3O), 62.3 (+, 
Val-CHN), 68.3 (-, Fmoc-CH2), 121.0 (+, Fmoc-Ar-CH, 2C), 126.3 (+, Fmoc-Ar-CH, 2C), 
128.2 (+, Fmoc-Ar-CH, 2C), 128.3 (+, Fmoc-Ar-CH, 2C), 128.9 (+, Fmoc-Ar-CH, 2C), 
142.6 (Cquat, Fmoc-Ar-C, 2C), 145.1 (Cquat, Fmoc-Ar-C), 145.3 (Cquat, Fmoc-Ar-C) 158.8 
(Cquat, N(CO)O), 172.8 (Cquat, C=O, CH3O), 174.9 (Cquat, Val-C=O), 176.2 (Cquat, C=O, 
CO2H). - MS FAB (MeOH/Glycerine) m/z (%) 999 (2M+K+, 40), 961 (2M+H+, 10), 519 
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(MK+, 20) 481 (MH+, 100). - IR 3320, 2957, 1718, 1670, 1450, 1275, 1171, 1034, 770 cm-1. - 
HR MS calcd for C26H28N2O7 + H 481.1975, found 481.1975 
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Fmoc-Asp(OtBu)-(+)-βACC-OBn, (+)-17: 
 
1-methyl 2-phenyl (1R,2R,3S)-3-[((2S)-4-(tert-butoxy)-2-{[(9H-fluoren-9-ylmethoxy) 
carbonyl]amino}-4-oxobutanoyl)amino]-1,2-cyclopropanedicarboxylate; 
A solution of (+)-9 (320 mg, 0.86 mmol) in HCl 3 M in ethyl acetate (33 ml) was stirred at 
0 °C for 3 h. The solvent was evaporated the solid was resospended in CH2Cl2 (30 ml) and a 
solution of Fmoc-Asp(OtBu)-OH (708 mg, 1.72 mmol, 2 eq.), EDC (330 mg, 1.72 mmol, 2 
eq) and HOBt (209 mg, 1.55 mmol, 1.8 eq.) in CH2Cl2 (40 ml) (previously stirred 1 h at 
0 °C) was added. Pyridine  (123 µl, 1.55 mmol, 1.8 eq.) was then added dropwise. The 
mixture was stirred overnight at room temperature. The solution was washed with saturated 
NaHCO3 (50 ml), 1 M KHSO4 (50 ml) and saturated NaHCO3 (50 ml). The organic phase 
was dried over Na2SO4 and concentrated. The product was purified by chromatography 
(PE/EA 3:1 Rf = 0.1). 497 mg, 89 %. 
mp 44-46 °C . [ ]21Dα  -15.0 (c 0.5, CH3OH). - 1H NMR (CDCl3, 300 MHz): δ 1.46 (s, 9H, 
OtBu), 2.32 (dd, J = 4.9, 4.9 Hz, 1H, cyclopropyl-CH), 2.55 (dd, J = 8.2, 5.2 Hz, 1H, 
cyclopropyl-CH), 2.53-2,60 (m, 1H, Asp-βCH2), 2.89 (dd, J = 16.9, 4.5 Hz, 1H, Asp-βCH2), 
3.70 (s, 3H, CH3O), 4.02 (ddd, J = 7.9. 7.9, 4.7 Hz, 1H, cyclopropyl-CHN), 4.22-4.27 (m, 1H, 
Fmoc-CH), 4.31-4.37 (m, 1H, Fmoc-CH2), 4.45-4.51 (m, 2H, Fmoc-CH2, Asp-αCH), 5.03 (d, 
J = 12.3 Hz, 1H, CH2O), 5.10 (d, J = 12.3 Hz, 1H, CH2O), 5.94 (d, J = 8.5 Hz, 1H, Asp-NH), 
7.28-7.43 (m, 9H, Fmoc-Ar-CH, Bn-Ar-CH), 7.54-7.66 (m, 3H, Fmoc-Ar-CH, βACC-NH), 
7.76 (pseudo d, J = 7.4 Hz, 2H, Fmoc-Ar-CH). - 13C NMR (CDCl3, 75.5 MHz): δ 26.2 (+, 
cyclopropyl-CH), 28.1 (+, (CH3)3C), 28.7 (+, cyclopropyl-CH), 36.0 (+, cyclopropyl-CHN), 
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37.1 (-, Asp-CH2), 47.1 (+, Fmoc-CH), 51.2 (+, Asp-CHN), 52.5 (+, CH3O), 67.4 (-, Fmoc-
CH2, 1C), 68.8 (-, Bn-CH2, 1C), 82.0 (Cquat, (CH3)C), 120.0 (+, Ar-CH), 120.2 (+, Fmoc-Ar-
CH), 124.4 (+, Ar-CH), 125.1 (+, Ar-CH), 125.2 (+, Ar-CH), 127.1 (+, Ar-CH), 127.8 (+, Ar-
CH), 127.9 (+, Ar-CH),128.4 (+, Ar-CH), 128.5 (+, Ar-CH), 128.6 (+, Ar-CH, 2C), 129.4 (+, 
Ar-CH), 135.0 (Cquat, Ph-Ar-C), 139.7 (Cquat, Fmoc-Ar-C), 141.3 (Cquat, Fmoc-Ar-C), 143.6 
(Cquat, Fmoc-Ar-C), 143.9 (Cquat, Fmoc-Ar-C), 156.0 (Cquat, N(CO)O), 169.7 (Cquat, C=O), 
169.9 (Cquat, C=O), 171.1 (Cquat, C=O), 171.2 (Cquat, C=O). - MS FAB (MeOH/Glycerine) 
643 (MH+, 86), 587 (100). - IR 3329, 2978, 1718, 1522, 1308, 1217, 1169, 1051, 741 cm-1. - 
HR MS calcd for C36H38N2O9 + H 643.2656, found 643.2650. 
 
 
 
N
H
FmocHN COOH
CO2Me
O
CO2tBu
(+)-17a
 
 
Fmoc-Asp(OtBu)-(+)-βACC-OH, (+)-17a: 
 
(1R,2R,3R)-2-[((2S)-4-(tert-butoxy)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-
oxobutanoyl)amino]-3-(methoxycarbonyl)cyclopropanecarboxylic acid; 
(+)-17 (497mg, 0.77 mmol) was dissolved under nitrogen atmosphere in MeOH (20 ml), then 
1,4-cyclohexadiene (0.49 ml, 4M in pentane, 5 eq) and Pd/C 5 % (100 mg) were added. The 
reaction mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm 
celite pad and concentrated to afford the product as a white solid (353 mg, 83 %). mp 88-
90 °C . [ ]21Dα  _ 21.7 (c 0.5, CH3OH). - 1H NMR (CD3OD, 300 MHz): δ 1.42 (s, 9H, OtBu), 
2.37 (m, 2H, cyclopropyl-CH), 2.53 (dd, J = 16.2, 9.2 Hz, 1H, Asp-βCH2), 2.75 (dd, J = 16.2, 
4.7 Hz, 1H, Asp-βCH2), 3.65-3.70 (m, 1H, cyclopropyl-CHN) 3.71 (s, 3H, CH3O), 4.20-4.24 
(m, 2H, Fmoc-CH2), 4.33-4.35 (d, J = 6.6 Hz, 1H, Fmoc-CH), 4.47-4.51 (m, 1H, Asp-αCH), 
7.29-7.40 (m, 4H, Fmoc-Ar-CH), 7.63-7.67 (m, 2H, Fmoc-Ar-CH), 7.77-7.79 (m, 2H, Fmoc-
Ar-CH). - 13C NMR (CD3OD, 75.5 MHz): δ 28.5 (+, cyclopropyl-CH), 28.7 (+, cyclopropyl-
CH), 36.7 (+, cyclopropyl-CHN), 38.6 (-, Asp-CH2), 48.4 (+, Fmoc-CH), 53.0 (+, CH3O), 
53.1 (+, Asp-CHN), 68.3 (-, Fmoc-CH2), 82.5 (Cquat, (CH3)C), 121.0 (+, Fmoc-Ar-CH, 2C), 
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126.3 (+, Fmoc-Ar-CH, 2C), 128.2 (+, Fmoc-Ar-CH, 2C), 128.8 (+, Fmoc-Ar-CH, 2C), 
142.6 (Cquat, Fmoc-Ar-C, 2C), 145.2 (Cquat, Fmoc-Ar-C), 145.4 (Cquat, Fmoc-Ar-C), 158.4 
(Cquat, N(CO)O), 170.7 (Cquat, C=O), 171.3 (Cquat, C=O), 175.0 (Cquat, C=O), 172.1 (Cquat, 
C=O), 174.5 (Cquat, C=O). - MS  ESI (DCM/MeOH + 10 mmol/l NH4Ac) m/z (%) 570.3 
(MNH4+, 100), 553.3 (MH+, 78), 497.1 (MH+-C4H8, 30). - IR 3329, 2980, 1717, 1522, 1450, 
1302, 1217, 1157, 756 cm-1. - HR MS calcd for C29H32N2O9+H 553.21861, found 553.21846. 
 
E.2.2 Peptides containing (–)-βACC unit. 
 
 
Boc
H
N
N
H
CO2Me
O H
N
O
CO2Bn
3
(-)-5
 
Boc-[Ala-(–)-β-ACC]3-Ala-OBn, (–)-5: 
 
methyl(1S,2S,3S)-2-{[((1S)-2-{[(1S,2S,3S)-2-{[((1S)-2-{[(1S,2S,3S)-2-({[(1S)-2-(benzy-
loxy)-1-methyl-2-oxoethyl]amino}carbonyl)-3-(methoxycarbonyl)cyclopropyl]amino}-1-
methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-methyl-
2-oxoethyl)amino]carbonyl}-3-({(2S)-2-[(tert-butoxycarbonyl)amino]propanoyl}amino) 
cyclopropanecarboxylate; 
(-)-13 (536 mg, 0.76 mmol) was deprotected by treatment with HCl 3 M in ethyl acetate (10 
ml) for 3 h at 0 °C. The solution was concentrated in vacuum, the salt was resuspended in 
CH2Cl2 (20 ml). Separately the (-)-11 (284 mg, 0.86 mmol, 1.13 eq.) was dissolved in 
CH2Cl2 (20  ml) and cooled in an ice bath and activated with HOBt (116 mg, 0.86 mmol, 
1.13 eq.) and EDC (166 mg, 0.86 mmol, 1.13 eq.). After 10 minutes the mixture of the 
deprotected (-)-13 and triethylamine (0.16 ml, 1.17 mmol, 1.53 eq.) were added. The mixture 
was stirred at room temperature 80 h. The solution was then concentrated in vacuum and the 
product was obtained by chromatography (CH2Cl2/MeOH 25:2; Rf = 0.4) as a white solid 
(578 mg, 83 %). - mp 132-134 °C. - [ ]21Dα  -137.4 (c 1, CH3OH). - 1H NMR (CD3OD, 300 
MHz) δ 1.23 (d, J = 7.2 Hz, 3H, CH3CH), 1.32 (d, J = 7.2 Hz, 3H, CH3CH), 1.32 (d, J= 
7.2 Hz, 3H, CH3CH), 1.40 (d, J= 7.4 Hz, 3H, CH3CH), 1.43 (s, 9H, (CH3)3C), 2.27 (dd, J 
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=5.2, 4.6 Hz, 1H, cyclopropyl-CH), 2.35-2.56 (m, 5H, cyclopropyl-CH), 3.48 (dd, J = 8.2, 
4.3 Hz 1H, cyclopropyl-CHN), 3.56-3.66 (m, 2H, cyclopropyl-CHN), 3.70 (s, 3H, CH3O), 
3.71 (s, 3H, CH3O), 3.71 (s, 3H, CH3O), 3.96-4.05 (m, 1H, Ala-CHN), 4.25-4.37 (m, 2H, 
Ala-CHN), 4.51 (q, J = 7.3 Hz, 1H, Ala-CHN), 5.15 (d, J = 12.3 Hz, 1H, CH2O), 5.22 (d, J = 
12.3 Hz, 1H, CH2O), 7.31-7.39 (m, 5H, Ph-CH). - 13C NMR (CD3OD, 75.5 MHz) δ 16.0 (+, 
CH3CH, 3C), 16.9 (+, CH3CH), 26.4 (+, cyclopropyl-CH), 26.8 (+, cyclopropyl-CH), 26.9 (+, 
cyclopropyl-CH), 27.2 (+, cyclopropyl-CH, (CH3)3C, 6C), 35.1 (+, cyclopropyl-CHN, 2C), 
35.2 (+, cyclopropyl-CHN), 48.4 (+, Ala-CHN), 49.3 (+, Ala-CHN), 49.4 (+, Ala-CHN), 50.3 
(+, Ala-CHN), 51.4 (+, CH3O, 2C), 51.4 (+, CH3O), 66.7 (-, CH2O), 79.3 (Cquat, (CH3)3C), 
127.8 (+, Ph-CH, 2C), 128.0 (+, Ph-CH), 128.2 (+, Ph-CH, 2C), 135.7 (Cquat, Ph-C), 156.0 
(Cquat, N(CO)O), 167.9 (Cquat, C=O), 168.1 (Cquat, C=O, 2C), 170.9 (Cquat, C=O, 2C), 171.1 
(Cquat, C=O), 172.3 (Cquat, C=O), 174.3 (Cquat, C=O), 174.4 (Cquat, C=O). 175.4 (Cquat, C=O). - 
MS  FAB (MeOH/Glycerin) m/z (%) 917 (MH+, 6), 817 (MH+-Boc, 100), 727 (MH+-Boc-Bn, 
8). - IR (KBr) 3333, 2982, 1728, 1665, 1526, 1443, 1315 cm-1 - HR MS calcd for 
C42H57N7O16 + H 916.39400, found 916.39560. 
 
 
 
H
H
N
N
H
CO2Me
O H
N
O
CO2H
3
HCl
(-)-5a
 
HCl.H-[Ala-(–)-β-ACC]3-Ala-OH, (–)-5a: 
 
(2S)-1-{[(1S,2S,3S)-2-{[((1S)-2-{[(1S,2S,3S)-2-{[((1S)-2-{[(1S,2S,3S)-2-({[(1S)-1-carboxy-
ethyl]amino}carbonyl)-3-(methoxycarbonyl)cyclopropyl]amino}-1-methyl-2-oxoethyl) 
amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-methyl-2-oxoethyl)amino] 
carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-oxo-2-propanaminium chloride; 
(-)-5 (100 mg, 0.109 mmol) was stirred in HCl 3 M in ethyl acetate (2 ml) at 0°C for 3 h. The 
solution was then concentrated in vacuum and the salt redissolved in methanol (10 ml). Then 
Pd/C 10 % (60 mg) and cyclohexadiene (0.17 ml, 42 % in pentane) were added. The reaction 
mixture was stirred overnight, filtrated over a celite pad and concentrated in vacuum to afford 
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the deprotected peptide as a white solid (80 mg, 96 %). - mp 200 °C decomposed. - [ ]21Dα  -
168.8 (c 0.5, MeOH). - 1H NMR (CD3OD, 300 MHz) δ 1.32 (d, J = 7.2 Hz, 3H, CH3CH), 
1.35 (d, J = 7.3 Hz, 3H, CH3CH), 1.44 (d, J = 7.4 Hz, 3H, CH3CH), 1.46 (d, J = 7.1 Hz, 3H, 
CH3CH), 2.28 (dd, J = 5.4, 4.5 Hz, 1H, cyclopropyl-CH), 2.36 (d, J = 5.3, 4.3 Hz, 1H, 
cyclopropyl-CH), 2.40 (dd, J = 5.3, 4.7 Hz, 1H, cyclopropyl-CH), 2.44-2.59 (m, 3H, 
cyclopropyl-CH), 3.40 (dd, J = 8.3, 4.5 Hz, 1H, cyclopropyl-CHN), 3.50-3.54 (m, 2H, 
cyclopropyl-CHN), 3.71 (s, 3H, CH3O), 3.72 (s, 3H, CH3O), 3.72 (s, 3H, CH3O), 3.91 (q, J = 
7.0 Hz, 1H, Ala-CHN), 4.22 (q, J = 7.2 Hz, 1H, Ala-CHN), 4.23 (q, J = 7.3 Hz, 1H, Ala-
CHN), 4.39 (q, J = 7.3 Hz, 1H, Ala-CHN). - 13C NMR (CD3OD, 75.5 MHz) δ 17.4 (+, 
CH3CH), 17.5 (+, CH3CH), 17.6 (+, CH3CH), 17.7 (+, CH3CH), 27.9 (+, cyclopropyl-CH), 
28.1 (+, cyclopropyl-CH), 28.7 (+, cyclopropyl-CH), 28.9 (+, cyclopropyl-CH, 2C ), 29.5 (+, 
cyclopropyl-CH), 36.3 (+, cyclopropyl-CHN, 2C), 36.7 (+, cyclopropyl-CHN), 50.2 (+, 
CHN), 50.3 (+, CHN), 51.4 (+, CHN, 2C), 52.9 (+, CH3O), 52.9 (+, CH3O, 2C), 168.8 (Cquat, 
C=O), 169.3 (Cquat, C=O), 169.6 (Cquat, C=O), 172.4 (Cquat, C=O, 2C), 172.5 (Cquat, C=O, 2C), 
176.2 (Cquat, C=O), 176.4 (Cquat, C=O), 176.6 (Cquat, C=O). - MS  FAB (MeOH/Glycerin) m/z 
(%) 727 (MH+, 100), 369 (28), 277 (76). - IR (KBr) 3360, 3060, 2956, 1730, 1655, 1536, 
1450, 1314, 1209, 1174 cm-1. - HR MS  calcd for C30H43N7O14 + H 726.29462, found 
726.29456. 
 
Boc
H
N
N
H
CO2Me
O H
N
O
CO2Bn
4
(-)-6
 
Boc-[Ala-(–)-β-ACC]4-Ala-OBn, (–)-6: 
 
methyl (1S,2S,3S)-2-{[((1S)-2-{[(1S,2S,3S)-2-{[((1S)-2-{[(1S,2S,3S)-2-({[(1S)-2-(benzy-
loxy)-1-methyl-2-oxoethyl]amino}carbonyl)-3-(methoxycarbonyl)cyclopropyl]amino}-1-
methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-methyl-
2-oxoethyl)amino]carbonyl}-3-{[(2S)-2-({[(1S,2S,3S)-2-({(2S)-2-[(tert-butoxycarbonyl) 
amino]propanoyl}amino)-3-(methoxycarbonyl)cyclopropyl]carbonyl}amino)propanoyl] 
amino}cyclopropanecarboxylate;  
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(-)-5 (200 mg, 0.22 mmol) was deprotected by treatment with HCl 3 M in ethyl acetate (10 
ml) for 3 h at 0 °C. The solution was concentrated in vacuum, the salt was resuspended in 
CH2Cl2 (20 ml). Separately the (-)-11 (100 mg, 0.30 mmol, 1.35 eq.) was dissolved in 
CH2Cl2 (20  ml) and cooled in an ice bath and activated with HOBt (41 mg, 0.30 mmol, 
1.35 eq.) and EDC (58 mg, 0.30 mmol, 1.35 eq.). After 10 minutes the mixture of the 
deprotected (-)-5 and triethylamine (0.052 ml, 0.32 mmol, 1.70 eq.) were added. The mixture 
was stirred at room temperature 48 h. The solution was then concentrated in vacuum and the 
product was obtained by chromatography (CH2Cl2/MeOH 25:2; Rf = 0.3) as a white solid 
(185 mg, 76%). - mp 149-151 °C. - [ ]21Dα  - 16.2 (c 0.5, CHCl3). - 1H NMR (CD3OD, 300 
MHz) δ 1.26 (d, J = 7.1 Hz, 3H, CH3CH), 1.31 (d, J = 7.1 Hz, 3H, CH3CH), 1.33 (d, J= 
7.1 Hz, 3H, CH3CH), 1.33 (d, J= 7.1 Hz, 3H, CH3CH), 1.42 (d, J= 7.1 Hz, 3H, CH3CH), 1.44 
(s, 9H, (CH3)3C), 2.28 (dd, J =5.2, 4.4 Hz, 1H, cyclopropyl-CH), 2.36-2.56 (m, 7H, 
cyclopropyl-CH), 3.46 (dd, J = 8.2, 4.4 Hz 1H, cyclopropyl-CHN), 3.52 (dd, J = 8.2, 4.4 Hz 
1H, cyclopropyl-CHN), 3.58-3.66 (m, 2H, cyclopropyl-CHN), 3.71 (s, 3H, CH3O), 3.71 (s, 
3H, CH3O), 3.71 (s, 3H, CH3O), 3.72 (s, 3H, CH3O), 4.05 (q, J = 7.1 Hz, 1H, Ala-CHN), 
4.30 (q, J = 7.1 Hz, 1H, Ala-CHN), 4.33 (q, J = 7.1 Hz, 1H, Ala-CHN), 4.37 (q, J = 7.1 Hz, 
1H, Ala-CHN), 4.53 (q, J = 7.1 Hz, 1H, Ala-CHN), 5.17 (d, J = 12.4 Hz, 1H, CH2O), 5.24 (d, 
J = 12.3 Hz, 1H, CH2O), 7.30-7.41 (m, 5H, Ph-CH). - 13C NMR (CD3OD, 75.5 MHz) δ 16.0 
(+, CH3CH), 16.1 (+, CH3CH), 16.1 (+, CH3CH), 16.2 (+, CH3CH), 16.9 (+, CH3CH), 26.4 
(+, cyclopropyl-CH), 26.7 (+, cyclopropyl-CH), 26.8 (+, cyclopropyl-CH), 26.9 (+, 
cyclopropyl-CH), 27.3 (+, cyclopropyl-CH, (CH3)3C, 3C), 27.3 (+, cyclopropyl-CH), 27.5 (+, 
cyclopropyl-CH), 27.6 (+,cyclopropyl-CH), 35.1 (+, cyclopropyl-CHN, 3C), 35.2 (+, 
cyclopropyl-CHN), 49.3 (+, Ala-CHN, 3C), 49.4 (+, Ala-CHN), 50.3 (+, Ala-CHN), 51.4 (+, 
CH3O, 2C), 51.4 (+, CH3O, 2C), 66.6 (-, CH2O), 79.3 (Cquat, (CH3)3C), 127.7 (+, Ph-CH, 2C), 
128.0 (+, Ph-CH), 128.2 (+, Ph-CH, 2C), 135.7 (Cquat, Ph-C), 156.0 (Cquat, N(CO)O), 167.9 
(Cquat, C=O), 168.0 (Cquat, C=O), 168.1 (Cquat, C=O, 2C), 170.9 (Cquat, C=O, 2C), 171.0 (Cquat, 
C=O, 2C), 172.3 (Cquat, C=O), 174.3 (Cquat, C=O), 174.4 (Cquat, C=O, 2C). 175.4 (Cquat, C=O). 
- MS  FAB (MeOH/Glycerin) m/z (%) 1150 (MNa+, 2), 1128 (MH+, 4), 1028 (MH+-Boc, 
100). - IR (KBr) 3304, 2963, 1730, 1649, 1523, 1447, 1313, 1169, 752 cm-1. - HR MS calcd 
for C51H69N9O20 + H 1128.47390, found 1128.4737. 
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H
H
N
N
H
CO2Me
O H
N
O
CO2H
4
HCl
(-)-6a
 
HCl.H-[Ala-(–)-β-ACC]4-Ala-OH, (–)-6a: 
 
(2S)-1-{[(1S,2S,3S)-2-{[((1S)-2-{[(1S,2S,3S)-2-{[((1S)-2-{[(1S,2S,3S)-2-{[((1S)-2-{[(1S,2S, 
3S)-2-({[(1S)-1-carboxyethyl]amino}carbonyl)-3-(methoxycarbonyl)cyclopropyl]amino} 
-1-methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-
methyl-2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-methyl-
2-oxoethyl)amino]carbonyl}-3-(methoxycarbonyl)cyclopropyl]amino}-1-oxo-2-propan-
aminium chloride  
(-)-6 (100 mg, 0.09 mmol) was stirred in HCl 3 M in ethyl acetate (2 ml) at 0°C for 3 h. The 
solution was then concentrated in vacuum and the salt redissolved in methanol (10 ml). Then 
Pd/C 10 % (30 mg) and cyclohexadiene (0.14 ml, 42 % in pentane) were added. The reaction 
mixture was stirred overnight, filtrated over a celite pad and concentrated in vacuum to afford 
the deprotected peptide as a white solid (80 mg, 96 %). - mp 170 °C decomposed. - [ ]21Dα  - 
46.6 (c 0.5, CHCl3). - 1H NMR (CD3OD, 300 MHz) δ 1.34 (d, J = 7.1 Hz, 3H, CH3CH), 1.35 
(d, J = 7.1 Hz, 3H, CH3CH), 1.36 (d, J = 7.1 Hz, 3H, CH3CH), 1.44 (d, J = 7.4 Hz, 3H, 
CH3CH), 1.48 (d, J = 7.1 Hz, 3H, CH3CH), 2.30-2.33 (m, 2H, cyclopropyl-CH), 2.37-2.42 
(m, 2H, cyclopropyl-CH), 2.47-2.60 (m, 4H, cyclopropyl-CH, 3.42 (dd, J = 6.3, 4.5 Hz, 1H, 
cyclopropyl-CHN), 3.45 (dd, J = 6.6, 4.4 Hz, 1H, cyclopropyl-CHN), 3.57 (dd, J = 8.4, 
4.8 Hz, 1H, cyclopropyl-CHN), 3.61 (dd, J = 8.5, 4.4 Hz, 1H, cyclopropyl-CHN), 3.73 (s, 3H, 
CH3O), 3.73 (s, 3H, CH3O), 3.73 (s, 3H, CH3O), 3.73 (s, 3H, CH3O), 3.93 (q, J = 7.0 Hz, 1H, 
Ala-CHN), 4.21 (q, J = 7.2 Hz, 1H, Ala-CHN), 4.22 (q, J = 7.2 Hz, 1H, Ala-CHN), 4.38 (q, J 
= 7.1 Hz, 1H, Ala-CHN) 4.40 (q, J = 7.5 Hz, 1H, Ala-CHN). - 13C NMR (CD3OD, 75.5 
MHz) δ 15.9 (+, CH3CH), 16.0 (+, CH3CH), 16.1 (+, CH3CH), 16.1 (+, CH3CH), 16.2 (+, 
CH3CH), 26.2 (+, cyclopropyl-CH), 26.6 (+, cyclopropyl-CH), 27.2 (+, cyclopropyl-CH, 2C), 
27.3 (+, cyclopropyl-CH), 27.4 (+, cyclopropyl-CH), 27.6 (+, cyclopropyl-CH), 27.9 (+, 
cyclopropyl-CH), 34.8 (+, cyclopropyl-CHN), 34.9 (+, cyclopropyl-CHN), 35.0 (+, 
cyclopropyl-CHN), 35.0 (+, cyclopropyl-CHN), 48.5 (+, Ala-CHN), 48.8 (+, Ala-CHN), 49.4 
(+, Ala-CHN), 49.7 (+, Ala-CHN), 50.1 (+, Ala-CHN), 51.4 (+, CH3O, 4C), 167.3 (Cquat, 
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C=O), 167.9 (Cquat, C=O), 168.0 (Cquat, C=O, 2C), 170.7 (Cquat, C=O, 2C), 170.9 (Cquat, C=O), 
171.0 (Cquat, C=O), 173.7 (Cquat, C=O), 174.3 (Cquat, C=O), 174.6 (Cquat, C=O). 174.8 (Cquat, 
C=O), 174.9 (Cquat, C=O).-MS  FAB (MeOH/Glycerin) m/z (%) 938 (MH+, 100). - IR (KBr) 
3362, 3060, 2960, 1725, 1645, 1520, 1440, 1315, 1210, 1120 cm-1. - HR MS calcd for 
C39H55N9O18 + H 938.3743, found 938.3759. 
 
N
H
FmocHN COOBn
CO2Me
O
NHBoc
(-)-14
 
 
 
Fmoc-Lys(Boc)-(–)-βACC-OBn, (–)-14: 
 
1-methyl 2-phenyl (1S,2S,3R)-3-[((2S)-6-[(tert-butoxycarbonyl)amino]-2-{[(9H-fluoren-
9-ylmethoxy)carbonyl]amino}hexanoyl)amino]-1,2-cyclopropanedicarboxylate; 
A solution of (–)-9 (300 g, 0.86 mmol) in HCl 3 M in ethyl acetate (33 ml) was stirred at 0 °C 
for 3 h. The solvent was evaporated the solid was resospended in CH2Cl2 (30ml) and a 
solution of Fmoc-Lys(Boc)-OH (806 mg, 1.72 mmol, 2 eq.), EDC (330 mg, 1.72 mmol, 2 eq) 
and HOBt (209 mg, 1.55 mmol, 1.8 eq.) in CH2Cl2 (50 ml) (previously stirred 1 h at 0 °C) 
was added. pyridine  (123 µl, 1.55 mmol, 1.8 eq.) was then added dropwise. The mixture was 
stirred overnight at room temperature. The solution was washed with saturated NaHCO3 (50 
ml), 1 M KHSO4 (50 ml) and saturated NaHCO3 (50 ml). The organic phase was dried over 
Na2SO4 and concentrated. The product was purified by chromatography (CH2Cl2/MeOH 
50:1; Rf = 0.2). 640 mg, 70 %. 
mp 118-120 °C. [ ]21Dα  - 7.6 (c 0.5, CHCl3). - 1H NMR (CDCl3, 300 MHz) δ 1.28-1.39 (m, 2H, 
Lys-γ-CH2), 1.44 (s, 9H, Boc), 1.44-1.56 (m, 2H, Lys-δ-CH2), 1.57-1.65 (m, 1H, Lys-β-CH2), 
1.81-1.88 (m, 1H, Lys-β-CH2), 2.30 (dd, J = 5.0, 4.8 Hz, 1H, cyclopropyl-CH), 2.55 (dd, J = 
8.2, 4.8 Hz, 1H, cyclopropyl-CH), 3.05-3.15 (m, 2H, Lys-ε-CH2), 3.70 (s, 3H, CH3O), 4.00-
4.12 (m, 2H, cyclopropyl-CHN, Lys-α-CH) 4.24 (t, 1H, J = 7.1 Hz, Fmoc-CH), 4.37 (dd, J = 
10.2, 7.1 Hz, 1H, Fmoc-CH2), 4.48 (dd, J = 10.2, 7.1 Hz, 1H, Fmoc-CH2), 4.58-4.63 (m, 1H, 
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NH), 5.03 (d, J = 12.2 Hz, 1H, CH2O), 5.13 (d, J = 12.2 Hz, 1H, CH2O), 7.11 (d, J = 6.9 Hz, 
1H, NH), 7.28-7.42 (m, 9H, Ar-CH), 7.60-7.62 (m, 2H, Fmoc-Ar-CH), 7.75-7.78 (m, 2H, 
Fmoc-Ar-CH). - 13C NMR (CDCl3, 75.5 MHz): δ 22.5 (-, Lys-γ-CH2), 26.2 (+, cyclopropyl-
CH), 28.4 (+, 3C, C(CH3)3) 28.7 (+, cyclopropyl-CH), 29.7 (-, Lys-δ-CH2), 31.7 (-, Lys-β-
CH2), 35.9 (+, cyclopropyl-CHN), 39.9 (-, Lys-ε-CH2), 47.2 (+, Fmoc-CH), 52.5 (+, CH3O), 
54.9 (+, Lys-CHN), 67.1 (-, Fmoc-CH2), 67.4 (-, Bn-CH2), 79.2 (Cquat, (CH3)3C), 120.0 (+, 
Fmoc-Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH, 2C), 127.1 (+, Fmoc-Ar-CH, 2C), 127.4 (+, 
Fmoc-Ar-CH, 2C), 128.5 (+, Bn-Ar-CH, 2C), 128.6 (+, Bn-Ar-CH), 128.7 (+, Bn-Ar-CH, 
2C), 135.0 (Cquat, Bn-Ar-C), 141.3 (Cquat, Fmoc-Ar-C, 2C), 143.7 (Cquat, Fmoc-Ar-C), 144.0 
(Cquat, Fmoc-Ar-C), 156.2 (Cquat, N(CO)O, 2C), 169.8 (Cquat, C=O), 169.9 (Cquat, C=O), 172.4 
(Cquat, C=O). - MS ESI (DCM/MeOH + 10 mmol/l NH4Ac) m/z (%) 700 (MH+, 50) 600 
(MH+-Boc) - IR 3312, 2951, 1715, 1520, 1450, 1248, 1171, 758 cm-1. - HR MS calcd for 
C39H45N3O9 + H 700.3234, found 700.3223. 
 
 
N
H
FmocHN COOH
CO2Me
O
NHBoc
(-)-14a
 
 
Fmoc-Lys(Boc)-(–)-βACC-OH, (–)-14a: 
 
(1S,2S,3S)-2-[((2S)-6-[(tert-butoxycarbonyl)amino]-2-{[(9H-fluoren-9-ylmethoxy) 
carbonyl]amino}hexanoyl)amino]-3-(methoxycarbonyl)cyclopropanecarboxylic acid; 
 (–)-14 (600 mg, 0.86 mmol) was dissolved under nitrogen atmosphere in MeOH (40 ml), 
then 1,4-cyclohexadiene 4M in pentane (1.1 ml, 5 eq.) and Pd/C 5 % (240 mg) were added. 
The reaction mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 
cm celite pad and concentrated to afford the product as a white solid (420 mg, 80%).  
mp 67-69 °C. [ ]21Dα  - 5.8  (c 0.5, CH3OH). - 1H NMR (CD3OD, 300 MHz) δ 1.17-1.27 (m, 2H, 
Lys-γ-CH2), 1.41 (s, 9H, Boc), 1.41-1.49 (m, 2H, Lys-δ-CH2), 1.58-1.78 (m, 2H, Lys-β-CH2), 
2.29-2.41 (m, 2H, cyclopropyl-CH), 3.00-3.03 (m, 2H, Lys-ε-CH2), 3.70 (s, 3H, CH3O), 4.03 
(dd, J = 9.3, 5.2 Hz, 1H, cyclopropyl-CHN) 4.09 (q, J = 7.1 Hz, 1H, Lys-α-CH), 4.15-4.23 
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(m, 1H, Fmoc-CH), 4.33-4.40 (m, 2H, Fmoc-CH2), 7.28-7.40 (m, ´4H, Ar-CH), 7.64-7.68 (m, 
2H, Fmoc-Ar-CH), 7.77-7.80 (m, 2H, Fmoc-Ar-CH). - 13C NMR (CD3OD, 75.5 MHz): δ 
24.2 (-, Lys-γ-CH2), 28.6 (+, cyclopropyl-CH), 28.8 (+, cyclopropyl-CH), 28.9 (+, 3C, 
C(CH3)3), 30.5 (-, Lys-δ-CH2), 32.3 (-, Lys-β-CH2, 1C), 32.8 (-, Lys-β-CH2 , 1C), 36.6 (+, 
cyclopropyl-CHN), 41.1 (-, Lys-ε-CH2), 48.5 (+, Fmoc-CH), 52.9 (+, CH3O), 56.7 (+, Lys-
CHN), 68.0 (-, Fmoc-CH2), 79.9 (Cquat, (CH3)3C), 121.0 (+, Fmoc-Ar-CH, 2C), 126.3 (+, 
Fmoc-Ar-CH, 2C), 128.2 (+, Fmoc-Ar-CH, 2C), 128.9 (+, Fmoc-Ar-CH, 2C), 142.7 (Cquat, 
Fmoc-Ar-C, 2C), 145.2 (Cquat, Fmoc-Ar-C), 145.4 (Cquat, Fmoc-Ar-C), 158.6 (Cquat, N(CO)O, 
2C), 172.3 (Cquat, C=O), 174.7 (Cquat, C=O), 176.1 (Cquat, C=O). - MS FAB (MeOH/Glycerin) 
m/z (%) 610 (MH+, 10), 554 (15), 510 (M-Boc, 100) - IR 3338, 2951, 1707, 1522, 1450, 1366, 
1250, 1171, 1043, 741 cm-1. - HR MS calcd for C32H39N3O9 + H 610.2765, found 610.2757. 
 
 
 
 
 
N
H
FmocHN COOBn
CO2Me
O
(-)-16
 
 
Fmoc-Val-(–)-βACC-OBn, (–)-16: 
 
1-methyl 2-phenyl (1S,2S,3R)-3-[((2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-
methylbutanoyl)amino]-1,2-cyclopropanedicarboxylate;  
A solution of (–)-9 (514 g, 1.47 mmol) in HCl 3 M in ethyl acetate (56 ml) was stirred at 0 °C 
for 3 h. The solvent was evaporated the solid was resospended in CH2Cl2 (40 ml)  Fmoc-Val-
OH (650 mg, 1.91 mmol, 1.3 eq.), EDC (508 mg, 2.65 mmol, 1.8 eq) and pyridine (153 µl, 
1.91 mmol, 1.3 eq.) were added. The mixture was stirred overnight at room temperature. The 
solution was washed with saturated NaHCO3 (50 ml), 1 M KHSO4 (50 ml) and saturated 
NaHCO3 (50 ml). The organic phase was dried over Na2SO4 and concentrated. The product 
was purified by chromatography (CH2Cl2/MeOH 50:1; Rf = 0.2). 735 mg, 88 % - mp 175-
177 °C. [ ]21Dα  -9.2 (c 0.5, CHCl3). - 1H NMR (CDCl3, 300 MHz): δ 0.89 (d, J = 6.9 Hz, 3H, 
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Val-CH3), 0.96 (d, J = 6.9 Hz, 3H, Val-CH3), 2.09-2.20 (m, 1H, Val-βCH), 2.29 (dd, J = 5.2, 
4.8 Hz, 1H, cyclopropyl-CH), 2.57 (dd, J = 8.2, 5.2 Hz, 1H, cyclopropyl-CH), 3.71 (s, 3H, 
CH3O), 4.00 (dd, J = 8.1, 5.9, 1H, Val-αCH) 4.11 (m, 1H, cyclopropyl-CHN), 4.24 (t, J = 6.9 
Hz, 1H, Fmoc-CH), 4.42 (d, J = 6.9 Hz, 2H, Fmoc-CH2), 5.08 (d, J = 12.2 Hz, 1H, CH2O), 
5.17 (d, J = 12.2 Hz, 1H, CH2O), 5.29 (d, J = 8.1 Hz, 1H, Val-NH), 6.97 (d, J = 7.7 Hz, 1H, 
cyclopropyl-NH), 7.29-7.43 (m, 9H, Ar-CH), 7.60-7.62 (m, 2H, Fmoc-Ar-CH), 7.75-7.78 (m, 
2H, Fmoc-Ar-CH). - 13C NMR (CDCl3, 75.5 MHz): δ 17.6 (+, Val-CH3), 19.2 (+, Val-CH3), 
26.0 (+, cyclopropyl-CH), 28.9 (+, cyclopropyl-CH), 30.9 (+, Val-βCH), 35.9 (+, 
cyclopropyl-CHN), 47.2 (+, Fmoc-CH), 52.5 (+, CH3O), 60.3 (+, Val-CHN), 67.1 (-, Fmoc-
CH2), 67.6 (-, Bn-CH2), 120.0 (+, Fmoc-Ar-CH, 2C), 125.1 (+, Fmoc-Ar-CH, 2C), 127.1 (+, 
Ar-CH, 2C), 127.8 (+, Ar-CH, 2C), 128.5 (+, Ar-CH, 2C), 128.6 (+, Ar-CH), 128.7 (+, Ar-
CH, 2C), 134.9 (Cquat, Ph-C), 141.3 (Cquat, Fmoc-Ar-C, 2C), 143.8 (Cquat, Fmoc-Ar-C, 2C), 
156.4 (Cquat, N(CO)O), 169.8 (Cquat, C=O), 170.1 (Cquat, C=O), 171.9 (Cquat, C=O). - MS ESI 
(DCM/MeOH + 10 mmol/l NH4Ac) m/z (%) 593 (MNa+, 11), 588 (MNH4+, 40) 571 (MH+, 
100). - IR 3306, 2957, 1726, 1664, 1533, 1450, 1294, 1219, 1171, 771 cm-1. - Anal. Calcd for 
C33H34N2O7 C, 69.46; H, 6.01; N, 4.91. Found: C, 68.85; H, 5.77; N, 4.54. 
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Fmoc-Val-(–)-βACC-OH, (–)-16a: 
 
(1S,2S,3S)-2-[((2S)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-methylbutanoyl) 
amino]-3-(methoxycarbonyl)cyclopropanecarboxylic acid;  
(–)-16 (150 mg, 0.35 mmol) was dissolved under nitrogen atmosphere in MeOH (20 ml), 
then 1,4-cyclohexadiene 4M in pentane (332 µl, 5 eq) and Pd/C 5% (80 mg) were added. The 
reaction mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 cm 
celite pad and concentrated to afford the product as a white solid (156 mg, 93 %).  
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mp 180 decomposed °C . [ ]21Dα  - 26.7 (c 0.5, CH3OH). - 1H NMR (CD3OD, 600 MHz): δ 0.93 
(d, J = 5.5 Hz, 6H, Val-CH3), 2.07-2.11 (m, 1H, Val-βCH), 2.25 (dd, J = 5.3, 4.2 Hz, 1H, 
cyclopropyl-CH), 2.29 (dd, J = 7.8, 5.3 Hz, 1H, cyclopropyl-CH), 3.68 (s, 3H, CH3O), 3.72 
(dd, J = 7.8, 4.2 Hz, 1H, cyclopropyl-CHN), 3.85 (d, J = 7.2 Hz, 1H, Val-αCH), 4.22 (t, J = 
7.1 Hz, 1H, Fmoc-CH), 4.34 (dd, J = 10.2, 7.1 Hz, 1H, Fmoc-CH2), 4.41 (dd, J = 10.2, 
7.1 Hz, 1H, Fmoc-CH2), 7.29-7.40 (m, 4H, Ar-CH), 7.66 (m, 2H, Fmoc-Ar-CH), 7.79 (m, 2H, 
Fmoc-Ar-CH). - 13C NMR (CD3OD, 150.9 MHz): δ 18.6 (+, Val-CH3), 19.8 (+, Val-CH3), 
28.6 (+, cyclopropyl-CH), 29.9 (+, cyclopropyl-CH), 31.5 (+, Val-βCH), 36.4 (+, 
cyclopropyl-CHN), 48.4 (+, Fmoc-CH), 52.7 (+, CH3O), 62.5 (+, Val-CHN), 68.2 (-, Fmoc-
CH2), 120.9 (+, Fmoc-Ar-CH, 2C), 126.3 (+, Fmoc-Ar-CH, 2C), 128.1 (+, Fmoc-Ar-CH, 2C), 
128.2 (+, Fmoc-Ar-CH, 2C), 128.8 (+, Fmoc-Ar-CH, 2C), 142.6 (Cquat, Fmoc-Ar-C, 2C), 
145.0 (Cquat, Fmoc-Ar-C), 145.3 (Cquat, Fmoc-Ar-C) 158.8 (Cquat, N(CO)O), 172.8 (Cquat, 
C=O, CH3O), 174.8 (Cquat, Val-C=O), 176.5 (Cquat, C=O, CO2H). - MS FAB 
(MeOH/Glycerine) m/z (%) 999 (2M+K+, 40), 961 (2M+H+, 10), 519 (MK+, 20) 481 (MH+, 
100). - IR 3320, 2957, 1718, 1670, 1450, 1275, 1171, 1034, 770 cm-1. - HR MS calcd for 
C26H28N2O7 + H 481.1975, found 481.1975 
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Fmoc-Asp(OtBu)-(–)-βACC-OBn, (–)-17: 
 
1-methyl 2-phenyl (1S,2S,3R)-3-[((2S)-4-(tert-butoxy)-2-{[(9H-fluoren-9-ylmethoxy) 
carbonyl]amino}-4-oxobutanoyl)amino]-1,2-cyclopropanedicarboxylate; 
A solution of (-)-9 (300 g, 0.86 mmol) in HCl 3 M in ethyl acetate (35 ml) was stirred at 0 °C 
for 3 h. The solvent was evaporated the solid was resospended in CH2Cl2 (30 ml) and a 
solution of Fmoc-Asp(OtBu)-OH (708 mg, 1.72 mmol, 2 eq.), EDC (330 mg, 1.72 mmol, 2 
eq) and HOBt (209 mg, 1.55 mmol, 1.8 eq.) in CH2Cl2 (40 ml) (previously stirred 1 h at 
0 °C) was added. Pyridine  (123 µl, 1.55 mmol, 1.8 eq.) was then added dropwise. The 
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mixture was stirred overnight at room temperature. The solution was washed with saturated 
NaHCO3 (50 ml), 1 M KHSO4 (50 ml) and saturated NaHCO3 (50 ml). The organic phase 
was dried over Na2SO4 and concentrated. The product was purified by chromatography 
(PE/EA 3:1; Rf = 0.1). 408 mg, 74 %  
mp 75-77 °C . [ ]21Dα  + 5.0 (c 0.5, CH3OH). - 1H NMR (CDCl3, 300 MHz): δ 1.46 (s, 9H, 
OtBu), 2.32 (dd, J = 5.1, 4.9 Hz, 1H, cyclopropyl-CH), 2.56 (dd, J = 8.2, 5.1 Hz, 1H, 
cyclopropyl-CH), 2.62 (dd, J = 16.9, 5.0 Hz, 1H, Asp-βCH2), 2.93 (dd, J = 17.0, 4.7 Hz, 1H, 
Asp-βCH2), 3.70 (s, 3H, CH3O), 4.06-4.13 (m, 1H, cyclopropyl-CHN), 4.25-4.30 (m, 1H, 
Fmoc-CH), 4.33-4.39 (m, 1H, Fmoc-CH2), 4.47-4.55 (m, 2H, Fmoc-CH2, Asp-αCH), 5.03 (d, 
J = 12.2 Hz, 1H, CH2O), 5.12 (d, J = 12.2 Hz, 1H, CH2O), 5.86 (d, J = 8.8 Hz, 1H, Asp-NH), 
7.29-7.43 (m, 4H, Fmoc-Ar-CH), 7.52 (d, J = 8.0 Hz, 1H, βACC-NH), 7.61-7.64 (m, 2H, 
Fmoc-Ar-CH), 7.77 (pseudo d, J = 7.7 Hz, 2H, Fmoc-Ar-CH). - 13C NMR (CDCl3, 75.5 
MHz): δ 26.1 (+, cyclopropyl-CH), 28.1 (+, (CH3)3C), 28.6 (+, cyclopropyl-CH), 36.1 (+, 
cyclopropyl-CHN), 36.8 (-, Asp-CH2), 47.1 (+, Fmoc-CH), 51.3 (+, Asp-CHN), 52.5 (+, 
CH3O), 67.4 (-, Fmoc-CH2, 1C), 67.5 (-, Bn-CH2, 1C), 81.9 (Cquat, (CH3)C), 120.0 (+, Fmoc-
Ar-CH, 2C), 125.2 (+, Fmoc-Ar-CH, 2C), 127.1 (+, Fmoc-Ar-CH), 127.2 (+, Fmoc-Ar-CH), 
127.8 (+, Ar-CH, 2C), 128.4 (+, Ar-CH, 2C), 128.5 (+, Ar-CH, 1C), 128.7 (+, Ar-CH, 2C),   
135.0 (Cquat, Ph-Ar-C), 141.3 (Cquat, Fmoc-Ar-C, 2C), 143.7 (Cquat, Fmoc-Ar-C), 143.9 (Cquat, 
Fmoc-Ar-C), 156.2 (Cquat, N(CO)O), 169.8 (Cquat, C=O), 169.9 (Cquat, C=O), 171.0 (Cquat, 
C=O), 172.2 (Cquat, C=O). - MS FAB (MeOH/Glycerine) 643 (MH+, 86), 587 (100). - IR 
3329, 2978, 1718, 1522, 1308, 1217, 1169, 1051, 741 cm-1. - HR MS calcd for C36H38N2O9 + 
H 643.2656, found 643.2650. 
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Fmoc-Asp(OtBu)-(–)-βACC-OH, (–)-17a: 
 
(1S,2S,3S)-2-[((2S)-4-(tert-butoxy)-2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-4-oxo-
butanoyl)amino]-3-(methoxycarbonyl)cyclopropanecarboxylic acid; 
 (–)-17 (300 mg, 0.47 mmol) was dissolved under nitrogen atmosphere in MeOH (30 ml), 
then 1,4-cyclohexadiene 4M in pentane (0.60 ml, 5 eq.) and Pd/C 5 % (120 mg) were added. 
The reaction mixture was stirred under inert atmosphere overnight, then it was filtrated on a 2 
cm celite pad and concentrated to afford the product as a white solid (227 mg, 88.%).  
 
mp 78-80 °C . [ ]21Dα  -10.42 (c 0.5, CH3OH). - 1H NMR (CD3OD, 300 MHz): δ 1.42 (s, 9H, 
OtBu), 2.32-2.39 (m, 2H, cyclopropyl-CH), 2.54 (dd, J = 16.2, 8.8 Hz, 1H, , Asp-βCH2), 2.78 
(dd, J = 16.2, 5.2 Hz, 1H, , Asp-βCH2), 3.65 (dd, J = 7.9, 4.9 Hz, 1H, cyclopropyl-CHN) 
3.71 (s, 3H, CH3O), 4.20-4.25 (m, 1H, Fmoc-CH), 4.33-4.38 (m, 2H, Fmoc-CH2), 4.49 (dd, J 
= 8.7, 5.2 Hz,, 1H, Asp-αCH), 7.27-7.40 (m, 4H, Fmoc-Ar-CH), 7.66 (pseudo t, J = 6.4 Hz, 
2H, Fmoc-Ar-CH), 7.66 (pseudo d, J = 7.8 Hz, 2H, Fmoc-Ar-CH). - 13C NMR (CD3OD, 75.5 
MHz): δ 28.4 (+, cyclopropyl-CH), 28.8 (+, cyclopropyl-CH), 36.7 (+, cyclopropyl-CHN), 
38.6 (-, Asp-CH2), 48.4 (+, Fmoc-CH), 53.0 (+, CH3O), 53.4 (+, Asp-CHN), 68.4 (-, Fmoc-
CH2), 82.5 (Cquat, (CH3)C), 121.0 (+, Fmoc-Ar-CH, 2C), 128.3 (+, Fmoc-Ar-CH, 2C), 128.9 
(+, Fmoc-Ar-CH, 2C), 129.9 (+, Fmoc-Ar-CH, 2C), 142.6 (Cquat, Fmoc-Ar-C, 2C), 145.2 
(Cquat, Fmoc-Ar-C), 145.4 (Cquat, Fmoc-Ar-C), 158.4 (Cquat, N(CO)O), 171.3 (Cquat, C=O), 
172.3 (Cquat, C=O), 172.8 (Cquat, C=O), 174.4 (Cquat, C=O), 174.5 (Cquat, C=O). - MS FAB 
(MeOH/Glycerine) m/z (%) 553 (MH+, 12), 497 (MH+-tBu, 62), 275 (100). - IR 3337, 3066, 
2979, 1724, 1530, 1449, 1370, 1302 cm-1. - HR MS calcd for C29H32N2O9 + H 553.21861, 
found 553.21846. 
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E.3 Solid phase synthesis 
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H-Lys-(–)-βACC-Phe-(–)-βACC-Ala-(–)-βACC-Phe-(–)-βACC-Lys-(–)-βACC-Phe-(–)-βACC-Ala-OH 
(–)-7  
It was synthesized using a solid phase protocol. It was carried out by manual coupling using 
Fmoc/tBu strategy on the acid labile HMPA-AM resin (130 mg).  
The first amino acid, alanine (92 mg), was attached activating the carboxylic function with 
DIC (0.046 ml) and HOBt (40 mg) in the presence of DMAP (1.44 mg) in CH2Cl2/DMF 9:1, 
stirring overnight. The loading of the resin was determined spectrophotometrically by Fmoc 
cleavage with piperidine in DMF (theoretical loading: 0.91 mmol/gr; found: 0.6 mmol/gr). 
After capping by treatment with acetic anhydride and DIPEA in DMF, the peptide chain was 
assembled by single manual coupling of the dipeptides Fmoc-Xaa-βACC-OH (3-3.8 eq) 
activated by DIC/HOBt (1 eq in respect of the dipeptide) overnight in DCM/DMF 9:1 in the 
presence of DIPEA (2 eq in respect of dipeptide). The deprotection of the Fmoc was 
performed by treatment with 20% piperidine in DMF, one cycles of 10 and one of 15 minutes. 
After every two coupling-steps small scale cleavages were performed to control with 
analytical HPLC and mass analysis the growing peptide chain.   
The cleavage of the peptide from the resin with simultaneous side chains deprotection was 
achieved by treatment with a TFA/water/TIS mixture (95:5:5) for 2,5 hours. The peptide was 
precipitated from ice-cold diethyl ether and recovered by centrifugation. The purification was 
achieved by using RP-preparative HPLC and the product (–)-7 was characterized by 
analytical HPLC and MALDI-MS spectroscopy. 
MALDI MS: calcd for C81H105N15O26 + H 1705.8, found 1705.6. 
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F. Appendix of NMR and X-Ray Data 
 
 
NMR 
 
 
1H-Spectra  (top of the page) 
 
 
13C-Spectra  (botton of the page) 
 
 
 
For the peptide (–)-7, obtained by solid phase synthesis, the HPLC chromatogram after 
purification is given. 
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      Boc-[Ala-(+)-β-ACC]3-Ala-OBn, (+)-5 measured in CD3OD. 
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     HCl.H-[Ala-(+)-β-ACC]3-Ala-OH, (+)-5a measured in CD3OD. 
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      Boc-[Ala-(+)-β-ACC]4-Ala-OBn, (+)-6 measured in DMSO d6. 
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      HCl.H-[Ala-(+)-β-ACC]4-Ala-OH, (+)-6a measured in CD3OD. 
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    Fmoc-Val-(+)-βACC-OBn, (+)-16 measured in CDCl3. 
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      Fmoc-Val-(+)-βACC-OH, (+)-16a measured in CD3OD/CDCl3 10:1. 
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     Fmoc-Asp(OtBu)-(+)-βACC-OBn, (+)-17 measured in CDCl3. 
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      Fmoc-Asp(OtBu)-(+)-βACC-OH, (+)-17a measured in CD3OD. 
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   Boc-[Ala-(–)-β-ACC]3-Ala-OBn, (–)-5 measured in CD3OD. 
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      HCl.H-[Ala-(–)-β-ACC]3-Ala-OH, (–)-5a measured in CD3OD. 
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    Boc-[Ala-(–)-β-ACC]4-Ala-OBn, (–)-6 measured in CD3OD. 
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    HCl.H-[Ala-(–)-β-ACC]4-Ala-OH, (–)-6a measured in CD3OD. 
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8.0
8.5
 
 
 
HCl.H-[Ala-(–)-β-ACC]4-Ala-OH, (–)-6a 
DQF-COSY 600 MHz, 300 K, 4.5 mg in 0.8 ml in CDCl3 
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HCl.H-[Ala-(–)-β-ACC]4-Ala-OH, (–)-6a 
TOCSY 600 MHz, 300 K, 4.5 mg in 0.8 ml in CDCl3 
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HCl.H-[Ala-(–)-β-ACC]4-Ala-OH, (–)-6a 
ROESY 600 MHz, 300 K, 4.5 mg in 0.8 ml in CDCl3 
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      Fmoc-Lys(Boc)-(–)-βACC-OBn, (–)-14 measured in CDCl3. 
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      Fmoc-Lys(Boc)-(–)-βACC-OH, (–)-14a measured in CD3OD. 
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    Fmoc-Val-(–)-βACC-OBn, (–)-16 measured in CDCl3. 
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      Fmoc-Val-(–)-βACC-OH, (–)-16a measured in CD3OD. 
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      Fmoc-Asp(OtBu)-(–)-βACC-OBn, (–)-17 measured in CDCl3. 
 
 
 
 
 
(p p m)
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      Fmoc-Asp(OtBu)-(–)-βACC-OH, (–)-17a measured in CD3OD. 
 
 
 
 
 
(p p m)
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H-Lys-(–)-βACC-Phe-(–)-βACC-Ala-(–)-βACC-Phe-(–)-βACC-Lys-(–)-βACC-Phe-(–)-βACC-Ala-OH, (–)-7 
 
 
HPLC chromatogram, after purification, using Phenomenex luna C18; Injection 20 µl; 
Gradient 5-95%ACN in 40 min, 95% for 5 min; Wavelength = 220 nm. 
 
 
  
0 10 20 30 40 50
mAU
0
200
400
600
800
1000
1200
1400
 
2.
20
1
 
10
.
42
5
 
11
.
28
7
 
11
.
62
0
 
12
.
77
0
 
14
.
35
3
 
14
.
60
0
 
15
.
14
0
 
19
.
00
5
 
20
.
18
9
 
38
.
61
5
 
44
.
68
5
 
48
.
41
6
 
49
.
39
3
138  F. Appendix 
 
 
 
 
 
Crystal data of (+)-11: 
 
Empirical formula  C14H22N2O7  
      Formula weight  330.34  
      Crystal size  0.48 x 0.32 x 0.12 mm  
      Crystal description  bar  
      Crystal colour  colourless  
      Crystal system Monoclinic  
      Space group  C 2  
      Unit cell dimensions              a = 20.847(2) Å   alpha = 90°.  
                                         b = 5.1817(3) Å    beta = 107.825(11)°.  
                                         c = 16.9359(16) Å   gamma = 90°.  
      Volume  1741.6(3) Å3  
      Z, Calculated density  4,  1.260 Mg/m3  
      Absorption coefficient  0.101 mm-1  
      F(000)  704  
   
Data Collection  
 
  
      Measurement device type  STOE-IPDS diffractometer  
      Measuremnet method  rotation  
      Temperature  173(1) K  
      Wavelength  0.71073 Å 
      Monochromator   graphite  
      Theta range for data collection  2.05 to 25.17°.  
      Index ranges  -24<=h<=24, -6<=k<=6, -20<=l<=20  
      Reflections collected / unique  8027 / 8033 [R(int) = 0.0000]  
      Reflections greater I>2\\s(I) 6620  
      Absorption correction  None  
      Refinement    
      Refinement method  Full-matrix least-squares on F2  
      Hydrogen treatment  :  
      Data / restraints / parameters  8033 / 1 / 226  
      Goodness-of-fit on F^2  0.994  
      Final R indices [I>2sigma(I)]     R1 = 0.0532, wR2 = 0.1435  
      R indices (all data)               R1 = 0.0651, wR2 = 0.1516  
      Absolute structure parameter  0.2(12)  
      Largest diff. peak and hole  0.225 and -0.164 e.Å-3  
 
 
 
 
 
CO2Me
N
H
CO2H
O
BocHN
(+)-11
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 x y z U(eq) 
O(1) -2514(1) -2251(4) -2606(1) 43(1) 
O(2) -1377(1) 4258(3) -852(1) 46(1) 
O(3) -1251(1) 1177(3) 147(1) 42(1) 
O(4) -4788(1) 2789(4) -3367(1) 53(1) 
O(5) -4682(1) 6612(4) -3922(1) 49(1) 
O(6) -2712(1) 2769(4) -4404(1) 51(1) 
O(7) -3196(1) -1076(4) -4851(1) 51(1) 
N(1) -2663(1) 2037(4) -2641(1) 32(1) 
N(2) -1364(1) 8(4) -1146(1) 34(1) 
C(1) -3368(1) 1794(5) -3046(2) 30(1) 
C(2) -3750(1) 3860(5) -3605(2) 33(1) 
C(3) -3636(1) 1291(5) -3971(1) 32(1) 
C(4) -2271(1) -77(5) -2458(1) 31(1) 
C(5) -1515(1) 355(5) -2037(2) 32(1) 
C(6) -1103(1) -1497(6) -2386(2) 45(1) 
C(7) -1337(1) 2014(5) -631(2) 33(1) 
C(8) -1165(2) 3045(5) 838(2) 43(1) 
C(9) -1785(2) 4735(6) 678(2) 47(1) 
C(10) -514(2) 4541(8) 967(2) 63(1) 
C(11) -1100(3) 1262(6) 1575(2) 78(2) 
C(12) -4457(1) 4307(5) -3612(2) 35(1) 
C(13) -5375(1) 7196(7) -3973(2) 62(1) 
C(14) -3137(1) 1133(6) -4437(1) 37(1) 
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
           
O(1)-C(4) 1.229(3) 
O(2)-C(7) 1.217(3) 
O(3)-C(7) 1.345(3) 
O(3)-C(8) 1.486(3) 
O(4)-C(12) 1.200(3) 
O(5)-C(12) 1.331(3) 
O(5)-C(13) 1.453(4) 
O(6)-C(14) 1.214(4) 
O(7)-C(14) 1.328(4) 
O(7)-H(7O) 0.91(4) 
N(1)-C(4) 1.344(3) 
N(1)-C(1) 1.425(3) 
N(2)-C(5) 1.455(3) 
N(2)-C(7) 1.348(3) 
N(1)-H(1N) 0.82(3) 
N(2)-H(2N) 0.93(3) 
C(1)-C(2) 1.488(4) 
C(1)-C(3) 1.517(3) 
C(2)-C(3) 1.518(4) 
C(2)-C(12) 1.490(4) 
C(3)-C(14) 1.487(4) 
C(4)-C(5) 1.535(4) 
C(5)-C(6) 1.522(4) 
C(8)-C(9) 1.516(4) 
C(8)-C(10) 1.520(5) 
C(8)-C(11) 1.526(4) 
C(1)-H(1) 1.0000 
C(2)-H(2) 1.0004 
C(3)-H(3) 1.0001 
C(5)-H(5) 1.0004 
C(6)-H(6A) 0.9801 
C(6)-H(6B) 0.9797 
C(6)-H(6C) 0.9793 
C(9)-H(9A) 0.9805 
C(9)-H(9B) 0.9800 
C(9)-H(9C) 0.9800 
C(10)-H(10A) 0.9796 
C(10)-H(10B) 0.9792 
C(10)-H(10C) 0.9801 
C(11)-H(11A) 0.9805 
C(11)-H(11B) 0.9789 
C(11)-H(11C) 0.9803 
C(13)-H(13A) 0.9795 
C(13)-H(13B) 0.9805 
C(13)-H(13C) 0.9808 
  
C(7)-O(3)-C(8) 120.54(18) 
C(12)-O(5)-C(13) 115.7(2) 
C(14)-O(7)-H(7O) 113(2) 
C(1)-N(1)-C(4) 120.2(2) 
C(5)-N(2)-C(7) 122.0(2) 
C(4)-N(1)-H(1N) 120.6(17) 
C(1)-N(1)-H(1N) 119.2(17) 
C(7)-N(2)-H(2N) 117.4(14) 
C(5)-N(2)-H(2N) 119.7(14) 
C(2)-C(1)-C(3) 60.67(17) 
N(1)-C(1)-C(2) 120.9(2) 
N(1)-C(1)-C(3) 120.7(2) 
C(3)-C(2)-C(12) 114.3(2) 
C(1)-C(2)-C(3) 60.60(16) 
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C(1)-C(2)-C(12) 116.8(2) 
C(1)-C(3)-C(14) 117.5(2) 
C(1)-C(3)-C(2) 58.73(16) 
C(2)-C(3)-C(14) 119.2(2) 
O(1)-C(4)-N(1) 121.1(2) 
O(1)-C(4)-C(5) 121.9(2) 
N(1)-C(4)-C(5) 116.9(2) 
N(2)-C(5)-C(6) 110.8(2) 
C(4)-C(5)-C(6) 110.5(2) 
N(2)-C(5)-C(4) 109.2(2) 
O(2)-C(7)-O(3) 125.8(2) 
O(2)-C(7)-N(2) 123.5(2) 
O(3)-C(7)-N(2) 110.6(2) 
O(3)-C(8)-C(11) 102.1(2) 
C(9)-C(8)-C(10) 114.0(3) 
C(9)-C(8)-C(11) 110.7(3) 
O(3)-C(8)-C(9) 110.2(2) 
O(3)-C(8)-C(10) 109.4(2) 
C(10)-C(8)-C(11) 109.8(3) 
O(4)-C(12)-O(5) 123.7(2) 
O(4)-C(12)-C(2) 124.6(2) 
O(5)-C(12)-C(2) 111.8(2) 
O(6)-C(14)-C(3) 123.7(3) 
O(7)-C(14)-C(3) 111.1(2) 
O(6)-C(14)-O(7) 125.1(2) 
N(1)-C(1)-H(1) 114.64 
C(2)-C(1)-H(1) 114.69 
C(3)-C(1)-H(1) 114.69 
C(1)-C(2)-H(2) 117.53 
C(3)-C(2)-H(2) 117.51 
C(12)-C(2)-H(2) 117.60 
C(1)-C(3)-H(3) 116.39 
C(2)-C(3)-H(3) 116.38 
C(14)-C(3)-H(3) 116.32 
N(2)-C(5)-H(5) 108.81 
C(4)-C(5)-H(5) 108.80 
C(6)-C(5)-H(5) 108.73 
C(5)-C(6)-H(6A) 109.47 
C(5)-C(6)-H(6B) 109.49 
C(5)-C(6)-H(6C) 109.47 
H(6A)-C(6)-H(6B) 109.48 
H(6A)-C(6)-H(6C) 109.50 
H(6B)-C(6)-H(6C) 109.41 
C(8)-C(9)-H(9A) 109.42 
C(8)-C(9)-H(9B) 109.44 
C(8)-C(9)-H(9C) 109.47 
H(9A)-C(9)-H(9B) 109.55 
H(9A)-C(9)-H(9C) 109.49 
H(9B)-C(9)-H(9C) 109.46 
C(8)-C(10)-H(10A) 109.49 
C(8)-C(10)-H(10B) 109.45 
C(8)-C(10)-H(10C) 109.47 
H(10A)-C(10)-H(10B) 109.50 
H(10A)-C(10)-H(10C) 109.45 
H(10B)-C(10)-H(10C) 109.47 
C(8)-C(11)-H(11A) 109.50 
C(8)-C(11)-H(11B) 109.57 
C(8)-C(11)-H(11C) 109.41 
H(11A)-C(11)-H(11B) 109.51 
H(11A)-C(11)-H(11C) 109.40 
H(11B)-C(11)-H(11C) 109.43 
O(5)-C(13)-H(13A) 109.42 
O(5)-C(13)-H(13B) 109.49 
O(5)-C(13)-H(13C) 109.49 
H(13A)-C(13)-H(13B) 109.46 
H(13A)-C(13)-H(13C) 109.50 
H(13B)-C(13)-H(13C) 109.46 
  
Table 3.  Bond lengths [Å] and angles [°] for c048a.    
 
 
 
 
             
 U11   U22   U33    U23    U13  U12  
O(1) 43(1) 20(1) 55(1) 1(1) 1(1) -7(1)  
O(2) 70(1) 21(1) 45(1) 5(1) 17(1) 2(1)  
O(3) 66(1) 23(1) 32(1) -3(1) 10(1) 1(1)  
O(4) 45(1) 41(1) 88(2) 6(1) 40(1) 0(1)  
O(5) 29(1) 49(1) 68(1) 20(1) 13(1) 5(1)  
O(6) 49(1) 55(1) 62(1) -3(1) 37(1) -12(1)  
O(7) 38(1) 64(1) 58(1) -26(1) 26(1) -9(1)  
N(1) 38(1) 22(1) 34(1) 1(1) 9(1) -5(1)  
N(2) 46(1) 19(1) 32(1) 3(1) 6(1) -3(1)  
C(1) 34(1) 25(1) 36(1) -1(1) 16(1) -3(1)  
C(2) 35(1) 29(1) 40(1) 4(1) 18(1) -1(1)  
C(3) 29(1) 32(1) 36(1) 0(1) 13(1) -2(1)  
C(4) 38(1) 26(1) 28(1) 1(1) 9(1) 2(1)  
C(5) 36(1) 24(1) 36(1) 3(1) 10(1) -4(1)  
C(6) 47(2) 44(2) 51(2) 1(1) 25(1) 1(1)  
C(7) 38(1) 25(1) 32(1) -1(1) 4(1) -3(1)  
C(8) 62(2) 30(1) 32(1) -3(1) 6(1) 4(1)  
C(9) 57(2) 40(2) 45(1) -7(1) 17(1) 2(1)  
C(10) 50(2) 61(2) 64(2) -25(2) -3(1) 3(2)  
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C(11) 156(4) 39(2) 33(1) -4(2) 20(2) 22(2)  
C(12) 32(1) 34(1) 41(1) 1(1) 16(1) -2(1)  
C(13) 30(1) 59(2) 92(2) 16(2) 14(2) 5(1)  
C(14) 29(1) 53(2) 29(1) -1(1) 9(1) -4(1)  
     
Table 4.  Anisotropic displacement parameters (Å2 x 103). The anisotropic displacement factor 
exponent takes the form:  -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
 
 x y z U(eq) 
H(1) -3623 911 -2710 36 
H(1N) -2499(11) 3480(50) -2528(13) 9(5) 
H(2) -3489 5382 -3704 40 
H(2N) -1360(11) -1640(50) -930(13) 14(5) 
H(3) -4035 122 -4162 38 
H(5) -1399 2165 -2148 39 
H(6A) -1200 -3277 -2263 54 
H(6B) -622 -1142 -2131 54 
H(6C) -1221 -1264 -2987 54 
H(7O) -2879(17) -1270(60) -5113(19) 56(9) 
H(9A) -1769 5676 1186 57 
H(9B) -2190 3653 510 57 
H(9C) -1797 5968 235 57 
H(10A) -574 5812 522 75 
H(10B) -152 3345 960 75 
H(10C) -396 5431 1503 75 
H(11A) -1010 2292 2083 94 
H(11B) -729 49 1629 94 
H(11C) -1521 300 1487 94 
H(13A) -5675 5905 -4321 74 
H(13B) -5495 8913 -4217 74 
H(13C) -5424 7165 -3415 74 
 
Table 5. Hydrogen coordinates ( x104) and isotropic displacement parameters (Å2 x 103).  
 
C(7)-O(3)-C(8)-C(9) 61.4(3) 
C(7)-O(3)-C(8)-C(10) -64.8(3) 
C(7)-O(3)-C(8)-C(11) 179.0(3) 
C(8)-O(3)-C(7)-N(2) 176.4(2) 
C(8)-O(3)-C(7)-O(2) -2.7(4) 
C(13)-O(5)-C(12)-C(2) 178.5(2) 
C(13)-O(5)-C(12)-O(4) -1.6(4) 
C(4)-N(1)-C(1)-C(2) -150.2(2) 
C(1)-N(1)-C(4)-C(5) 178.9(2) 
C(4)-N(1)-C(1)-C(3) -78.1(3) 
C(1)-N(1)-C(4)-O(1) -2.6(3) 
C(5)-N(2)-C(7)-O(2) -6.6(4) 
C(7)-N(2)-C(5)-C(4) -95.2(3) 
C(5)-N(2)-C(7)-O(3) 174.4(2) 
C(7)-N(2)-C(5)-C(6) 142.9(2) 
N(1)-C(1)-C(3)-C(14) -1.6(4) 
N(1)-C(1)-C(3)-C(2) -110.6(3) 
C(2)-C(1)-C(3)-C(14) 109.1(3) 
N(1)-C(1)-C(2)-C(12) -145.6(2) 
N(1)-C(1)-C(2)-C(3) 110.3(3) 
C(3)-C(1)-C(2)-C(12) 104.2(2) 
C(12)-C(2)-C(3)-C(14) 145.4(2) 
C(1)-C(2)-C(3)-C(14) -106.3(2) 
C(12)-C(2)-C(3)-C(1) -108.3(2) 
142  F. Appendix 
 
C(1)-C(2)-C(12)-O(5) 161.2(2) 
C(3)-C(2)-C(12)-O(4) 49.3(3) 
C(1)-C(2)-C(12)-O(4) -18.7(4) 
C(3)-C(2)-C(12)-O(5) -130.8(2) 
C(2)-C(3)-C(14)-O(7) -167.5(2) 
C(1)-C(3)-C(14)-O(6) -51.8(4) 
C(1)-C(3)-C(14)-O(7) 124.8(2) 
C(2)-C(3)-C(14)-O(6) 15.9(4) 
O(1)-C(4)-C(5)-N(2) -80.7(3) 
O(1)-C(4)-C(5)-C(6) 41.4(3) 
N(1)-C(4)-C(5)-N(2) 97.9(2) 
N(1)-C(4)-C(5)-C(6) -140.0(2) 
 
Table 6. Torsion angles [°].  
 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
     
N(1)-H(1N)...O(1)#1 0.82(3) 2.22(3) 2.975(3) 154(2) 
N(2)-H(2N)...O(2)#2 0.93(3) 2.13(3) 3.022(3) 160.7(19) 
O(7)-H(7O)...O(6)#3 0.91(4) 1.75(4) 2.646(3) 170(3) 
C(1)-H(1)...O(4) 1.0000 2.5400 2.887(3) 100.00 
C(3)-H(3)...O(5)#2 1.0000 2.3700 3.280(3) 150.00 
C(5)-H(5)...O(2) 1.0000 2.4400 2.802(3) 101.00 
C(9)-H(9C)...O(2) 0.9800 2.4300 2.975(3) 114.00 
C(10)-H(10A)...O(2) 0.9800 2.5500 3.059(4) 113.00 
     
 
Table 7.  Hydrogen-bonds [Å and °].  
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Crystal data of (rac)-9  
   
Empirical formula C18H23NO6  
Formula weight 349.37  
Crystal size 0.48 x 0.40 x 0.16 mm  
Crystal description platelike  
Crystal colour translucent colourless  
Crystal system Orthorhombic  
Space group P 21 21 21  
Unit cell dimensions a = 5.4517(3) Å   alpha = 90°.  
 b = 16.3923(11) Å    beta = 90°.  
 c = 20.2978(12) Å   gamma = 90° 
Volume 1813.93(19) Å3  
Z, Calculated density 4,  1.279 Mg/m3  
Absorption coefficient 0.096 mm-1  
F(000) 744  
   
Data Collection   
Measurement device type STOE-IPDS diffractometer  
Measuremnet method rotation  
Temperature 173(1) K  
Wavelength 0.71073 Å  
Monochromator  graphite  
Theta range for data collection 2.36 to 25.73 °.  
Index ranges -6<=h<=6, -19<=k<=20, -24<=l<=24  
Reflections collected / unique 17998 / 3445 [R(int) = 0.0486]  
Reflections greater I>4\\s(I) 3102  
Absorption correction None  
Refinement   
Refinement method Full-matrix least-squares on F2  
Hydrogen treatment mixed  
Data / restraints / parameters 3445 / 0 / 246  
Goodness-of-fit on F^2 1.049  
Final R indices [I>2sigma(I)] R1 = 0.0339, wR2 = 0.0849  
R indices (all data) R1 = 0.0386, wR2 = 0.0868  
Absolute structure parameter 0.2(8)  
Largest diff. peak and hole 0.231 and -0.198 e.Å-3  
 
 
 
CO2Me
BocHN CO2Bn
(rac)-9
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 x y z U(eq) 
O(6) -3014(2) -2089(1) -3686(1) 48(1) 
O(7) -6041(2) -3012(1) -3909(1) 35(1) 
O(13) -7499(2) 789(1) -3267(1) 39(1) 
O(14) -10933(2) 528(1) -2690(1) 34(1) 
O(17) -6798(2) -1928(1) -2030(1) 46(1) 
O(18) -3049(2) -1386(1) -1916(1) 34(1) 
N(4) -7044(3) -1797(1) -3529(1) 33(1) 
C(1) -6564(3) -968(1) -3348(1) 30(1) 
C(2) -8269(3) -564(1) -2873(1) 28(1) 
C(3) -5651(3) -759(1) -2663(1) 27(1) 
C(5) -5153(3) -2289(1) -3709(1) 31(1) 
C(8) -4391(3) -3669(1) -4144(1) 35(1) 
C(9) -2618(4) -3918(1) -3607(1) 58(1) 
C(10) -6154(5) -4357(1) -4270(2) 88(1) 
C(11) -3057(6) -3400(2) -4755(1) 70(1) 
C(12) -8818(3) 321(1) -2975(1) 27(1) 
C(15) -11622(3) 1382(1) -2739(1) 37(1) 
C(16) -5298(3) -1424(1) -2173(1) 28(1) 
C(19) -2367(3) -2013(1) -1427(1) 35(1) 
C(20) -2238(3) -1639(1) -754(1) 29(1) 
C(21) -4071(3) -1774(1) -290(1) 34(1) 
C(22) -3920(3) -1429(1) 333(1) 39(1) 
C(23) -1917(3) -952(1) 499(1) 41(1) 
C(24) -74(3) -817(1) 45(1) 39(1) 
C(25) -235(3) -1157(1) -578(1) 36(1) 
   
 
Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor.  
   
 
O(6)-C(5) 1.212(2) 
O(7)-C(5) 1.343(2) 
O(7)-C(8) 1.482(2) 
O(13)-C(12) 1.2058(19) 
O(14)-C(12) 1.334(2) 
O(14)-C(15) 1.4528(19) 
O(17)-C(16) 1.198(2) 
O(18)-C(16) 1.333(2) 
O(18)-C(19) 1.476(2) 
N(4)-C(1) 1.432(2) 
N(4)-C(5) 1.359(2) 
N(4)-H(4A) 0.8799 
C(1)-C(3) 1.516(2) 
C(1)-C(2) 1.493(2) 
C(2)-C(12) 1.496(2) 
C(2)-C(3) 1.524(2) 
C(3)-C(16) 1.488(2) 
C(8)-C(10) 1.504(3) 
C(8)-C(11) 1.505(3) 
C(8)-C(9) 1.512(3) 
C(19)-C(20) 1.499(2) 
C(20)-C(25) 1.394(2) 
C(20)-C(21) 1.392(2) 
C(21)-C(22) 1.387(3) 
C(22)-C(23) 1.385(2) 
C(23)-C(24) 1.381(2) 
C(24)-C(25) 1.386(3) 
C(1)-H(1) 0.923(19) 
C(2)-H(2) 0.949(16) 
C(3)-H(3) 0.936(18) 
C(9)-H(9A) 0.9804 
C(9)-H(9B) 0.9794 
C(9)-H(9C) 0.9801 
C(10)-H(10A) 0.9800 
C(10)-H(10B) 0.9794 
C(10)-H(10C) 0.9806 
C(11)-H(11A) 0.9797 
C(11)-H(11B) 0.9800 
C(11)-H(11C) 0.9796 
C(15)-H(15A) 0.9801 
C(15)-H(15B) 0.9809 
C(15)-H(15C) 0.9805 
C(19)-H(19A) 0.97(2) 
C(19)-H(19B) 0.98(2) 
C(21)-H(21A) 0.9497 
C(22)-H(22A) 0.9499 
C(23)-H(23A) 0.9498 
C(24)-H(24A) 0.9503 
C(25)-H(25A) 0.9495 
  
C(5)-O(7)-C(8) 121.32(12) 
C(12)-O(14)-C(15) 116.02(12) 
C(16)-O(18)-C(19) 117.52(12) 
C(1)-N(4)-C(5) 119.59(15) 
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C(5)-N(4)-H(4A) 120.19 
C(1)-N(4)-H(4A) 120.21 
N(4)-C(1)-C(3) 120.67(13) 
N(4)-C(1)-C(2) 118.22(14) 
C(2)-C(1)-C(3) 60.85(11) 
C(3)-C(2)-C(12) 115.46(13) 
C(1)-C(2)-C(3) 60.31(11) 
C(1)-C(2)-C(12) 117.72(13) 
C(1)-C(3)-C(16) 119.39(13) 
C(1)-C(3)-C(2) 58.84(10) 
C(2)-C(3)-C(16) 117.54(13) 
O(6)-C(5)-N(4) 123.98(16) 
O(6)-C(5)-O(7) 126.65(15) 
O(7)-C(5)-N(4) 109.37(14) 
O(7)-C(8)-C(10) 102.24(15) 
O(7)-C(8)-C(11) 110.19(15) 
C(9)-C(8)-C(11) 111.36(18) 
C(10)-C(8)-C(11) 112.9(2) 
C(9)-C(8)-C(10) 109.14(18) 
O(7)-C(8)-C(9) 110.67(15) 
O(14)-C(12)-C(2) 111.05(13) 
O(13)-C(12)-C(2) 124.41(15) 
O(13)-C(12)-O(14) 124.53(14) 
O(17)-C(16)-C(3) 125.29(15) 
O(17)-C(16)-O(18) 124.45(15) 
O(18)-C(16)-C(3) 110.26(13) 
O(18)-C(19)-C(20) 109.87(13) 
C(19)-C(20)-C(21) 121.24(14) 
C(21)-C(20)-C(25) 118.62(15) 
C(19)-C(20)-C(25) 120.13(15) 
C(20)-C(21)-C(22) 120.64(15) 
C(21)-C(22)-C(23) 119.95(16) 
C(22)-C(23)-C(24) 120.08(17) 
C(23)-C(24)-C(25) 119.92(16) 
C(20)-C(25)-C(24) 120.78(16) 
N(4)-C(1)-H(1) 114.9(11) 
C(2)-C(1)-H(1) 116.0(12) 
C(3)-C(1)-H(1) 115.5(12) 
C(1)-C(2)-H(2) 118.1(10) 
C(3)-C(2)-H(2) 117.0(10) 
C(12)-C(2)-H(2) 116.4(10) 
C(1)-C(3)-H(3) 116.1(11) 
C(2)-C(3)-H(3) 116.4(10) 
C(16)-C(3)-H(3) 116.2(11) 
C(8)-C(9)-H(9A) 109.47 
C(8)-C(9)-H(9B) 109.45 
C(8)-C(9)-H(9C) 109.42 
H(9A)-C(9)-H(9B) 109.49 
H(9A)-C(9)-H(9C) 109.52 
H(9B)-C(9)-H(9C) 109.47 
C(8)-C(10)-H(10A) 109.48 
C(8)-C(10)-H(10B) 109.44 
C(8)-C(10)-H(10C) 109.43 
H(10A)-C(10)-H(10B) 109.50 
H(10A)-C(10)-H(10C) 109.46 
H(10B)-C(10)-H(10C) 109.51 
C(8)-C(11)-H(11A) 109.50 
C(8)-C(11)-H(11B) 109.44 
C(8)-C(11)-H(11C) 109.42 
H(11A)-C(11)-H(11B) 109.49 
H(11A)-C(11)-H(11C) 109.49 
H(11B)-C(11)-H(11C) 109.48 
O(14)-C(15)-H(15A) 109.52 
O(14)-C(15)-H(15B) 109.48 
O(14)-C(15)-H(15C) 109.47 
H(15A)-C(15)-H(15B) 109.40 
H(15A)-C(15)-H(15C) 109.46 
H(15B)-C(15)-H(15C) 109.50 
O(18)-C(19)-H(19A) 106.4(13) 
O(18)-C(19)-H(19B) 102.5(11) 
C(20)-C(19)-H(19A) 110.7(12) 
C(20)-C(19)-H(19B) 112.9(11) 
H(19A)-C(19)-H(19B) 113.8(17) 
C(20)-C(21)-H(21A) 119.69 
C(22)-C(21)-H(21A) 119.67 
C(21)-C(22)-H(22A) 120.03 
C(23)-C(22)-H(22A) 120.01 
C(22)-C(23)-H(23A) 119.94 
C(24)-C(23)-H(23A) 119.98 
C(23)-C(24)-H(24A) 120.05 
C(25)-C(24)-H(24A) 120.03 
C(20)-C(25)-H(25A) 119.61 
C(24)-C(25)-H(25A) 119.61 
 
Table 3.  Bond lengths [Å] and angles [°].  
 
 
 U11 U22 U33 U23 U13 U12 
O(6) 35(1) 37(1) 73(1) -15(1) 6(1) -3(1) 
O(7) 32(1) 27(1) 44(1) -9(1) 1(1) 2(1) 
O(13) 39(1) 28(1) 49(1) 9(1) 12(1) 2(1) 
O(14) 31(1) 23(1) 47(1) 2(1) 7(1) 2(1) 
O(17) 34(1) 36(1) 68(1) 20(1) -4(1) -8(1) 
O(18) 34(1) 33(1) 36(1) 7(1) -7(1) -4(1) 
N(4) 33(1) 27(1) 39(1) -9(1) 0(1) 0(1) 
C(1) 34(1) 25(1) 31(1) -2(1) 3(1) 1(1) 
C(2) 27(1) 23(1) 33(1) 1(1) 1(1) -1(1) 
C(3) 27(1) 21(1) 33(1) -1(1) 1(1) -3(1) 
C(5) 35(1) 29(1) 30(1) -3(1) 0(1) 1(1) 
C(8) 35(1) 29(1) 43(1) -8(1) 3(1) 5(1) 
C(9) 67(1) 56(1) 51(1) 4(1) 2(1) 27(1) 
C(10) 47(1) 49(1) 167(3) -58(2) 0(2) 4(1) 
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C(11) 104(2) 58(1) 47(1) 9(1) 29(1) 36(1) 
C(12) 28(1) 26(1) 27(1) -1(1) -1(1) 0(1) 
C(15) 42(1) 25(1) 45(1) -1(1) 7(1) 5(1) 
C(16) 29(1) 23(1) 31(1) -3(1) 1(1) 1(1) 
C(19) 39(1) 28(1) 38(1) 4(1) -4(1) 5(1) 
C(20) 28(1) 25(1) 35(1) 6(1) -3(1) 5(1) 
C(21) 28(1) 32(1) 42(1) 8(1) -3(1) -2(1) 
C(22) 40(1) 41(1) 37(1) 8(1) 7(1) -1(1) 
C(23) 50(1) 37(1) 36(1) 2(1) -5(1) 0(1) 
C(24) 36(1) 34(1) 47(1) 1(1) -6(1) -5(1) 
C(25) 31(1) 35(1) 43(1) 6(1) 2(1) 0(1) 
  
 
Table 4.  Anisotropic displacement parameters (A^2 x 10^3). The anisotropic displacement factor 
exponent takes the form: -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
 
 x y z U(eq) 
H(1) -5970(40) -643(11) -3683(9) 31(4) 
H(2) -9540(30) -883(10) -2684(8) 21(4) 
H(3) -4570(30) -317(11) -2633(9) 26(4) 
H(4A) -8554 -1986 -3525 40 
H(9A) -3527 -4027 -3200 70 
H(9B) -1741 -4412 -3743 70 
H(9C) -1438 -3477 -3532 70 
H(10A) -5241 -4843 -4408 105 
H(10B) -7064 -4478 -3865 105 
H(10C) -7305 -4199 -4618 105 
H(11A) -2018 -2929 -4652 83 
H(11B) -2034 -3848 -4918 83 
H(11C) -4252 -3247 -5094 83 
H(15A) -10357 1720 -2531 45 
H(15B) -11781 1534 -3204 45 
H(15C) -13193 1468 -2514 45 
H(19A) -3630(40) -2425(13) -1445(10) 43(5) 
H(19B) -770(40) -2199(11) -1588(9) 31(5) 
H(21A) -5439 -2106 -400 41 
H(22A) -5189 -1520 645 47 
H(23A) -1811 -717 926 49 
H(24A) 1303 -491 160 47 
H(25A) 1035 -1062 -889 43 
 
Table 5.  Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103).  
 
 
C(5)-O(7)-C(8)-C(11) -63.1(2) 
C(5)-O(7)-C(8)-C(9) 60.5(2) 
C(5)-O(7)-C(8)-C(10) 176.66(18) 
C(8)-O(7)-C(5)-O(6) -0.9(3) 
C(8)-O(7)-C(5)-N(4) 179.12(14) 
C(15)-O(14)-C(12)-C(2) 178.12(13) 
C(15)-O(14)-C(12)-O(13) -0.6(2) 
C(16)-O(18)-C(19)-C(20) -108.22(15) 
C(19)-O(18)-C(16)-C(3) -178.90(13) 
C(19)-O(18)-C(16)-O(17) 0.4(2) 
C(1)-N(4)-C(5)-O(7) -174.99(13) 
C(1)-N(4)-C(5)-O(6) 5.1(3) 
C(5)-N(4)-C(1)-C(3) -80.7(2) 
C(5)-N(4)-C(1)-C(2) -151.74(15) 
N(4)-C(1)-C(3)-C(2) -107.38(17) 
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C(2)-C(1)-C(3)-C(16) 106.24(16) 
N(4)-C(1)-C(2)-C(12) -143.65(15) 
N(4)-C(1)-C(3)-C(16) -1.1(2) 
N(4)-C(1)-C(2)-C(3) 111.32(16) 
C(3)-C(1)-C(2)-C(12) 105.03(16) 
C(12)-C(2)-C(3)-C(1) -108.76(15) 
C(1)-C(2)-C(3)-C(16) -109.36(15) 
C(3)-C(2)-C(12)-O(13) 44.6(2) 
C(1)-C(2)-C(12)-O(13) -23.7(2) 
C(3)-C(2)-C(12)-O(14) -134.14(14) 
C(1)-C(2)-C(12)-O(14) 157.55(14) 
C(12)-C(2)-C(3)-C(16) 141.88(14) 
C(1)-C(3)-C(16)-O(18) 127.76(15) 
C(2)-C(3)-C(16)-O(18) -164.32(13) 
C(1)-C(3)-C(16)-O(17) -51.5(2) 
C(2)-C(3)-C(16)-O(17) 16.4(2) 
O(18)-C(19)-C(20)-C(21) 105.11(17) 
O(18)-C(19)-C(20)-C(25) -76.13(18) 
C(19)-C(20)-C(21)-C(22) 179.54(15) 
C(25)-C(20)-C(21)-C(22) 0.8(2) 
C(19)-C(20)-C(25)-C(24) -179.10(16) 
C(21)-C(20)-C(25)-C(24) -0.3(2) 
C(20)-C(21)-C(22)-C(23) -0.7(3) 
C(21)-C(22)-C(23)-C(24) 0.2(3) 
C(22)-C(23)-C(24)-C(25) 0.3(3) 
C(23)-C(24)-C(25)-C(20) -0.2(3) 
 
Table 6.  Torsion angles [°].  
 
 
   
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(4)-H(4A)...O(6)#1 0.8799 2.4590 3.305(2) 161.45 
C(3)-H(3)...O(14)#2 0.936(18) 2.421(17) 3.3270(19) 162.8(15) 
C(9)-H(9C)...O(6) 0.9801 2.4520 3.011(3) 115.79 
C(11)-H(11A)...O(6) 0.9797 2.4572 3.054(3) 118.97 
C(19)-H(19A)...O(17) 0.97(2) 2.25(2) 2.712(2) 108.3(15) 
C(19)-H(19B)...O(17)#2 0.98(2) 2.39(2) 3.277(2) 151.0(15) 
 
 
Table 7.  Hydrogen-bonds [Å and °]. 
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